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 Abstract 
 
In this thesis, a miniaturised field asymmetric waveform ion mobility spectrometry (FAIMS) 
device is combined with mass spectrometry (MS), and liquid chromatography, for the 
development and application of bioanalytical methodologies. FAIMS is a highly orthogonal 
to MS and LC and has the potential to enhance both targeted and non-targeted bioanalytical 
applications.  
Chapter two demonstrates the capability of the FAIMS combined with mass spectrometry to 
reduce the complexity of the mass spectrum by separating species of different charge states 
and overlapping mass-to-charge ratios that are challenging to separate by MS. FAIMS 
selected transmission shows improvement in signal-to-noise ratios for low intensity species 
and enables visualisation of species undetectable without FAIMS. Chapter three describes the 
development of an LC-FAIMS-MS method for the rapid analysis of saliva for the 
identification of potential biomarkers as a result of oxidative stress. The combination of 
FAIMS showed a reduction in saliva matrix interferences resulting in improved 
discrimination and peak integration of two salivary oxypurine compounds in a rapid LC-
FAIMS-MS method. Chapter four investigates the FAIMS separation of seven steroid 
metabolites with a range of cationic adducts, in order to develop a rapid screening LC-
FAIMS-MS method for the determination of isobaric steroid metabolites in urine. LC-
FAIMS-MS analysis of the steroid metabolites shows improved discrimination of co-eluting 
and isobaric steroid metabolites with improvements in signal-to-noise ratio with reductions in 
chemical noise, demonstrating the potential of combining FAIMS with LC-MS. Chapter five 
demonstrates the potential of FAIMS to increase peak capacity in non-targeted omics 
applications, by combining rapid compensation field scanning of the FAIMS with ultra-high 
performance LC-MS. The rapid scanning of the FAIMS allows acquisition of full scan 
FAIMS and MS nested data sets within the timescale of a UHPLC chromatographic peak, 
and is applied to the non-targeted profiling of human urine. Improvements in the number of 
features detected using LC-FAIMS-MS were as a result of reductions in chemical noise and 
separation of co-eluting isobaric species across the whole analytical space, demonstrating the 
potential of combining FAIMS with LC and MS.  
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 Glossary of terms 
 
%RSD % Relative standard deviation 
3-MX 3-Methylxanthine 
ACN Acetonitrile 
ADG Androsterone glucuronide 
CCS Collision cross section 
CEM Chain ejection model 
CF Compensation field 
CID Collision induced dissociation 
CRM Charge residue model 
CV Compensation voltage 
Da Dalton 
DC Direct current 
DF  Dispersion field 
DHEAS Dehydroepiandrosterone sulfate 
DI Direct infusion 
DMS Differential mobility spectrometry 
DTIMS Drift tube ion mobility spectrometry 
DV Dispersion voltage 
ECG Etiocholanolone glucuronide 
EHSS Exact hard spheres scattering 
EIC Extracted ion chromatogram 
E/N Buffer gas density ratio 
ESI Electrospray ionisation 
ETD Electron transfer dissociation 
ETG Epitestosterone glucuronide 
ETS Epitestosterone sulfate 
FA Formic acid 
FAIMS Field asymmetric waveform ion mobility spectrometry 
FISCID FAIMS ion selection collision induced dissociation 
GC Gas chromatography 
HMDB Human metabolome database 
HPLC High performance liquid chromatography 
HX Hypoxanthine 
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IEM Ion evaporation model 
IM-MS Ion mobility-mass spectrometry 
IMS Ion mobility spectrometry 
LC Liquid chromatography 
LOD Limit of detection 
LOQ Limit of quantification 
m/z Mass-to-charge ratio 
MCP Microchannel plate 
MeOH Methanol 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
NaOAc Sodium acetate 
nESI Nanoelectrospray ionisation 
PA Projection approximation 
PCA Principal component analysis 
PSA Projected superposition approximation 
Q Quadrupole 
Q-TOF Quadrupole time-of-flight 
QC Quality control 
RF Radio frequency 
RT Retention time 
S:N Signal-to-noise ratio 
TIC Total ion chromatogram 
TG Testosterone glucuronide 
TM Trajectory method 
TOF Time-of-flight 
TS Testosterone sulfate 
TWIMS Travelling wave ion mobility spectrometry 
UA Uric acid 
UHPLC Ultra-high pressure liquid chromatography 
XA Xanthine 
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 Chapter One 
1. Introduction 
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1.1. Ion mobility spectrometry (IMS) 
1.1.1. Principles of ion mobility and differential mobility spectrometry 
Ion mobility spectrometry (IMS), originally termed plasma chromatography,1,2 is a gas phase 
electrophoretic technique which separates ions based upon their relative mobilities in an 
electric field and a drift gas. The electric field accelerates ions through a drift cell while 
collisions with the drift gas causes them to decelerate resulting in a constant drift velocity (vd, 
cm s-1) defined by: 
vd = KE     Equation 1.1 
Where K (cm2 s-1 V-1) is the ion mobility and E (V cm-1) is the electric field strength. The 
mobility of an ion is inherently based upon its size, shape, ionic charge and reduced mass and 
its mobility co-efficient is calculated using the Mason-Schamp equation3: 
K =
3ze
16N
√
2π
µkBTeff
1
Ω
   Equation 1.2 
Where z is the charge on the ion, e is the electronic charge (1.602 x 10-19 C), N is the number 
density of the gas, µ is the reduced mass: µ = (m x M) / (m + M) where m is the mass of the 
ion and M is the mass of the drift gas, kB is the Boltzmann constant (1.381 x 10-23 J K-1), Teff 
is the effective temperature of the drift gas, and Ω is the rotationally averaged ionic collision 
cross section (CCS). IMS separates ions based upon their drift times through a drift cell due 
to the inverse relationship of K and Ω. This results in small compact molecules travelling 
faster through the drift cell than larger ions or extended conformations (larger CCS). The 
charge of an ion (z) and Ω are directly proportional which results in ions with greater charge 
having shorter drift times through the cell.  
Altering the buffer gas in IMS based techniques will affect the mobility of an ion. Increasing 
the gas number density (N) will alter the ion velocity due to an increased number of collisions 
of the gas with the ion. The loss in velocity of the ion by the increased number of collisions is 
related to the reduced mass of the ion (see Mason-Schamp Equation 1.2), where the lower the 
reduced mass (µ) the higher the mobility of the ion as dictated by the inverse relationship of 
K to (1/µ)1/2. The temperature and pressure of the gas will affect its density and therefore the 
mobility of the ion. For this reason, the mobility of an ion is usually expressed as reduced 
mobility (K0) where the value is normalised to standard conditions of temperature (T, Kelvin) 
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and pressure (P, Torr) of the buffer gas (Equation 1.3). This allows mobilities of ions to be 
compared across different IMS analyses.  
K0 = K
273.15
T
P
760
     Equation 1.3 
In IMS systems the electric field strength is expressed in Townsends (Td), where 1 Td = 10-17 
V cm2, of the ratio E/N where E is the electric field strength and N is the gas number density. 
The E/N ratio can be calculated for a given field strength by: 
(
E
N
) =
EkBT
P
      Equation 1.4 
Where E (V cm-1) is defined as the voltage applied across the electrodes (V) / gap size (cm).  
1.1.2. Field dependence of mobility in low and high fields 
When the electric field is low (< 10 Td, referred to below as the low-field limit) and remains 
constant, ions gated into a drift tube ion mobility device obtain a velocity proportional to the 
mobility coefficient and the electric field strength (Equation 1.1). Under these circumstances 
the mobility coefficient can be related to the size, shape and charge of the ion using the 
Mason-Schamp equation (Equation 1.2). However, when the E/N ratio is high (> 10 Td) the 
mobility of an ion is altered from the low-field response and becomes field-dependent. The 
response of individual ions varies and ions with the same low-field mobility may have 
significantly different high-field mobility due to ion-molecule interactions forming the basis 
of differential mobility separations,2 which are discussed in more detail in Section 1.3.2. The 
differential mobility separation coefficient is not adequately defined by a fixed constant like 
K0 (low-field reduced mobility constant) but is rather expressed as a function known as alpha 
(α) which describes how mobility changes with E/N. The mobility of an ion under high field 
conditions (Kh), under constant pressure, can be expressed as
4: 
Kh (
E
N
) = K0 [1 + α (
E
N
)]     Equation 1.5 
α(E/N) is the alpha function (Equation 1.6) and is equal to α2(E/N)2 + α4(E/N)4 + … αn(E/N)n 
where n is an even integer.2,5 α(E/N) can be used to quantify the differential mobility of an 
ion at different field strengths > 10 Td, as when the electric field strength is low Kh(E/N) 
reduces to be equal to K0.  
α (
E
N
) =
Kh(
E
N
)−K0
K0
=
∆Kh(
E
N
)
K0
     Equation 1.6 
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1.2. Low-field IMS 
IMS utilising the low electric field strength separation principles, can provide useful insights 
into the structure of molecules and their complexes.6,7 IMS has been applied to the study of 
small molecules and metabolites,8–11 nucleotides,12 peptides and proteins,13–15 
carbohydrates,16 and lipids.12,17,18 The use of a weak electric field for the separation of 
gaseous ions was first described by Mason and Schamp in 19583 and developed by Mason, 
Viehland and McDaniel.19,20 IMS has since grown with advances in engineering and 
instrumental development to produce both bench top instrumentation, which can be combined 
with mass spectrometry, and hand-held portable devices for biological,21–23 
pharmaceutical,24,25 security and chemical warfare,26–28 military,29 and environmental 
applications.30–33 Progression of IMS development has resulted in two distinct fields: low-
field techniques such as drift tube IMS (DTIMS) and travelling wave IMS (TWIMS), and 
high-field techniques FAIMS or DMS (discussed in Section 1.3). Instrumental features and 
the use of DTIMS and TWIMS to determine structural information and collision cross section 
(CCS) measurements and calculations will be discussed in this section.  
1.2.1. Drift tube IMS 
The drift tube configuration of low-field IMS gave rise to the mechanistic understanding of 
IMS theory (described in Section 1.1.1) utilising the separation of ions based upon their 
mobilities through a drift cell, accelerated by an electric field in the presence of an opposing 
buffer gas. The drift region of an IMS is the core separation component. Early development 
of DTIMS utilised a drift cell which consisted of two parallel plates,7 however most 
commonly utilised is a series of stacked ring electrodes where a near-uniform field is created 
along the axis of the drift tube30,34; a schematic representation of a stacked ring electrode 
DTIMS cell is shown in Figure 1.1. 
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Figure 1.1 Principle of drift tube ion mobility separation. Ions are pulsed into the drift region 
and travel through the uniform electric field against a buffer gas flow and are separated based 
upon their size, shape and charge. Arrival time distributions can be converted to collition cross 
section (CCS) 
 
Ions from an ionisation source are pulsed into the drift region of the device and accelerated 
towards a detector. Ionisation sources for standalone DTIMS have predominantly used 63Ni 
to generate gas phase ions by atmospheric pressure chemical ionisation of the analytes.26,35 
Hyphenation of DTIMS with mass spectrometry utilises electrospray ionisation and other 
ionisation sources. The ionisation source is separated from the drift cell by electronic shutter 
grid that prevent ions from passing into the drift cell to produce a discrete ‘packet’ of ions 
that can be pulsed into the cell together and be separated based upon their mobilities under a 
uniform weak electric field as described in Equation 1.1. A drift (or buffer) gas is present in 
the drift region at a constant pressure (typically between 1-10 Torr or at atmospheric 
pressure). The analyte ions collide with the buffer gas impeding progress through the device, 
with more collisions for ions with larger CCS. Detectors for standalone devices are usually 
faraday plates, however when DTIMS is combined with MS, the mass spectrometer is used as 
the detector. DTIMS is regularly combined with time-of-flight and quadrupole mass 
spectrometers with mobility separation prior to entry into the mass analyser of the mass 
spectrometer, providing an added level of separation to the analysis.36  
Commercially available DTIMS devices include30: 6560 ion mobility Q-TOF from Agilent 
Technologies;37 IONSCAN 400B, 500DT and 600 (portable) from Smiths Detection (Smiths 
Group Plc.)38–40; RAID M100 from Bruker Corp.41,42; B220 (bench top) and H150 (handheld) 
from L3 Security & Detection Systems43; IMS-ODOR, GC-IMS, UV-IMS and Analytical-
IMS from G.A.S. Gesellschaft für analytische Sensor-systeme mbH44; HPIMS from 
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Excellims45; GDA series from AIRSENSE Analytics GmbH46; EN3300 Illicit Substance 
Detector and E5000 (GC-IMS) from Scintrex Trace a division of Autoclear LLC.47; and 
BioScout from B&S Analytik GmbH.48  
1.2.2. Travelling wave IMS 
Travelling wave IMS (TWIMS) was first reported by Giles et al. in 2004,49 and released as a 
commercial instrument in combination with mass spectrometry called Synapt HDMS in 2006 
by Waters.50 TWIMS consists of a stacked-ring ion guide (representation shown in Figure 
1.2) to which a travelling voltage wave is applied.49,51 Ions are propelled through the device 
by a repeating pattern of DC voltage pulses in a gas-filled drift tube, where opposite phases 
of an RF voltage are applied to adjacent ring electrodes and the DC voltage is superimposed. 
Analyte ions in the drift tube move in the direction of the travelling wave and separate 
according to their size, with larger ions colliding more with gas molecules, resulting in a 
lower mobility of the ion. Large lower mobility ions roll over the waves more often than 
small higher mobility ions, causing them to take longer to traverse the cell (Figure 1.2); this is 
the principle of operation in TWIMS. Altering the height and velocity of the travelling wave 
can induce mobility separation. TWIMS is operated at low electric field strengths like 
DTIMS, but the relationship between CCS and K0 is not direct due to the continuously 
altering electric field (travelling wave) and requires calibration, using standards of known 
CCS, to measure the CCS of target analytes (see Section 1.2.3). Currently commercially 
available versions of the Synapt from Waters include the Synapt G2-S and Synapt G2-Si with 
improved ion transmission through the IM-MS.52  
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Figure 1.2 Principle of travelling wave ion mobility separation. Ions are pulsed into the drift 
region and propelledby a traveeling voltage wave. Ions are separated according to their size, 
shape and charge 
 
1.2.3. Experimental collision cross section determination 
Determination of CCS can provide characteristic structural information for each ion and an 
indication of the size and shape of an ion. The proportional relationship between CCS (Ω) 
and reduced mobility (K0), described in Section 1.1.1, is only true at or below the ‘low-field 
limit’ of < 10 Td, where the ratio between electric field strength and buffer gas density (E/N) 
is small.7 Therefore CCS can be experimentally measured with temporal-based mobility 
devices such as DTIMS (directly measured) and TWIMS (with calibration), but cannot be 
measured with FAIMS as the electric field strengths in FAIMS exceed the low-field limit 
during part of the applied waveform.  
CCS determination using DTIMS 
Using DTIMS, the time it takes an ion to traverse a drift cell filled with buffer gas (usually 
helium) under a weak electric field (E), allows for determination of CCS. The electric field is 
defined by the length of the drift cell (L) and the voltage applied across the cell (V): 
E =
V
L
       Equation 1.7 
Under low field conditions, where the ratio of the electric field across the cell (E) to the 
buffer gas density (N) expressed in Td is below 10 Td, an ion’s velocity is constant and 
linearly proportional to the electric field as described in Equation 1.1. K is proportional to the 
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buffer gas pressure and inversely proportional to the CCS (Ω), so to decouple the K from 
experimental variables, K must be converted to the reduced mobility K0 by Equation 1.3. 
The drift time (td) of the ions in the cell can be determined by: 
td =
L
vd
=
L
KE
=
P
V
L2T0
K0P0T
    Equation 1.8 
The arrival time (ta) of an ion measured during a DTIMS experiment, is equal to the sum of 
the drift time through the device (td) and the time ions spend outside of the device, known as 
the dead time (t0); the arrival time is experimentally calculated by multiplying the scan 
number by the pusher pulse (µs). A graph of ta versus P/V (at a constant temperature) 
provides a linear relationship where the intercept is equal to t0; an example plot is shown in 
Figure 1.3. The slope of the linear trend line is equal to 1/K0 and the rotationally averaged 
CCS of the ion can then be directly measured using a rearranged form of the Mason Schamp 
equation (Equation 1.2).3 
 
Figure 1.3 Example of a linear calibration to measure inverse of the reduced mobility of an ion 
and the dead time of the measurement from the slope and intercept respectively 
 
CCS determination using TWIMS 
Direct measurement of CCS is more difficult in TWIMS, due to the extra kinetic energy 
imparted on the ions from the propulsion of the ions by the waves in TWIMS. Small compact 
ions will have a higher mobility and therefore velocity in the drift cell incurring fewer 
collisions with the drift gas than larger lower mobility ions. These lower mobility ions will 
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have greater interactions with the buffer gas and roll over the waves to be propelled by 
further waves. The basis of these different velocities allows for separation of the ions but also 
the determination of rotationally averaged CCS values. The determination of CCS in TWIMS 
is performed using a calibration based on standards of known CCS (calculated using DTIMS 
in helium), measured under the same experimental conditions in the TWIMS drift cell as the 
ions of interest. The known DTIMS CCS (Ω) measurement is first adjusted for the TWIMS 
calibration by: 
ΩTWIMS =
ΩDTIMS
(
1
Mion
+
1
Mgas
)
1 2⁄     Equation 1.9 
Where Mion is the mass of the ion of interest and Mgas is the mass of the buffer gas used in the 
TWIMS. The drift time (td) in TWIMS is determined by multiplication of the bin number by 
the pusher pulse (msec). A correction is then applied to drift time (td’) to account for the time 
taken to pass through the transfer and mobility drift cell: 
td′ = td − 0.920     Equation 1.10 
A second correction is then applied to the corrected drift time (td’) to account for the time 
taken for the ion to exit the transfer region and reach the detector, which is defined by the 
corrected effective drift time (td’’): 
td′′ = td′ − √(
𝑚 𝑧⁄
1000
) × 0.085    Equation 1.11 
A calibration graph of the calculated (ΩTWIMS) of the standards against the measured td’’ can 
then be plotted with a linear trend line fitted to provide values for the constants A and B used 
in Equation 1.12, where A is the gradient of the trend line and B is the intercept. A is a 
correction factor for temperature, pressure and electric field parameters and B is the 
correction factor for the non-linear effect of the TWIMS. These constants can then be used to 
calculate the unknown CCS (ΩTWIMS) of ions of interest using: 
ΩTWIMS = td′′
B × A × e × (
1
Mion
+
1
Mgas
)
1 2⁄
   Equation 1.12 
One shortcoming of CCS determination via the TWIMS-MS calibration method is that the 
CCS measurement of the calibration standards by DTIMS-MS is usually performed in one 
gas (He) and the CCS converted to that of another gas (usually N2) using Equation 1.9. 
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Therefore, direct measurement of the CCS using DTIMS is considered more accurate than 
calibration measurement using TWIMS.  
1.2.4. Theoretical collision cross section determination 
Modelling CCS values can allow for the comparison of theoretical data with experimentally 
determined values to predict or support observed results. CCS values are generally calculated 
using three different models: the projection approximation (PA), the exact hard spheres 
scattering (EHSS) and the trajectory method (TM).53–55 A fourth method was also recently 
developed called the projected superposition approximation (PSA).56–59  
The PA method models molecules as overlapping hard spheres by measuring the radii at 
different orientations of a projected ‘shadow’ of the ion in the yz-plane, in order to obtain a 
rotationally averaged CCS value; this method is the fastest model and works well for small 
molecules but is limited for larger ions where the buffer gas may collide with the molecule 
more than once.55 
The EHSS model similarly uses hard sphere approximations of the ions, however EHSS 
measures the CCS by calculating the scattering angles of incoming and departing buffer gas 
atoms that ricochet off the orientationally averaged hard sphere radii of the molecule. EHSS 
models can overestimate the effects of multiple scattering and produce larger than expected 
values for the CCS.53,54 
The TM sums all of the individual contributions of the atoms in a molecule based upon 
Lennard Jones potentials of repulsive and attractive forces between two atoms in a molecule, 
to obtain effective trajectories and orientationally averaged scattering angles for the 
determination of CCS. The TM model is the most arduous and time-consuming of the 
modelling methods but is considered to give the most reliable values for small and large 
molecules. 
PSA is a method recently developed by the Bowers research group (University of California, 
Santa Barbara) for the calculation of CCS values, which was also employed here for 
comparison with the three more traditional methods. The PSA algorithm calculates an 
orientationally averaged projection cross section which is then scaled by a shape factor.56–59 
This shape factor is calculated as a ratio of the molecular surface area to the surface area of a 
completely convex envelope of the molecule, and therefore provides a measure of the 
concaveness of the molecule compared to a fully convex molecule.56 This method has been 
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shown to give accuracies similar to the trajectory method but is considerably less time-
consuming computationally.56 
 
1.3. Field asymmetric waveform ion mobility spectrometry (FAIMS) 
Field asymmetric waveform ion mobility spectrometry (FAIMS), also known as differential 
mobility spectrometry (DMS), is an analytical technique that separates gas phase ions in an 
alternating radio frequency waveform utilising low and high-field separation. FAIMS was 
first reported in English in the 1990s,4 building upon initial fundamental development in 
Russia in the 1980s.4,60,61 FAIMS is a gas phase ion separation technique that exploits the 
non-linear differences of ions in high electric fields compared to low electric fields,35,62,63 the 
mechanism that govern separation are discussed in detail in Section 1.3.2. IMS differs from 
FAIMS as IMS uses low electric fields to separate ions on the proportional relationship 
between the ion velocity and electric field strength.7 FAIMS devices can have different 
electrode designs, mainly planar or cylindrical, which are discussed in more detail in Section 
1.3.3 along with a brief history of the development of FAIMS instrumentation.  
1.3.1. Principles of operation 
In a FAIMS or DMS separation, a continuous ion beam is subjected to alternating high and 
low electric field strength by applying an asymmetric radio frequency (RF) waveform across 
parallel electrodes,64 shown in Figure 1.4. This waveform is referred to as the dispersion field 
(DF) and exposes an ion to a high field (Eh) for a short amount of time (th), forcing the ion 
toward one of the electrodes, followed by a low field (El) portion of opposite polarity for a 
longer duration (tl), reversing the ion’s trajectory towards the opposite electrode: 
Ehth + Eltl = 0     Equation 1.13 
Different ratios of Ehth and Eltl and different waveform profiles have been investigated and a 
rectangular shaped waveform (Figure 1.4) of a 2:1 ratio of high and low electric field 
strengths is considered ideal to maximise FAIMS performance.64–67 Practically the 
rectangular waveform profile is difficult to generate at high frequencies and amplitudes and 
so the waveform is designed to satisfy Equation 1.13, which experimentally is a sinusoidal 
curve shaped waveform.68,69 The maximum value of the amplitude of the waveform (in Td) is 
the value of the dispersion field (DF). The asymmetric waveform, applied perpendicular to 
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the gas flow and direction of ion travel, causes the ion to undergo a saw-tooth like trajectory 
through the length of the mobility cell, as shown in Figure 1.4. The distance that the ion will 
be displaced during the high-field portion of the waveform is defined by Equation 1.14 and 
the distance travelled in the low-field portion is defined by Equation 1.15.65  
dh = KhEhth      Equation 1.14 
dl = K0E𝑙t𝑙      Equation 1.15 
As the asymmetric waveform ensures that Ehth and Eltl are equal in magnitude, if an ion has 
the same mobility in both the low and high fields (Kh=K0) then its α function is equal to 0 
(α=0) and the ion’s trajectory will be a saw-tooth motion down the centre of the electrodes 
without striking either along the way (green ion in Figure 1.4).  
 
Figure 1.4 Schematic of a planar electrode FAIMS device, showing the relationship between 
mobility, alpha function, dispersion field and compensation field 
 
However, all ions to some degree will experience a net positive or negative α function, where 
Kh ≠ K0, resulting in migration towards one of the electrodes (blue and pink ions in Figure 
1.4). Upon hitting the electrodes, the ion will become neutralised and not pass through the 
device to the detector. A direct current (DC) voltage, called the compensation field (CF), can 
be superimposed on the waveform to correct the ion trajectory allowing it to pass through the 
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electrodes and be detected. The α function (Equation 1.6) of an ion may be positive or 
negative in polarity and will define the CF needed to be applied to correct an ion’s trajectory 
through the FAIMS electrodes (Figure 1.4). Analytes are separated in FAIMS due to differing 
ratios of Kh to K0 which require different CFs to prevent their drift towards the electrodes. 
Therefore, the CF can be utilised in two modes of operation to either selectively transmit an 
ion of interest from the continuous ion beam entering the device by setting the CF to a 
particular value, or the CF can be ramped or scanned sequentially to transmit ions across a 
range of CF values to produce a FAIMS spectrum.64 The static CF mode is particularly useful 
for targeting chemical species of interest, whereas the scanning mode is more useful in the 
analysis of unknown chemical species.  
The CF is directly related to the alpha function on an ion under particular experimental 
conditions at a selected DF to correct ion trajectory through the electrodes. However, the CF 
required will alter depending on the electric field strength and therefore amplitude of the RF 
waveform (DF). If the DF is changed a different CF will be required to transmit the ion as the 
α function is dependent upon E/N. Plots of CF vs DF can be particularly useful and are 
widely used to describe the behaviour of an ion across a spectrum of electric field strengths; 
examples of CF vs DF plots can be found throughout the results presented in this thesis in 
Chapters 2-5.  
In FAIMS ions are separated according to the electric field in a continuous ion beam, whereas 
in conventional drift tube IMS (below the low field limit) ions are separated temporally in 
discrete packets of ions.  
1.3.2. Differential mobility separation mechanisms 
The relationship between mobility and electric field strength described in Equation 1.5, can 
result in three types of behaviour, denoted A, B and C, which are largely governed by ion-
molecule interactions and can be viewed as ‘alpha curves’ plotting the determined α function 
vs electric field strength (Figure 1.5).65,70,71 Type A ions show an increase in ion mobility 
with increasing electric field strength (α > 0). Type B ions show an initial increase followed 
by a decrease in mobility with increasing field strength. Type C ions show a decrease in ion 
mobility with increasing field strength (α < 0). Nazarov et al. presented ways in which the 
field dependence of the mobility of ions could be understood.72 These mechanisms which 
direct ion behaviour will be discussed in this section, however it’s also worthy of note that 
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instrumental factors will also affect an ion’s mobility and shall be discussed further in Section 
1.5. 
 
 
Figure 1.5 Three general shapes of alpha curves that indicate the different types of ion-molecule 
interactions that can occur. The curves portray the change in an ion’s differential mobility as 
the amplitude of the RF waveform is increased. The field strength (E) is normalised to the 
background gas density (N) and expressed in Townsends (Td) [Reprinted with permission from 
B. Schneider, E. Nazarov, F. Londry, P. Vouros and T. Covey, Mass Spec. Rev., 2016, 35, 687-
737, © 2015 Wiley Periodicals, Inc., from John Wiley & Sons, Inc.] 
 
Clustering/declustering model 
Type A behaviour is generally understood to occur due to rapid clustering and declustering of 
an ion with neutral gas molecules in the low and high field portions of the asymmetric 
waveform respectively. Under the low-field portion of the waveform, the ion forms a cluster 
with small neutral molecules from the carrier gas via non-covalent interactions. The size of 
the cluster formed is dependent on the chemistry and structure of each ion and the carrier gas 
neutral molecules. As the waveform switches to the high-field portion, increased field heating 
caused by greater numbers of collisions with higher energy, cause the ion to decluster (or at 
least significantly reduce the extent of clustering). The removal of the neutral molecules 
results in a smaller CCS and increases ion velocity in the high field portion of the DF.72 The 
magnitude of this clustering/declustering effect is inversely related to the size of the ions 
(with the same charge) because a smaller ion will experience a larger relative change in CCS. 
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This results in a higher mobility of the ions in the high field portion and a net increase in 
mobility as the amplitude of the waveform increases with increasing field strength; that is to 
say as the DF increases the ion mobility increases with a positive slope on an alpha curve 
(Figure 1.5).74 Therefore, the α value of the ion increases as the DF increases.  
Chemical clustering/declustering using gas modifiers has been shown to provide dramatic 
changes in ion separation and can in some cases induce separation where none was 
previously observed.5,75–77 Moisture can affect the mobility of ions susceptible to hydration 
with increasing hydration numbers affecting the mobility, shown for organophosphorus 
monomers at moisture levels above 50 ppm causing an increase in mobility; however an 
increase in α was also observed below 50 ppm supporting the theory of clusters with neutral 
gas molecules.72,78 Ion-neutral clustering/declustering is also affected by the DF waveform 
frequency, reducing the significance of this separation mechanism in high frequency devices 
(such as the miniaturised FAIMS).79  
Hard-sphere interactions 
Type C behaviour can be explained based upon the simple concept of collisions of the ions, 
with little to no clustering, with the carrier gas and neutral molecules. This collision 
behaviour is usually observed or dominant with ions that either do not chemically form 
clusters or are larger in m/z and such the relative change in CCS from clustering is small 
(mass-to-charge > 300), or under purified inert transport gas conditions. During the high-field 
portion of the waveform, the high energy collisions result in the ion losing forward 
momentum and can be deflected backwards.73 This can also occur in the low portion of the 
field but to a lesser extent. The mobility is further decreased as the electric field strength 
increases and the collisions have greater energy, causing the alpha curve to have a negative 
slope (Figure 1.5) and the α value of the ion decreases as the DF increases.  
Field heating and conformational changes 
Another effect that can lead to Type C behaviour in ions is conformational switching, where 
field heating during the high-field portion of the waveform can cause ions to undergo 
structural changes such as adopting an unfolded conformation. The open conformation causes 
the ion velocity to reduce, due to an increased numbers of collisions from the larger relative 
CCS resulting in a decrease in ion mobility at high-field. This effect is heightened as the DF 
increases and causes the α value to decrease as the DF increases. The separation of ubiquitin 
conformers by Purves et al.80 and Shvartsburg et al.81 showed that collisionally heated 
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ubiquitin ions in the FAIMS device to some extent, conformer specific, unfold and the α 
value decreases as the DF increases (within the same charge state) exhibiting type C 
behaviour. The distortion of structure of unfolding labile molecules in this manner using the 
high electric field strengths in FAIMS can limit intact native-state protein structure studies, 
with IMS being preferable for these analyses in the literature, but FAIMS has shown valuable 
in increasing protein/peptide identification,82 and the separation of peptide isomers.83,84  
Dipole alignment 
Dipole alignment in FAIMS can theoretically occur in biomacromolecules with a permanent 
dipole moment of ~ 300-400 Debye at ambient temperature and pressure under the high 
electric field.85–87 This is usually only prevalent in large biomacromolecules, such as native 
proteins, that have a mass of ~30 kDa and greater, where the size of the dipole moment 
increases with protein mass.88 Ion mobility is usually defined by an ions average CCS with 
free rotation to permit a number of different orientations, however a dipole moment can 
impose a certain orientation (in the direction of E) which, under the high field portion of the 
waveform in FAIMS, will define the mobility instead of the average CCS. An ion will have 
both average and directional CCS in low and high field conditions respectively. In the 
analysis of proteins by FAIMS, the combination of the high electric field strengths and field 
heating from the increased energy of collisions can result in protein unfolding which could 
hinder this separation mechanism. However, Shvartsburg in 2014 made a case for dipole 
alignment of unfolded ubiquitin protein conformers, where the native conformation had a 
lower dipole than the threshold for alignment.86 FAIMS microchips (ultraFAIMS) combined 
with mass spectrometry have been applied to the separation of ubiquitin and bovine serum 
albumin (small and large proteins) where the high electric field strengths of the FAIMS chips 
allowed a further probe into the dipole moment locking theory. These experiments by 
Shvartsburg et al.89 showed that for all charge states ubiquitin (small protein) exhibited type 
C behaviour, whereas bovine serum albumin (large protein) exhibited type A behaviour.  
Combinations of mechanisms 
The actual mechanism by which ion mobility is affected by field strength resulting in the 
separation of ions, may actually be due to a combination of mechanisms and dependent upon 
a number of factors including the chemical nature of the analytes, the size, shape and charge, 
ion-molecule interactions and the non-linear dependence of ion velocity. These mechanisms 
were summarised as falling under the following categories by Nazarov et al. in 200672: elastic 
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scattering due to polarisation interaction (dipole moments), resonant charge transfer, 
scattering due to direct “contact”, clustering and declustering of ions, and change in structure 
due to effective ion temperature or strong RF electric field. Changes in ion structure due to 
the effective temperature of the ion under the high-field portion of the RF waveform could 
modify the conformation or dipole moment of the ion, or even induce fragmentation of ions 
or cause non-covalently bound structures to dissociate.72,85,90–92  
Type B behaviour (Figure 1.5) is generally considered to be due to a combination of 
mechanisms. One understanding is that weakly bound cluster mechanisms dominate initially, 
but as the electric field strength increases the extent of clustering lessens and the collision 
(hard-sphere interactions) mechanism turns the slope of the alpha curve negative. Another 
possible combination is that polarisation or dipole alignment affects can increase effective 
CCS by interactions between the ion and neutrals to produce a less pronounced clustering 
effect, which is then surpassed by the collision mechanism via hard sphere interactions as the 
field increases further. Schneider et al.74 investigated a range of low molecular weight species 
to show that FAIMS is a balance between the clustering model and the hard-sphere scattering 
model. Where the clustering model dominates with polar carrier gases and modifiers and type 
A behaviour is observed, and in the absence of polar modifiers, mainly in helium, type C 
behaviour is observed.  
Few predictive models are capable of accurately predicting differential ion mobility as there 
are a large number of interacting parameters that can affect the mobility of an ion. One 
method for determining the α function is using a spectrometer of ion mobility increments 
(SIMI).93 A comprehensive attempt to explain FAIMS theory without the α function was 
made by G. Spangler, to estimate where an ion would appear in the CF spectrum.94 Volmer’s 
group have developed a means of CF predictions based on linear regression calibration data 
from a homologous series of alcohol-based modifiers and other physical and chemical 
parameters considered; accuracies between 97-99% were achieved for a set of homologous 
alkylbenzoic acids.95 Simulation of ion behaviour in FAIMS with α-based calculations that 
take into account behaviour with different waveform shapes and chemical effects are 
presented by Prasad et al. and Tang et al. using the SIMION program.96,97 Schenider et al. in 
a recent review of differential mobility spectrometry present a new excel-based simulation to 
calculate the α function for specific ions.73 Research continues in the area of mobility 
prediction in FAIMS, however the best approach at present for determining the FAIMS 
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characteristics and separation potential of new analytes is to determine differential mobility 
experimentally.  
1.3.3. FAIMS instrumentation 
In the mid-1990s, after initial development across Russia, the further development of FAIMS 
instrumentation followed two paths with different electrode geometries: planar (Figure 1.6) 
and cylindrical (Figure 1.7).4,61 The first cylindrical device originated in Siberia and was 
transferred to Pittsburgh, Pennsylvania, to the Mine Safety Appliances Company.98 This 
developed further a decade later in the research group of Roger Guevremont and was 
renamed FAIMS after originally being called ‘Field ion spectrometers’.65,68,70,99,100 With the 
development of electrospray ionisation (Section 1.4.3) these cylindrical devices were 
incorporated with mass spectrometry by Ionalytics which subsequently became part of 
Thermo Fisher Scientific.101,102 Concurrently the second team located in Siberia and 
Tashkent,103 worked on the development of planar devices originally called ‘Drift 
spectrometers’ which later became known as DMS.62,72,73,104 These planar devices were 
further developed through the research group of Gary Eiceman at New Mexico State 
University,5,105–107 and became the basis for the development of the core Sionex technology 
which is now commercially available as the AB Sciex planar SelexION.108,109 The names 
FAIMS and DMS were now used interchangeably for both types of devices by various 
research groups and will be referred to as FAIMS for the remainder of this discussion. 
Advances in the field of micromachining led to the development of the miniaturised chip-
based planar FAIMS which can be used as a standalone device (Lonestar VOC analyzer) or 
the ultraFAIMS combined with mass spectrometry, by Owlstone (Owlstone Medical Ltd) in 
Cambridge, UK.110 Other groups that made significant either developments of 
instrumentation or use thereof for novel applications include the Pacific Northwest National 
Laboratories,111–113 the University of Florida,76,114 the University of North Carolina,115 
Northeastern University,77,116–118,79 and Loughborough University. 119–124  
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Figure 1.6 Generic schematic of a planar FAIMS electrode design 
 
 
Figure 1.7 Generic schematic of a cylindrical FAIMS electrode design 
 
The theory and mechanisms of separation (Section 1.3.2) in both planar and cylindrical 
geometries are the same, but the two geometries impart different analytical properties that 
warrant distinction. Other FAIMS design geometries exist in literature but their performance 
characteristics largely fall under the two categories of planar and cylindrical.125,126 Both 
geometries conventionally consist of two electrodes across which the electric field is applied 
with the analysis region between the two electrodes; planar devices consist of two flat 
electrodes, whereas cylindrical devices usually consist of concentric inner and outer 
electrodes where the electric field is applied to the outer electrode.  
Planar geometries (Figure 1.4 and Figure 1.6) have the benefit of being able to analyse both 
positive and negative polarities simultaneously due to the uniform distance between the 
electrodes, utilising opposite polarity faraday plates for detection as a standalone device 
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(Figure 1.6).127 Cylindrical FAIMS devices (Figure 1.7) can have greater ion transmission 
than planar devices due to ion focussing effects from the non-uniform field at different radial 
locations causing focussing of the ions to the same spatial position, resulting in a focussed ion 
beam and reduced losses of ions to the electrode walls.100,128 However, cylindrical devices 
can only be operated in one polarity at a time due to defocussing effects that occur when 
switching polarity, which do not affect all ions equally. No focussing of the ion beam occurs 
in planar devices, allowing the option for polarity switching, as when the electric field 
strength increases so does the velocity of the ions; but ion transmission can be reduced 
through the device due to increased energy collisions with more ions being scattered and 
neutralised as a result.128  
The Owlstone microchip FAIMS (Figure 1.8) features planar parallel electrodes with gap 
heights of 35-100 µm and ion path lengths of 300-700 µm, enabling ion residence times 
between 50 and 250 µs.122,129,130 The short ion path length in the miniaturised FAIMS can 
reduce ion dispersion effects within the device and allows fast scan cycle times, with reduced 
power demands.131 The small gap height of the device generates high electric field strengths, 
greater than any other device, without causing electrical breakdown of the transport gas up to 
DF 320 Td or 60 kV cm-1. The short ion residence time enables fast scanning and decreases 
the time for ion loss from diffusion effects to occur. The waveform frequency is 22-27 MHz 
compared to other devices ~3 MHz, meaning the ions experience a comparable number of 
asymmetric waveforms as other devices even with shorter ion residence times.  
The Owlstone ultraFAIMS interface,132 used throughout this thesis, allows incorporation of 
the planar FAIMS chip with existing mass spectrometers, in this case a time-of-flight mass 
spectrometer which is discussed further in Section 1.5. The Owlstone ultraFAIMS has been 
interfaced to LTQ ion trap MS (Thermo Fisher) and 6230 TOF MS (Agilent 
Technologies),119,130 see Section 1.5 for a further detailed description of the Agilent interface 
used in this thesis. The FAIMS chip used in this thesis is composed of parallel electrode 
channels (Figure 1.8) of trench length 78.1 mm and a gap size of 100 µm, with an ion path 
length of 700 µm.  
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Figure 1.8 (a) Owlstone miniaturised chip-based FAIMS, and (b) schematic diagram of the 
FAIMS chip showing the ion direction of travel through the device 
 
1.3.4. Effects of instrumental parameters on FAIMS performance 
The design of FAIMS/DMS devices varies between research groups and commercially 
available devices, with no particular ratio of dimensions or RF frequency or amplitude that 
provide ideal performance. Performance characteristics that can be affected by device design 
include the resolving power, peak capacity, scan speed and sensitivity. These are all 
determined by factors including the gap height, electrode width and length, ion residence 
time, ion transmission efficiency, and the amplitude and frequency of the RF waveform.73 
The principles of instrumental design that can affect FAIMS performance described below 
are mainly focused on planar geometry as this is the geometry of device used throughout the 
work presented in this thesis.  
The scan speed of a FAIMS device is limited by the ion residence time within the device 
electrodes, as the system cannot scan or jump from CF to CF faster than the time it takes ions 
to transit the cell. The residence time (τ) of ions can be calculated using73: 
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τ =
lwh
Q
     Equation 1.16 
Where l is the electrode length, w is the electrode width, h is the gap height between the 
electrodes and Q is the volumetric flow. Ion residence times for planar and cylindrical 
geometries are typically ~1 ms and ~100 ms respectively. The length and width of the 
electrodes can be varied to control the ion residence time, however as a general rule the width 
should be at least three times the gap height to minimise the defocussing effects of static 
charge. The greater the ion residence time the longer the ions will be subjected to the 
influence of the electric fields, increasing resolution and selectivity; however, the increased 
residence time also allows for more random collisions of ions with the neutral carrier gas 
leading to greater losses to the electrodes and decreasing sensitivity.  
In general, increasing the dispersion field or electric field strength will increase resolving 
power and peak capacity by amplifying the α function. The higher the amplitude of the high 
field portion of the waveform the more energetic the separation mechanisms will become, 
with declustering becoming more efficient and hard sphere collisions more energetic. The 
limitation of increasing the electric field strength is the electrical breakdown of the transport 
gas between the electrodes, where the voltage cannot be increased infinitely as when the 
medium (the carrier gas) between the electrodes exceeds the ‘breakdown voltage’ the 
medium will become electrically conductive and can form an arc between the electrodes, 
which can be described by Paschen’s law.133 Smaller gap heights can accommodate higher 
field strengths, due to an increase in the electrical breakdown threshold.129 The highest 
reported electric field strength of any FAIMS device was achieved using the Owlstone 
microchip FAIMS device of 323 Td in the work presented in this thesis in Chapter 2.92 High 
dispersion fields have a compound-dependent effect on ion transmission. Labile compounds 
can be fragmented due to energetic collisions which is referred to as field heating. 
Oscillations of the ion along its saw-tooth trajectory (Figure 1.4) through the electrodes can 
result in increased collisions with neutrals and increased effective temperature or internal 
energy, which can in turn result in fragmentation of the ion. These effects have been reported 
in literature using different gap height devices.66,74,92,129,134 These oscillations can also result 
in the ion being neutralised at the electrodes in a small gap height device, due to a larger 
radial amplitude. The term ‘effective gap’ can be used to describe these effects and is defined 
as the gap height of the electrodes minus the portion occupied with radial oscillations of the 
ions (maximum distance travelled by the ion of interest during a period of the asymmetric 
waveform). To minimise ion losses, the radial oscillations should be less than 10% of the gap 
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height. The effective gap height can be improved using higher RF frequencies to reverse the 
motion of an ion before it hits the electrodes.66,73  
The gap height has the most influence on performance characteristics as it influences the 
other dimensions and electronics required (as the electric field is applied across the gap 
between the electrodes); gap heights vary from 35 µm to 2 mm, with the range 35 to 100 µm 
for miniaturised devices, to 0.5 to 1 mm for planar FAIMS and 1 to 2 mm for cylindrical 
FAIMS devices.129,135 The available CF range is determined by the gap height, where larger 
CF ranges and greater resolving power are possible at larger gap heights. However, these 
generally require longer ion residence times for separation and broader peak widths than 
smaller gap height devices. It is possible to obtain similar small peak widths in larger gap 
height devices to those of smaller gap height devices by increasing the length and width of 
the electrodes. However, this involves implications on the RF power supply requirements and 
a trade-off between resolving power and long ion residence times and reduced ion 
transmission. Resolving power values as high as ~400 have been achieved by Shvartsburg in 
the analysis of protein conformers using a device with a gap height of 1.88 mm.86 Smaller 
gap height devices, such as the Owlstone microchip FAIMS, enable access to high electric 
field strengths (E/N as high as 320 Td) with short ion residence times to balance speed, 
resolving power, peak capacity and ion transmission. These high electric field strengths in 
conventional larger gap height devices are unattainable due to electrical breakdown effects.  
Balancing resolving power, ion transmission and scan speed can result in a compromise 
between sensitivity and selectivity for optimised analytical performance, with the most 
important instrumental parameters to optimise being the effective gap (g) and the ion 
residence time (τ). The analytical quality (A, Equation 1.17) as defined by E. Krylov,136 is 
based upon the inverse relationship between the ion transmission coefficient (G, Equation 
1.18) and peak width (W, Equation 1.19).  
A =
G
W
       Equation 1.17 
G = exp (
τDπ2
g2
)     Equation 1.18 
W =
g
Kτ
      Equation 1.19 
Where G corresponds to ion flux at the inlet and outlet of the analytical channel, D is the ion 
diffusion, and W is the ion displacement during the residence time to the effective gap. Plots 
of analytical quality against ion residence time (Figure 1.9 (a)) show that optimum ion 
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residence time changes with electrode gap size, and that different mobilities (Figure 1.9 (a)) 
are also affected by the analytical quality and ion residence time, implying an optimum 
condition for one set of compounds may be not be the optimum for another set of 
compounds.  
 
Figure 1.9 Modified FAIMS analytical quality defined as ratio of the ion transmission 
coefficient and peak width in dependence of the residence time for (a) different distances 
between the separation electrodes (ion mobility 2 cm2/Vs) and (b) for different mobilities 
(distance between separation electrodes 0.75 mm). Separation field amplitude 45 Td; frequency 
1.25 MHz; fly back waveform were used for the calculations [Int. J. Ion Mobil. Spectrom., 
Differential mobility spectrometer: optimization of the analytical characteristics, 15, 2012, 85-
90, E. Krylov, © Springer-Verlag 2012, With permission of Springer] 
 
The different designs of FAIMS devices each have advantages and disadvantages which need 
to be applied appropriately for the particular application. As instrumental parameters, 
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especially electrode geometry, affect all other considerations and cannot be changed 
following the fabrication of the FAIMS system. However, the mobility of ions in the FAIMS 
will also be affected by experimental parameters, and the effect that these can have on 
FAIMS performance is discussed in the next section and both can and will need to be 
optimised in the development of applications.  
1.3.5. Effects of experimental parameters on FAIMS performance 
The development of an experimental set of parameters for a particular application using 
FAIMS includes optimising the DF and CF and selecting a mode of operation for the FAIMS. 
This would initially include a two-dimensional scan of the DF and CF and then selecting the 
appropriate mode of operation whether that be a refined two-dimensional scan or fixing the 
DF and scanning the CF, or selecting fixed parameters for both, or stepping between a small 
number of fixed parameters. Experimentally there are other factors which can affect the 
FAIMS performance, including temperature, pressure, transport (or carrier) gas flow and 
composition (including gas modifiers), and adduct formation. Each of these factors can affect 
the FAIMS characteristics of separation, sensitivity and selectivity by affecting the ion 
residence time and peak position (mobility), resolution and peak capacity (peak width) and 
ion transmission (peak height).  
Temperature and pressure 
The temperature and pressure of the carrier gas in FAIMS can affect the peak position, height 
and width. Temperature has a larger effect on the FAIMS CF performance than pressure. This 
was shown by Krylov et al. in 2009,137 in the analysis of methyl salicylate where pressure 
changes resulted in large changes in peak height but only small positive changes in CF peak 
position. Whereas temperature had a much larger effect causing a positive peak shift of ~0.3 
Td in the CF peak position. An increase in the separation of the chemical warfare nerve agent 
sarin dimer and monomer ions from the background, by a shift in the compensation voltage 
of the dimer from -6.8 to -2.3 V and the monomer from -4.0 to -0.6 V, was observed by 
Maziejuk et al. in 2013 by increasing the carrier gas temperature from 50 to 80°C.138 The first 
known example of a study into the effects of temperature on the mobility of ions was reported 
in 1989 by Karpas et al.139 on the effect of temperature on the separation of protonated amine 
ions over a range of 87 to 250°C. Control of the carrier gas temperature can allow stability of 
the FAIMS transmission and CF position and optimal temperature settings can be explored 
using DF/CF plots, with the optimum temperature dependent on the application.102 It is 
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important to note that exploration of the temperature may also influence factors such as 
ionisation efficiency which may adversely affect the FAIMS transmission and separation.  
Carrier gas flow 
As discussed previously decreasing the gap height of the electrodes can increase the electric 
field strengths achievable, but larger gap sizes can have increased resolution. However, if the 
carrier gas flow is not adjusted accordingly then the ion residence time and transmission will 
be adversely affected. Even though gas flow and gap height are independent, both need to 
considered when optimising parameters as both the gas flow rate and distance between the 
electrodes govern residence time and effective gap.136 The effect on the ion residence time 
and ion transmission is more critical for smaller electrode gap heights.136  
Carrier gas composition and modifiers 
The selection of carrier gas can affect the separation, selectivity, and transmission of analytes 
through the FAIMS device. Typically N2 or air are used as the carrier gas in FAIMS, but 
other gases include He, O2, CO2, N2O, and SF6.
74,140 Different gases will interact with ions in 
different ways depending on the size and polarisability of the gas molecules. Mixtures of 
different gases, such as nitrogen mixed with He/CO2 or even H2 have also been explored.
141 
Increasing the size and polarisability of the gas composition decreases the mobility of an ion 
due to increased collisions which can improve separation, resolution and transmission.  
Gas modifiers are solvent molecules that are introduced into the carrier gas in the vapour 
phase. These can influence the interactions of the analytes with neutral molecules in the gas 
phase, which can change the relative CCS of the ion and therefore influence a larger change 
in mobility between the low and high field whilst maintaining peak widths.73,74,76,114 The 
improvement in peak capacity that can be obtained by using gas modifiers is demonstrated in 
Figure 1.10,73 where the peaks have maintained their peak width but the improvement in the 
coverage of the analytical space from 100% N2 to the addition of modifier is clear. This also 
demonstrates how the peak capacity can be improved using different modifiers as the peak 
capacity is improved using isopropanol in comparison to acetonitrile. These approaches have 
been utilised for the analysis of a range of analytes including explosives,5 isomers,114 and 
proteins.113  
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Figure 1.10 FAIMS spectra of a 54 component small-molecule mixture (molecular weight range 
from 115-530 Da) under different transport gas conditions: (A) 1.5% isopropanol in N2, (B) 
1.5% acetonitrile in N2, and (C) 100% N2 [Reprinted with permission from B. Schneider, E. 
Nazarov, F. Londry, P. Vouros and T. Covey, Mass Spec. Rev., 2016, 35, 687-737, © 2015 Wiley 
Periodicals, Inc., from John Wiley & Sons, Inc.] 
 
Adduct formation 
The addition of salts can promote cation/anion adduct formation and can facilitate or improve 
FAIMS separation in comparison to conventional protonated/deprotonated ion analysis. In 
positive ion mode ammonium and metal adducts are commonly used, including but not 
limited to: Li, Na, K, Rb, Cs, Ag.142–146 In negative ion mode chloride and acetate adducts can 
be used.142 This approach can be particularly useful in the separation of isomers and isobars 
where different structures can form different adducts or the adduct can change the structure or 
relative average CCS and therefore alter the mobility of the ion-adduct compared to the 
protonated ion. Separation of phospholipid isomers was reported utilising silver adduction by 
Maccarone et al. in 2014.143 The study of carbohydrates and their conjugates by mass 
spectrometry can be difficult to a large proportion of isobaric ions with biologically important 
differences that can be indistinguishable. Gabryelski and Froese, in 2003,142 reported that by 
utilising the Cs+ adduct little separation for disaccharide isomers was achieved, however the 
negative ion adducts of trichloroacetate achieved good separation. This approach using 
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different adducts to influence FAIMS separation is utilised and investigated further in 
Chapter 4 of this thesis in the separation of steroid metabolite isobars.  
1.4. An introduction to mass spectrometry and liquid chromatography 
Mass spectrometry (MS) is a widely used technique in which ions in the gas phase are 
separated according to their mass-to-charge ratio (m/z) and are detected in proportion to the 
abundance of each ion which is measured and recorded. MS is a powerful tool with 
unparalleled sensitivity, detection limits and speed that has been incorporated into a diverse 
array of analysis in many fields including: pharmaceutical, biological, environmental, 
forensic science, physics, and many more. The main components of a mass spectrometer 
consist of sample introduction, ionisation, ion separation, detection and data analysis (Figure 
1.11), with the mass analyser and detector maintained under vacuum. The techniques used in 
the thesis for the ion mobility-mass spectrometry (IM-MS) workflow presented here are 
discussed in the following sections.  
 
Figure 1.11 Schematic of the typical ion mobility-mass spectrometry workflow 
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MS has evolved from the first discovery of ‘positive rays’ and the construction of the first 
MS by J.J. Thompson in 1912 (then called a parabola spectrograph) and the ensuing 
development by A.J. Dempster and F.W. Aston of ionisation sources and ion focussing 
techniques,147–149 to become one of the most important analytical techniques in use today. MS 
has continued to develop and flourish from the early physicists’ laboratories to commercially 
available instruments widely used across all areas of science and discovery. The development 
of a broad range of sample introduction methods, a multitude of different ionisation 
techniques, and the possibility to combine multiple mass analysers, allows for ever more 
diverse targeted and untargeted applications. The development of high-throughput analysis 
workflows has paved the way to meet the needs of both targeted and untargeted ‘omics 
analyses with an ever growing potential.  
1.4.1. Sample introduction to the mass spectrometer 
The introduction of samples into a MS can be achieved using a variety of both gas and liquid 
phase techniques. Throughout the research presented here liquid sample introduction methods 
used include direct infusion (DI) via syringe pump and high performance liquid 
chromatography (HPLC). The simultaneous introduction of sample using direct syringe 
infusion is a fast and simple technique, however can result in the suppression of analytes 
without pre-separation. HPLC is the most widely used liquid phase separation technique, 
where analytes are separated based upon interactions with the stationary phase of a column as 
a liquid flow carries the sample through the chromatographic column and into the mass 
spectrometer ionisation source.  
1.4.2. High performance liquid chromatography 
The complex nature of biological samples can require pre-separation prior to mass 
spectrometric analyses. HPLC is used to separate components of a liquid mixture. HPLC 
hyphenated with mass spectrometry (LC-MS) is a powerful combination with robust dual 
separation of analytes by retention and m/z, with easy hyphenation and efficient ionisation 
using electrospray ionisation. The versatility offered by liquid chromatographic techniques, 
such as reversed phase (RP) and hydrophilic interaction chromatography (HILIC) used in this 
thesis, for the separation of chemically diverse compounds stems from the control of a range 
of variables including stationary phase composition, solvent selection, and choice of 
additives, pH, and temperatures.150,151 Hyphenation of MS with HPLC, or chromatographic 
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techniques, whilst improving the separation of analytes can however result in an increase in 
analysis time, cost and sample preparation.  
All chromatographic separations are based upon the principle that an analyte is in equilibrium 
between two immiscible phases, the stationary phase and the mobile phase, and the 
equilibrium constant is termed the partition coefficient (K); defined as the concentration of 
the analyte in the stationary phase divided by the concentration of the analyte in the mobile 
phase. K is determined by the nature of the analyte, the mobile phase, the stationary phase 
and temperature and is independent of the concentration of the analyte (or any other analytes 
in the sample). The retention time (tR) of an analyte is the time taken between the injection of 
a sample to the analyte peak reaching the detector. The retention factor (k’) of an analyte can 
be calculated using the time taken for a component that does not interact with the stationary 
phase (unretained component, tm) to reach the detector: 
k′ = (tR − tm) tm⁄      Equation 1.20 
The retention factors of analytes (A and B) can be used to calculate the selectivity factor (α) 
to describe the separation between two species:  
α = k′B k′A⁄       Equation 1.21 
The selectivity factor does not however take into account the widths of the chromatographic 
peaks, so a more useful measurement of separation is the resolution (R), defined for two 
species A and B: 
R =
2(tRB−tRA)
WbA+WbB
     Equation 1.22 
Where Wb is the width at the base of the peak. Baseline resolution is achieved when R ≥ 1.5.  
The efficiency of an LC column can be expressed as the number of theoretical plates (a 
theoretical representation of the column as a series of sections or plates), where the larger the 
number the more efficient the column. The number of plates (N) can be determined 
experimentally: 
N = 16 (
tR
Wb
)
2
= 5.54 (
tR
W1 2⁄
)
2
   Equation 1.23 
Where W1/2 is the peak width at half the height of the chromatographic peak. N can be used 
to calculate the plate height (or the length of each section), called the height equivalent to a 
theoretical plate (H), where the smaller the more efficient the column: 
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H = L N⁄       Equation 1.24 
Where L is the length of the column. The Van Deemter equation (Equation 1.25) can be used 
to explain the various contributions to H: 
H = A + B u⁄ + Cstu + Cmou   Equation 1.25 
Where u is the mobile phase flow rate and A, B and C are terms that can affect the efficiency 
of chromatographic separations. Eddy diffusion (A) is where solute molecules of the mobile 
phase pass through the stationary phase at random causing broadening of the analyte band; 
this is affected by the packing uniformity and the particle size of the stationary phase. 
Longitudinal diffusion (B) is where the concentration of analyte is less at the edges of an 
analyte band passing down the column than at the centre, causing the analyte to diffuse out 
from the centre; this is affected by the diffusion coefficient of the analyte in the mobile phase 
and a hindrance factor caused by the stationary phase particles. Non-equilibrium mass 
transfer (C) is where the analyte takes time to equilibrate between the mobile and stationary 
phases, which could cause analyte in the mobile phase (Cmo) to move ahead of analyte which 
has interacted with the stationary phase (Cst); this effect becomes worse with increasing 
mobile phase flow rate. Cst is determined by the analyte diffusion coefficient in the stationary 
phase and the effective film thickness of the stationary phase where higher efficiencies are 
obtained with a thin film thickness. Cmo is determined by the diameter of the stationary phase 
particles (diffusion distance) and the analyte diffusion coefficient in the mobile phase where 
higher efficiencies are obtained with small particles sizes (small diffusion distances). The 
optimum mobile phase flow rate is at the smallest plate height.  
Resolution can be related to the number of plates in the column, the selectivity factor and the 
retention of two analytes: 
R =
√N
4
(
tRB−tRA
tRB
) =
√N
4
(
α−1
α
) (
1+k′B
k′B
)  Equation 1.26 
Resolution can therefore be improved by maximising all of these terms. Increasing N by 
lengthening the column can increase retention times and resolution. Reducing the size of the 
particles will also improve resolution, as demonstrated by ultra high performance liquid 
chromatography (UHPLC) where < 2 µm particles are utilised to obtain increases in 
resolution, sensitivity and speed of analysis compared to HPLC.152,153 The selectivity factor 
can be improved by changing the mobile phase composition, the column temperature, the 
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stationary phase or the addition of chemical modifiers to the stationary phase to induce 
chemical effects with the analytes.  
In HPLC, samples are injected onto a column and carried through the column by a mobile 
phase, with a flow up to 2 mL min-1, using a set-up as represented in Figure 1.12. A wide 
range of stationary phases is available and can be selected based upon their suitability 
depending on the analysis. Samples are separated and commonly detected using an ultra-
violet diode array or by MS. The techniques used in this thesis were reversed phase and 
hydrophilic interaction chromatography combined with mass spectrometric detection as 
described in the following sections.  
 
Figure 1.12 Representation of a high performance liquid chromatography experimental set-up 
 
Originally HPLC utilised a hydrophilic polar stationary phase (silica or polar bonded phase) 
with a strong affinity for hydrophilic compounds where hydrophobic compounds would elute 
first from the column. Elution of the hydrophilic compounds was achieved by increasing the 
polarity of the mobile phase. This is called normal phase chromatography.  
Reversed phase is the opposite of normal phase in that a hydrophobic stationary phase 
(chemically bonded to the surface of a silica particle support) is used to retain compounds 
based on hydrophobicity. Common reverse phase stationary phases include alkyl chains such 
as C18 (most widely used), C8 and C4, cyano, phenyl and amino, in order of decreasing 
hydrophobicity or increasing retention of non-polar analytes. The mobile phase consists of 
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water and an organic solvent (most commonly used is acetonitrile and methanol) where 
elution of analytes is controlled by lowering the polarity of the mobile phase by increasing 
the organic solvent (up to 100% organic can be used when dealing with complex samples to 
ensure elution of all components). Solvent selection will affect the selectivity of the 
separation and therefore is an important consideration when optimising resolution.  
HILIC is a type of chromatography based upon a mixed mode of retention mechanisms, as it 
utilises a normal phase polar stationary phase with an aqueous-organic mobile phase, where 
the water is the ‘strong’ solvent causing elution of analytes. This technique is considered 
relatively new but dates back to the 1990s and was first described by A. Alpert.154 HILIC is 
compatible with MS and can be useful in applications where reversed phase is inefficient, 
such as samples with limited water solubility and very polar compounds that are not retained 
using reversed phase. In HILIC the stationary phase is hydrated with a slow-moving layer of 
water, as due to the polar nature of the stationary phase water molecules concentrate at the 
surface. The separation mechanism in HILIC is debated, however it is considered to be based 
mainly upon the differential partitioning of analytes between the mobile phase and the water-
enriched layer at the surface of the stationary phase.155 Stationary phases in HILIC can be 
divided into three main categories; neutral, a polar surface with no electrostatic interactions; 
charged, where the stationary phase contains anionic or cationic functional groups; or 
zwitterionic, where the stationary phase contains both anionic and cationic functional groups. 
In HILIC, acetonitrile is often used as the weak mobile phase eluent and water as the strong 
mobile phase, with starting water composition is usually in the range 2-5% water and can 
reach up to 40-70% water (dependent on column composition). However, the use of gradients 
in HILIC does include extended equilibration times, in comparison to reverse phase, to re-
equilibrate the column to the initial gradient composition.156,157  
1.4.3. Electrospray Ionisation 
The work presented in this thesis on the development of applications using FAIMS is based 
upon the FAIMS interfaced into the source region of an electrospray ionisation (ESI) source. 
Therefore, the principles of ESI are discussed below in this section. ESI is a ‘soft’ ionisation 
technique that was first reported by Dole et al in 1968,158 and further developed by Fenn et al 
in the 1980’s,159,160 that provides a means of ionising molecules intact from the liquid phase 
to produce gaseous phase molecular ions. ESI can produce intact protonated and metalated 
ions without fragmentation from which molecular weights can be determined and provides a 
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simple hyphenation to LC for the analysis of liquid samples which is of particular use in 
bioanalysis. There are three stages to ion formation in ESI: production of charged droplets at 
the electrospray capillary tip, shrinkage of the charged droplets due to solvent evaporation 
and charge-induced droplet disintegrations, and the mechanism from which gas-phase ions 
are produced from these very small charged droplets.161  
Liquid samples are introduced into the atmospheric pressure ESI source via a capillary flow, 
either by direct infusion or HPLC (see Sections 1.4.1 and 1.4.2), where the analytes in the 
solution are passed through a narrow tube which is subjected to a high voltage (1-5 kV). The 
applied voltage, either positive or negative depending upon the application, creates a strong 
electric field (106 V m-1) which results in the formation of ions at the tip of the capillary 
(Figure 1.13 (a)).162 Ions of the opposing charge will migrate towards the capillary walls and 
be neutralised, resulting in a conical liquid meniscus at the tip with a net charge (Figure 1.13 
(b)), called a Taylor cone.163 When the distorted droplet is subjected to a sufficiently high 
field the Taylor cone will become unstable and generate an electrospray plume (Figure 1.13 
(c)) of small droplets of solvent with a net charge containing analyte ions. Solvent 
evaporation aided by heated gas flows maintains the charge of the ion droplet whilst reducing 
the size until the point that Coulombic repulsion is equal to surface tension at the ‘Rayleigh 
limit’. Exceeding the Rayleigh limit results in a process of Coulombic fission producing 
smaller and smaller ions until droplets of ions ~10 nm in diameter are reached. The cone-jet 
mode as represented in Figure 1.13 (c) is typical of the stable mode of operation for the 
production of ions.164 
 
Figure 1.13 Representation of the formation of a Taylor cone 
 
The mechanism for formation of single gas phase ions is however widely debated, with two 
proposed methods (Figure 1.14) called the charge residue model (CRM) and the ion 
evaporation method (IEM).165 The CRM was proposed by Dole et al which suggests that a 
series of fissions and solvent evaporation continues until a single ion remains in the very 
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small droplet and is converted to a single gas phase ion.158 The IEM suggests that increased 
density in the primary droplets causes ions to overcome the surface tension of the droplet, due 
to Coulombic repulsion, and be ejected as a single gas phase ion.166 The mechanism by which 
gas phase ions are produced is believed to be a combination of the methods. 
 
Figure 1.14 Ion formation mechanisms in electrospray ionisation; the charge residue model 
(CRM) is depicted at the top and the ion evaporation method is depicted at the bottom 
 
As ion formation in ESI is a result of the accumulation of charge and desolvation processes, 
singly charged and multiply charged ions can be formed in both positive and negative ion 
modes. Ionisation in ESI is primarily through the formation of ions through proton transfer, to 
form [M+nH]n+ in positive ion mode or [M-nH]n- in negative ion mode (where n=1 for small 
molecules), or adduct formation [M+Cat]+, where Cat is a cation such as NH4
+, Na+, K+, Li+, 
Ag+, Cs+. The ionisation efficiency of target compounds will be determined by an ion’s 
ability to carry a charge, competitive gas phase proton affinity and the surface activity in the 
solvent analyte. This can lead to differences in the responses of ions even in an equimolar 
mixture under the same experimental parameters. The use of HPLC can separate the analytes 
prior to ESI and minimise competitive ionisation from complex mixtures such as biological 
matrices. The ESI approach is a ‘soft’ technique with little or no fragmentation of ions and 
information regarding the liquid phase chemistry can be retained. As a result, ESI is one of 
the most widely used ionisation techniques for many different analytical applications.  
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Nanoelectrospray ionisation 
Nanoelectrospray ionisation (nESI), sometimes referred to as nanospray, is a smaller ESI 
interface where less analyte is required as the spray tip has a much smaller diameter resulting 
in a more efficient generation of gas-phase ions, as smaller droplets are formed. 167,168 
Smaller droplet results in less solvent evaporation required and fewer fissions, leading to 
rapid ionisation and the tip can be placed closer to the orifice for entry to the mass 
spectrometer, allowing a greater percentage of ions to be transmitted and detected. Therefore, 
nESI is more sensitive to lower concentrations. nESI differs from ESI as no syringe pump is 
required as the applied electric field on the tip of capillary induces a ‘self-flow’ which is 
controlled by the diameter of the tip.161,169 nESI is more tolerant to a wide range of solvent 
compositions with an increased stability of spray when dealing with aqueous and high salt 
content samples.169  
1.4.4. Mass analysers 
Post ionisation in the source region, the ions are passed through a series of electrical lenses to 
the mass analyser region, which separates ions in a vacuum accoriding to their mass-to-
charge ratio (m/z). The gasoues ions formed in the ionisation region are separated in space 
and time in an electric or magnetic field according to their m/z are then transferred to the 
detector under vacuum, which minimises ion collisions with neutral molecules. There are 
many varied types of mass analyser available, however the focus in this thesis described 
hereafter will be on the techniques used in this research, which was primarily time-of-flight 
(TOF) mass spectrometry, with quadrupole (Q) mass spectrometry used also.  
Time-of-flight  
The concept of time-of-flight (TOF) mass spectrometry was first introduced in 1946 by 
Stephens titled ‘A pulsed mass spectrometer with time dispersion’,170 with the first reported 
construction of a TOF by Cameron and Eggers called a ‘Velocitron’ in 1948,171 and the first 
commerical linear TOF instrument was designed by Wiley and McLaren in 1955.172 
Significant progress in electronics allowed for the fast data acquisition and processing 
allowing TOF to be compatible with other pulse based techniques, such as laser desorption 
ionisation and secondary ionisation mass spectrometry.173  
In a TOF mass analyser ion separation and m/z determination are based upon the velocity of 
the ions, after initial acceleration, as they drift through a flight tube under vacuum. As all of 
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the ions gain the same kinetic energy, the m/z is determined from the time taken (flight time 
(t)) to reach the detector grid at the other end of the flight tube, as the ions drift through an 
electric field free region towards the detector (see Section 1.4.5). Smaller and more highly 
charged ions will be accelerated at higher velocities than heavier and lower charge state ions. 
The ions are accelerated by a potential (Vs) and its electric potential energy is converted to 
kinetic energy (Ek): 
Ek = zeVs =
mv2
2
     Equation 1.27 
Where z is the charge residing upon the ion, e is the fundamental unit of charge (1.602 x 10-19 
C), v is the velocity and m is the mass of the ion. An ion’s velocity is therefore defined as: 
v = √
2zeVs
m
       Equation 1.28 
After initial ion acceleration, the ions travel at a constant velocity to the detector and the time 
(t) for the ion to cover the length of the flight tube (L) can be described as: 
t =
L
v
       Equation 1.29 
The m/z of an ion can be caluclated by substituting for v in Equation 1.29 using Equation 
1.28: 
m
z
= t2 (
2eVs
L2
)     Equation 1.30 
However, in practice m/z ratios are measured and calibrated from the flight times of reference 
compounds (a and b) of known molecular weight for a given set of conditions: 
𝑚 𝑧⁄ = at2 + b     Equation 1.31 
Resolution (R) in TOF is derived from the relationship between m/z and flight time: 
R =
m
∆m
=
t
2∆t
     Equation 1.32 
Where Δm and Δt are the differences in mass and flight time for two adjacent peaks.174  
Early design linear flight tube TOFs suffered from poor resolution where ions with the same 
m/z (isobaric) can arrive at the detector grid in broad poorly resolved peaks as the distribution 
of the flight times were wide due to differences in kinetic energy resulting in variation of the 
intial velocity, and spatial and temporal distributions of the ions as they enter the flight tube. 
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One technique to improve resolution in TOF-MS was the introduction of a method called 
delayed pulse extraction, introduced shortly after the first commerical instruments by Wiley 
and McLaren in the 1950s. Delayed pulse extraction introduces a delayed pulse after allowing 
ions to enter and separate into the field-free region, to allow the initally less energentic ions 
to receive more kinetic energy and therefore corrects the dispersion of ions with the m/z so 
that they arrive at the detector in a narrower time frame and improves mass resolution via a 
two-stage acceleration.  
A second approach to improving mass resolution in TOF mass analysers was the introduction 
of an ‘ion mirror’ by Mamyrin experimentally in 1973, termed a mass reflectron.175  The 
electrostatic reflectron acts as an ion mirror by deflecting ions back through the flight tube, 
with the ion source and detector on the same side on the flight tube, as depicted in Figure 
1.15. The reflectron consists of a series of equally spaced ring-electrodes and is positioned at 
the end of the flight tube. Ions with greater kinetic energy will penetrate further into the 
reflectron than ions with a lower kinetic energy, resulting in ions with higher energies 
spending a longer time in the reflectron and reduces the difference between the free-field 
flight times for ions of the same m/z to reach the detector. This focussing effect can therefore 
correct the kinetic energy spread of ions of the same m/z and improve mass resolution. 
Reflectron TOF mass analysers have greater resolution than a linear TOF and with an 
increased flight time also have improved ion separation, but the upper mass range and 
transmission are reduced in reflectron TOFs.173,176,177 
 
 
Figure 1.15 Representation of a single-stage reflectron TOF mass analyser, where the solid and 
partially filled circles are ions of the same m/z but the partially filled circle has higher initial 
kinetic energy; both ions are detected simultaneously 
 
39 
 
A third approach to improving resolution and the combination of continuous ion beam 
ionisation sources with TOF mass analysers is the approach of orthogonal acceleration. This 
is where a continuous ion beam, such as those generated in ESI, is periodically pulsed by an 
electric field in a perpendicular direction to the ion beam converting the continous beam into 
discrete ion packets which are pushed into an orthogonally configured TOF flight tube.178 As 
the packet of ions travels through the flight tube, the orthogonal accelerator is filled with new 
ions from the continuous ion beam, and this configuration therefore allows the pulsing TOF 
mass analyser to be combined with continuous ion beam ionisation sources. In this manner, 
ions in an orthogonal acceleration TOF acquire an increased kinetic energy and the velocity 
and temporal distributions are reduced therefore increasing mass resolution. The orthogonal 
acceleration approach can be combined with both linear and reflectron TOF drift tubes.  
Quadrupole 
Quadrupole (Q) mass analysers use an oscillating electric field to separate ions, from a 
continous ion beam, based upon differences in their trajectory through four parallel metallic 
rods (Figure 1.16), with a central channel to allow passge of ions.179 The opposing rods are 
connected in pairs with superimposed oscillating RF and DC voltages, with one pair 
positively charged and one pair negatively charged at any one time respectively:  
ϕ0 = +(U − Vcosωt)    Equation 1.33 
−ϕ0 = −(U − Vcosωt)                            Equation 1.34 
Where ϕ0 is the potential applied to the rods, ω is the angular frequency (in radians per 
second = 2πv, where v is the frequency of the RF field), U is the DC potential and V is the 
‘zero-to-peak’ amplitude of the RF voltage.179  
Ions are accelrated into the device through the central channel in the z-axis, where the 
superimposed voltage cause the ions to deviate in both the x-axis and y-axis. Ion trajectory 
and forward motion is maintained in the z-axis as long as the ion remains stable through the 
central channel. Typical operation of a quadrupole mass analyser will scan both RF and DC 
voltages, at a linear uniform rate, so that ions at different m/z will have stable trajectories at 
different times to act as a sequential filter over the entire mass range.179  
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Figure 1.16 Representation of a linear quadrupole mass analyser 
 
Tandem mass analysers  
Mass analysers can be used in combination or in tandem (MS/MS) to gain even more 
specificity and functionality. MS/MS allows selection of a ion (precursor) based upon m/z 
using the first mass analyser, then accelrates the ion to cause collisions with inert gas 
molecules to induce fragmentation of the ion. The fragments are then separated based upon 
m/z in the second mass analyser. Hybrid instruments such as these include triple quadrupole 
(QQQ) or Q-TOF mass spectrometers, with two mass analysers separated by a collision cell. 
Alternatively trapping mass analysers such as ion traps, can perform precursor ion selection 
and fragmentation in a single mass analyser.  
Collision induced dissociation (CID) and in-source CID 
Fragmentation of ions used in MS/MS by the collision of ions with a buffer gas in a collision 
cell to induce fragmentation of ions is a two-stage mechanism referred to as collision-induced 
dissociation (CID). An ion is energised by the conversion of translational energy from 
collisions with a buffer gas into internal energy, known as collisional activation, followed by 
fragmentation by vibrational dissociation.180 Ions are accelerated by a voltage to increase the 
number and kinetic energy of collisions with an inert buffer gas (He, N2, Ar) to convert the 
kinetic energy into internal energy which results in ion instability and the breakage of 
chemical bonds to fragment the ion. The fragment ions are then mass analysed and separated 
based upon their m/z. With initial pre-selection of a precursor ion, the detected mass spectrum 
is of the fragments of the precursor ion, known as the product ion spectrum of the precursor 
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ion. The product ion spectrum for an analyte can be very useful in the identification of 
chemical species as ions, even ions of the same m/z but different structures, may fragment 
into different fragment ions based upon the chemical structure of the ions and the bonds that 
break in the collision cell.  
Ions can be alternatively fragmented in a single mass analyser by elevated interface voltages 
in the intermediate pressure region between the ionisation source (ESI) and the vacuum 
region of the mass spectrometer.181 This is called in-source CID and results in fragmentation 
of all ions generated in the ionisation source. The elevated voltages can give the ions enough 
kinetic energy to increase the energy of collisions with the neutral gas molecules present in 
the ion optics regions as the ions are focussed towards the vacuum region of the mass 
spectrometer, resulting in bonds breaking in the same mechanism as CID in MS/MS analysis. 
However, this production of fragment ions from multiple precursor ions with no pre-selection 
can result in complicated and difficult to interpret mass spectra.123 Useful structural 
information can still be obtained using in-source CID, and can be especially useful when 
combined with pre-selection from FAIMS in the ionisation region (further discussed in 
Section 1.5).120,121 
1.4.5. Detectors 
Post mass analysis in the mass spectrometer a detector is required to record the data that has 
been separated based on m/z to produce a mass spectrum. Detection in most TOF analysers 
use microchannel plate (MCP) detectors which utilise an array of parallel channels (Figure 
1.17 (a)) coated with a semiconductor substance. The MCP detector is based upon electron 
multiplication of which other detector configurations exist utilising multiple dynodes or one 
continuous dynode, where the MCP has multiple continuous dynodes in parallel channels.182  
Upon the incidence of an ion on the input side of the MCP, secondary particles are ejected 
including positive ions, negative ions, electrons and neutrals. The secondary particles strike 
the inside of the channel and a cascade of secondary electrons is produced (Figure 1.17 (b)) 
with the resulting amplified electrons exiting the channel converted to a measurable current. 
The snowball effect within the channel provides fast response times with a wide detection 
area making it highly suited for combination with TOF mass analysers. MCP arrays can be 
stacked to reach amplification by as much as 108.  
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Figure 1.17 (a) Representation of an MCP array with (b) cross-sectional schematic of electron 
multiplication within a channel 
 
1.5. Hyphenation of FAIMS with MS and LC-MS 
Mass spectrometry as an analytical technique is very powerful due to the sensitivity and 
selectivity of the technique. However, not all compounds can be separated by m/z alone in a 
complex chemical matrix such as a biological sample. Compounds that cannot be separated 
include naturally occurring isomers and isobars with the same nominal or exact mass, which 
cannot be separated by even the highest resolution mass spectrometer. Hyphenation of 
orthogonal separation techniques, such as liquid chromatography (LC), gas chromatography 
(GC) and ion mobility spectrometry (IMS), with mass spectrometry creates an even more 
powerful analytical tool with pre-separation of analytes prior to entry to the mass 
spectrometer. LC and GC are usually hyphenated prior to the ionisation source, whereas IMS 
based techniques are located between the ionisation source and the mass analyser. The first 
section of this discussion focuses primarily on the combination of FAIMS with MS, and will 
describe the relative ease with which FAIMS can be hyphenated with minor modifications to 
the inlet of the MS and the benefits of the additional differential mobility separation prior to 
mass analysis and detection. The second section focuses on the hyphenation of LC with 
FAIMS-MS to achieve orthogonal three-dimensional separation of analytes, with examples of 
the application of LC-FAIMS-MS to bioanalysis (with further examples provided in Section 
1.6).  
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1.5.1. Hyphenation of FAIMS-MS 
With the development of ESI-MS in the 1980s,159,160 occurring in parallel to the early FAIMS 
development across Russia, researchers demonstrated the coupling of FAIMS and MS with 
ionisation via ESI183 and APCI.103 Purves and Guevremont in the late 1990’s and early 
2000’s showed the successful coupling of a cylindrical FAIMS with ESI-MS using a curtain 
gas flow through the FAIMS device to aid in desolvation.65,100 They applied the system to the 
analysis of trace level perchlorate in water and human urine matrices, with ppb levels of 
detection.184 Since this development in the late 1990s the approach employed in all FAIMS-
MS couplings,185 and the number of publications describing the use of FAIMS-MS has 
increased significantly.186 The improvement in analytical performance that FAIMS offers 
with hyphenation to MS is dependent on the geometry of the FAIMS device and the type of 
mass spectrometer it is interfaced to.  
Initially, cylindrical FAIMS devices (Section 1.3.3) were preferred for interfacing with MS 
due to the focussed ion beam exiting the FAIMS device,63 which showed improved 
sensitivity when compared to MS alone. However, planar configuration FAIMS devices have 
been shown to have significant advantages over cylindrical geometries in terms of resolution, 
separation power, duty cycle, and the ability to analyse all species simultaneously without 
discrimination by focusing properties.187 The simpler planar electrode configurations is more 
amenable to miniaturisation, allowing for decreased ion residence times and faster scanning 
speeds. The resolution of planar devices is higher due to the uniform electric field with no 
focussing effect, and in planar FAIMS peak widths are narrower and do not increase in peak 
width with increasing CF. Planar FAIMS can be operated in a “transparent mode” by setting 
the electrode potential to ground, allowing the user to switch between FAIMS and non-
FAIMS analyses without altering any hardware.185 A direct comparison of planar FAIMS 
compared to cylindrical for coupling to MS was performed by Shvartsburg et al. where it was 
found that the resolution was improved four-fold with an analysis time twice as fast using the 
planar configuration in comparison to cylindrical.188  
The linear relationship between concentration and transmission of ions through the FAIMS, 
can extend MS limits of detection and quantification by improving the analysis of the lower 
end of a calibration plot by reducing chemical noise and improving signal-to-noise ratios. The 
potential of FAIMS to separate isomeric and isobaric ions can provide information that even 
the highest resolution mass spectrometer would be unable to provide. It has been suggested 
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that FAIMS may have a greater benefit to enhancing the performance of standalone MS 
systems compared to tandem MS (MS/MS) systems, demonstrated in the analysis of 
underivatised amino acids by McCooeye et al. using a cylindrical FAIMS device coupled 
with QQQ-MS.189 McCooeye et al. concluded that the improvement in sensitivity and signal-
to-noise ratios (average ten-fold improvement) of ESI-FAIMS-MS compared to ESI-MS, 
with the resolution of all of the isobaric amino acids analysed, were greater than 
improvements observed between ESI-FAIMS-MS and ESI-MS/MS.189  
There are three FAIMS modes of operation in FAIMS-MS: a two-dimensional scan of both 
the DF and the CF, which can be used to characterise the mobility of analyte(s) over different 
electric field strengths; a one-dimensional scan of the CF at a particular DF, in order to 
optimise separation between analyte(s) and/or matrix interferences; and a static mode where 
the DF and CF are fixed for optimum transmission of the analyte(s) of interest. The 
hyphenation of FAIMS with MS allows for multiple analytes to be optimised at once, with 
individual FAIMS mobility plots accessible by selecting the m/z of the different analytes of 
interest; isobaric species, if separable in the FAIMS would be visualised as multiple peaks in 
the m/z selected FAIMS mobility plot. As the FAIMS selection occurs prior to the ions 
entering the MS vacuum region it can be used as a pre-filter for pseudo tandem MS to create 
fragmentation patterns (using high voltages in the ion transfer region of the MS) of pre-
selected ions, combining FAIMS with in-source CID, referred to as FAIMS-in-source 
collision induced dissociation-MS (FISCID-MS).120  
The ESI source of the Agilent 6230 TOF-MS (Agilent), used predominantly throughout the 
research presented in this thesis, utilises a heated sheath gas flow that surrounds the nebuliser 
to aid in the desolvation and the focusing of the ions towards to spray shield inlet (Figure 
1.18 (a)). The hyphenation of miniaturised planar FAIMS with the TOF-MS required 
modification to the source region only, to accommodate the FAIMS chip and chip housing in 
front of the MS inlet (Figure 1.18 (b)); a modified spray shield fits over the FAIMS chip 
housing.  
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Figure 1.18 (a) Agilent JetStream ESI source schematic representation; (b) Modified Agilent 
JetStream ESI source to accommodate the Owlstone FAIMS chip behind a modified spray 
shield in front of the inlet capillary 
 
1.5.2. Hyphenation of LC-FAIMS-MS 
LC-MS is a well-established technique for studying biological systems, largely because of its 
high sensitivity and specificity. However, unresolved analytical challenges such as chemical 
background and isobaric interferences from the complex sample matrix can adversely affect 
performance aspects such as detection limits, precision and accuracy. In order to overcome 
these challenges, often elaborate sample preparation techniques or lengthy chromatographic 
separations are required to achieve sufficient chromatographic separations or levels of 
detection.159,190,191  
Some of the examples in the previous section indicate that the hyphenation of FAIMS with 
MS can result in chromatographic separation rendered unnecessary. However, these example 
applications are largely for targeted analyses that have been optimised for specific 
compounds within a matrix. In the analysis of biological samples by ESI-MS or ESI-FAIMS-
MS the simultaneous introduction of the biological matrix to the ESI source can result in ion 
suppression. As the FAIMS separation occurs after the ESI it has no impact on the ionisation, 
therefore steps to reduce these effects must be carried out prior to introduction of the sample 
into the ESI source.  
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One option to reduce these ionisation effects is to dilute the sample, reducing the 
concentration of matrix and analytes entering the ESI by direct infusion. Beach et al.192 
experimentally performed serial dilutions of urine samples of up to 20,000 times to explore 
the effects of sample dilution on ionisation efficiency. The ESI-FAIMS-MS analysis of the 
diluted urine was shown to effectively eliminate ESI chemical background from analytes of 
interest. However, with such diluted samples the MS analysis times had to be increased by 
slowing down the FAIMS scan rate in order to obtain a signal large enough to actually be 
detected, which in the sub nM range in the very diluted complex samples was reported to 
result in continuous analysis times of 1-2 hours.192 A second option is the use of sample pre-
treatment prior to analysis, such as solid-phase microextraction (SPME) as used by 
McCooeye et al.193 to reduce salt content and improve electrospray source conditions in the 
targeted analysis of recreational drugs in urine. 
The approaches described above have been successful for specific ESI-FAIMS-MS 
applications, however, many complex analyses require sample clean-up prior to the ESI (and 
therefore FAIMS). For example, where competing ionisation mechanisms or compounds with 
high ionisation efficiency can adversely affect or suppress the ionisation of analytes of 
interest. Therefore, a third option is to combine liquid chromatographic separation with ESI-
FAIMS-MS which requires no modification to the ESI-FAIMS-MS set-up (Figure 1.19), with 
the LC flow introduced directly into the ESI source.  
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Figure 1.19 Schematic diagram of direct syringe infusion (DI) or LC interfaced with the ESI-
FAIMS-MS  
 
The combination of the three highly orthogonal separations mechanisms, LC, FAIMS and 
MS, is complementary and FAIMS can be added to existing LC-MS workflows or analyses to 
further enhance the sensitivity and the specificity of analysis. As described in the previous 
section, FAIMS can improve limits of detection by removing chemical noise and 
interferences at the lower-end of a calibration plot. This was shown for the analysis of 
linoleic acid in cancer cell extracts as demonstrated by Kapron et al where the combination of 
LC-FAIMS-MS/MS lowered detection limits and increased sensitivity ten-fold in comparison 
to LC-MS/MS, which could potentially prove useful where volume of samples of cancer cell 
extracts may be limited.194 Another example was demonstrated by Guddat et al.195 in the 
analysis of steroids in sport drug testing of urine samples, where the interference removal 
obtained using LC-FAIMS-MS/MS effectively extends the post-dose detection time with 
improvements in signal-to-noise ratio of approximately five-fold, and may help in the trend 
towards ever decreasing concentration levels for banned substances.  
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FAIMS modes of operation in LC-FAIMS-MS include holding the FAIMS conditions static 
(useful for targeted applications) or stepping/scanning the FAIMS CF (useful for non-
targeted applications). Examples that utilise these modes of operation in biological 
applications are described in Section 1.6. For targeted applications where there are specific 
analytes of interest the FAIMS settings can be optimised for those analytes by FAIMS-MS, 
usually by direct infusion of the analytes as standards and scanning the FAIMS to find the 
optimal DF and CF settings for transmission. The matrix containing the analyte of interest 
can then be analysed using LC-FAIMS-MS at the optimised FAIMS settings, as shown by 
Smith et al. in the analysis of ibuprofen 1-β-O-acyl glucuronide metabolite in urine, where 
the linear dynamic range was increased with an improved limit of quantification 
approximately two-fold compared to LC-MS alone.123  
Scanning FAIMS experiments can be carried out by two methods: performing several static 
LC-FAIMS-MS analyses at fixed CFs that combine to provide a scan, referred to as external 
stepping of FAIMS conditions, or by rapid scanning of the FAIMS in a single analysis, 
referred to as internal scanning of FAIMS conditions. However, scanning of the FAIMS 
during LC-FAIMS-MS analysis requires the FAIMS to be able to scan fast enough to be 
compatible with LC peak widths. Early attempts at scanning the FAIMS for LC-FAIMS-MS 
resulted in a limited CF range or extended chromatographic analyses times to provide wide 
enough peaks to allow multiple FAIMS scans within the timescale of a peak.196,197 Using a 
cylindrical FAIMS for the application of shotgun proteomics, Creese et al. found the external 
stepping method to be more sensitive than the scanning FAIMS method, providing a greater 
coverage of identified peptides; however, the duty cycle of the FAIMS device meant that in 
the internal method with the scanning CF, the CF for transmission and the top of an LC peak 
of a peptide did not necessarily coincide with the mass spectral recording, lowering 
sensitivity for the internal scanning method.198 The short residence time and fast scanning of 
the Owlstone chip-based FAIMS device is compatible with UHPLC peak timescales.  
1.6. Bioanalysis using FAIMS 
The concept of examining biological fluids to predict disease and physiological state dates 
back to the ancient physicians in Egypt and Greece (before 400 BC). The oldest known test 
on biological fluids being performed on urine, where once poured on the ground it would be 
observed to see if it attracted insects, in which case the patient was diagnosed with boils. 
Hippocrates, in ancient Greece, advocated the examination of urine via taste, colour and 
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smell and the presence of sediments to diagnose disease.199 The development of diagnostic 
methods of analysis from empirical to experimental techniques still have the common factor 
of relating the chemical fingerprint of biofluids and tissues to the biological state of the 
organism. 
The profiling of biological samples is the systematic study of the complete set of chemicals 
within a sample.200 The measurement of samples over time can allow the detection of small 
changes in biological fluids which can be indicative of the physiological or disease state of an 
organism. As a result of bioanalysis, biomarkers can be identified that can lead to the early 
detection of disease, understanding of disease state and progression, and can be a valuable 
tool for diagnostic purposes and personalised medicine. However, the non-targeted detection 
of the complete set of chemicals within a sample and the identification of unknown analytes 
in biological matrices remains a significant challenge, whether the focus is on small molecule 
metabolites, proteins, lipids, carbohydrates or components of cellular extracts.200 
In biological applications, analysis of the complex sample matrix using LC-MS can leave 
unresolved analytical challenges. For example, high chemical background and isobaric 
interferences which can adversely affect identification, detection limits and analytical 
precision. Elaborate sample preparation or lengthy chromatographic methods can be applied, 
however the development of a suitable method for the application is not always 
accomplished.201 The addition of FAIMS of MS and LC-MS bioanalytical assays has proven 
valuable with the simplification of sample preparation methods and enhanced selectivity.202 
FAIMS can be incorporated with relative ease into existing bioanalytical workflows, such as 
with MS and LC-MS as described in Section 1.5. FAIMS can enhance the most challenging 
bioanalytical workflows by reducing chemical noise and detection limits, removing isobaric 
and isomeric interferences and reducing the requirement for extensive sample clean-up or 
derivatisation. Applications of FAIMS for other areas of interest have been published 
elsewhere,62 including the analysis of pharmaceuticals,203 pollutants and environmental 
analysis,204 chemical weapons and explosives.205,206  
1.6.1. Biological matrices 
Non-invasively collected biofluids such as saliva and urine are gaining precedence as 
diagnostic and clinical biofluids, due to the timely, cost-effective, accurate, sample collection 
with limited discomfort and stress to the patient or study.207,208  
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Saliva is an oral fluid produced by healthy human subjects in significant volumes every day 
(500-1500 mL), which serves several functions in oral health, taste perception, enamel 
maintenance and plays an essential role at the beginning of the digestive process.209 Human 
saliva is slightly acidic with a normal pH of 6 to 7 and composed of approximately 99% 
water, but consists of a variety of biologically relevant components including electrolytes, 
proteins, enzymes, immunoglobulins, mucins and nitrogenous products, such as urea and 
ammonia.210 Unstimulated saliva production is approximately at a rate of 0.3 – 0.5 mL min-1, 
with its flow varying between individuals. However, its production can be stimulated by 
senses such as taste and smell, chewing, psychological and hormonal status, drugs, age, 
hereditary influences, oral hygiene and physical exercise.209 Whole saliva can be collected 
easily from patients or study participants, including the young and elderly, and collection 
does not need to be performed by a trained specialist. The collection protocol should include 
information regarding sample collection time and activities such as brushing teeth, chewing 
gum and food and drink ingestion (with water usually allowed). Unstimulated whole saliva 
can be collected easily by a passive drool (no oral movements) approach, allowing saliva to 
drip into a collection vial, or by spitting directly into the vial. Stimulated whole saliva can be 
collected with oral movements, such as gentle mastication, or via the use of citric acid, which 
may lower sample pH and potentially interfere with some analytes of interest.209 Other 
approaches include the use of cotton swabs or suction apparatus to extract saliva from 
specific salivary glands.208  
Urine is a biofluid widely used in bioanalytical assays as it is readily available in large 
volumes, and is chemically diverse whilst being relatively free of proteins or lipids. Urine is a 
transparent, amber-coloured liquid produced by the kidneys of mammals. The kidneys extract 
soluble waste products from the bloodstream and typically contains metabolic breakdown 
products from a wide range of sources such as endogenous waste metabolites, bacterial by-
products, environmental contaminants, foods, drinks and drugs; high concentrations of urea, 
inorganic salts, creatinine, ammonia, organic acids, water-soluble toxins and pigments of 
haemoglobin breakdown (gives urine its characteristic colour).211 The average adult produces 
between 1.5-2.0 L of urine per day with a pH 4.5 to 8 depending on diet, disease processes 
and medications (typically pH 6).211 Urine can be collected in a variety of ways depending on 
the type of specimen required, the collection site and the patient type. Collection methods 
include: randomly collected specimens, first morning specimen, midstream clean catch 
specimen, timed collection or collection from catheters. For testing in the clinical laboratory, 
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sample collection is typically of randomly collected midstream specimens, with instructions 
provided to commence collection after voiding the first portion of the urine stream to the 
toilet, collecting the urine midstream into the clean container and voiding the remaining urine 
to the toilet. This method can be performed at any time of day or night, but randomly 
collected samples can be of varying dilution depending on participants’ consumption of 
fluids. First morning specimens are generally more concentrated and timed collections can be 
useful for quantitative measurement of certain analytes and their excretion rates.212  
1.6.2. Non-targeted bioanalytical applications using FAIMS 
FAIMS as a standalone device has been employed as a clinical tool for the non-targeted 
detection of different disease states, such as colorectal cancer detected from urinary volatile 
organic compound analysis,213 exhaled breath analysis to detect irritable bowel syndrome,214 
bile acid diarrhoea detection from urinary headspace analysis,215 and is being investigated as 
a medical diagnostic tool in a clinical setting.216  
The potential of FAIMS combined with MS or LC-MS to enhance non-targeted 
metabolomics and lipidomics is largely unexplored in literature to date, and has mainly 
focussed on proteomics. Beach et al. demonstrated the non-targeted direct infusion analysis 
of urine by FAIMS-MS showing enhanced signal-to-noise ratio of low abundance 
metabolites which aided in metabolite identification.192,217 Bowman et al. reported the use of 
planar FAIMS to separate four lipid isomer types from three classes of lipids, showing the 
potential utility of FAIMS in lipidomics to distinguish lipid isomers.218 Shvartsburg et al. 
reported the classification of subclasses of lipids analysed as cations: phosphor-, 
lysophospho- glycerol- and sphingolipids by FAIMS-MS, with distinct trendlines observed 
for the different subclasses on plots of compensation voltage vs m/z.145 Both of these 
examples demonstrate the potential of FAIMS to enhance the analysis of lipids in both non-
targeted shotgun lipidomics and targeted analysis of bioactive lipids. Application of LC-
FAIMS-MS into non-targeted proteomics has centred around the use of a cylindrical FAIMS 
device (see Section 1.2.3), and in comparison to LC-MS has shown an increase in proteome 
coverage and the number of features detected,197,198,219,220 with increased peptide detection 
and identification.196,221–223  
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1.6.3. Targeted bioanalytical applications using FAIMS 
Targeted bioanalysis focuses on a specific analyte or a class or subset of analytes of interest 
for a range of applications including bioanalytical analysis of proteins, metabolites and lipids, 
pharmaceutical applications in the detection of drugs and drug metabolites and environmental 
applications. Targeted FAIMS approaches require experimental determination of the DF and 
CF for transmission of the analyte(s) of interest, usually via the use of chemical standards. 
Upon determination of optimised FAIMS conditions for the targets of interest, the 
bioanalytical assay or matrix can be analysed via FAIMS-MS or by LC-FAIMS-MS. FAIMS-
MS analysis has been utilised for trace level analysis for components from complex matrices 
such as drug metabolites in plasma and urine.116,117,224  
The typical procedure for targeting a single analyte in a complex matrix using LC-FAIMS-
MS is a static approach where the FAIMS DF and CF for transmission of the analyte of 
interest are held at a single DF/CF condition throughout the analysis. This approach has been 
demonstrated in the analysis of drug metabolites where there are interfering metabolites,101 in 
complex matrices such as urine,123 and in the targeted analysis of peptides in serum and 
plasma to remove matrix interferences.225,226 
Where there are multiple analytes of interest with potentially multiple FAIMS conditions for 
LC-FAIMS-MS analysis, there are two approaches that have been adopted in literature. The 
first approach consists of repeated LC runs with the FAIMS set at a different fixed DF/CF 
fixed in each analysis to transmit different selected analytes in each run. An example of this 
approach was demonstrated by Xia et al. in the analysis of a peptide drug candidate in rat 
plasma, where two compensation voltage settings were used to reduce the 
chemical/endogenous background noise from the plasma matrix allowing the quantitation of 
the peptide drug candidate (I) and an internal standard (II).227 This approach has also shown 
utility in the targeted analysis of peptide sequences by Creese et al. where the LC-FAIMS-
MS approach, using nine different FAIMS conditions, identified 35% of a pre-defined 
peptide library of 4000 peptides whereas LC-MS/MS identified only 8%.82  
The second approach consists of a multi-dimensional FAIMS analysis where the FAIMS 
cycles through optimum DF/CF for transmission of each analyte in a single LC-FAIMS-MS 
run, as discussed in Section 1.5.2. This was demonstrated by Kapron et al. in the LC-FAIMS-
MS/MS analysis of prostanoids, including isomeric species (PGE2 and PGD2). Utilising five 
different DF/CF settings in one analysis enabled the resolution of the isomeric species along 
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with reduced interferences from the biological matrix (guinea pig spinal cord homogenate) 
allowing for more accurate quantification of the five lipids.228 Wu et al. demonstrated the 
development of an LC-FAIMS-MS/MS bioanalytical method for the simultaneous detection 
and quantification of three analytes (nefazodone and two metabolites) in plasma each with a 
different DF/CF setting for transmission.229 Wu et al. highlighted the importance with this 
multidimensional LC-FAIMS-MS/MS approach of maintaining a sufficient number of data 
points across a chromatographic peak which is limited by the FAIMS residence time and the 
selected reaction monitoring (SRM) dwell time.229 In the analysis of paralytic shellfish toxins 
by a multidimensional LC-FAIMS-MS analysis, Beach et al also commented on the 
requirement to limit the number of simultaneous DF/CF values to be monitored in a single 
analysis to minimise the impact on the duty cycle of the analysis.230 Ray et al. have applied 
the multi-DF/CF LC-FAIMS-MS approach in the quantitative analysis of five endogenous 
steroids (and internal standards) in human serum and plasma. The specificity gained via the 
use of FAIMS allows for reduction of the complexity of sample preparation and the 
chromatographic run time demonstrating that the LC-FAIMS-MS method developed is 
suitable for high-throughput routine clinical diagnostics.231 
1.7. Thesis overview 
This thesis details the development of FAIMS-MS and LC-FAIMS-MS based applications 
for bioanalysis, with a particular emphasis on small molecule analysis. All experiments were 
performed using a miniaturised FAIMS device interfaced with ESI-TOF-MS. Initial 
development included an investigation of the potential application of FAIMS-MS in the 
analysis of naturally occurring non-covalent complexes of 3-methylxanthine (Chapter 2). 
Other studies are concerned with the development and application of LC-FAIMS-MS for the 
targeted analysis of oxypurines in saliva from athletes subjected to oxidative stress (Chapter 
3), and steroid metabolites of relevance to doping control urine (Chapter 4). The final chapter 
reports the development of a scanning approach using LC-FAIMS-MS for non-targeted 
‘omics applications (Chapter 5).   
54 
 
1.8. Chapter one references 
1. Karasek, F. W.; Sep. Purif. Rev., 3, 207–244 (1974) 
2. Revercomb, H. E. and Mason, E. A.; Anal. Chem., 47, 970–983 (1975) 
3. Mason, E. A. and Schamp, H. W.; Ann. Phys., 4, 233–270 (1958) 
4. Buryakov, I. A., Krylov, E. V., Nazarav, E. G., and Rasulev, U. K.; Int. J. Mass Spec. 
Ion Proc., 128, 143–148 (1993) 
5. Eiceman, G. A., Krylov, E. V., Krylova, N. S., Nazarov, E. G., and Miller, R. A.; Anal. 
Chem., 76, 4937–4944 (2004) 
6. Lanucara, F., Holman, S. W., Gray, C. J., and Eyers, C. E.; Nat. Chem., 6, 281–294 
(2014) 
7. Creaser, C. S., Griffiths, J. R., Bramwell, C. J., Noreen, S., Hill, C. a., Thomas, C. L. 
P., Hill, A., Thomas, C. L. P., Sciences, N., Lane, C., and Science, A.; Analyst, 129, 
984 (2004) 
8. Lapthorn, C., Pullen, F., and Chowdry, B. Z.; Mass Spectrom. Rev., 32, 43–71 (2013) 
9. Harry, E. L., Weston, D. J., Bristow, A. W. T., Wilson, I. D., and Creaser, C. S.; J. 
Chromatogr. B Anal. Technol. Biomed. Life Sci., 871, 357–361 (2008) 
10. Kaur-Atwal, G., Reynolds, J. C., Mussell, C., Champarnaud, E., Knapman, T. W., 
Ashcroft, A. E., O’Connor, G., Christie, S. D. R., Creaser, C. S., Bowers, L. D., 
Amundsen, L. K., Nevanen, T. K., Takkinen, K., Rovio, S., Siren, H., Chen, H. X., 
Deng, Q. P., Zhang, L. W., Zhang, X. X. et al.; Analyst, 136, 3911–3916 (2011) 
11. Paglia, G., Williams, J. P., Menikarachchi, L. C., Thompson, J. W., Tyldesley-
Worster, R., Halldórsson, S., Rolfsson, O., Moseley, M. A., Grant, D. F., Langridge, J., 
Palsson, B. Ø., and Astarita, G.; Anal. Chem., 86, 3985–3993 (2014) 
12. Woods, A. S., Ugarov, M., Egan, T., Koomen, J., Gillig, K. J., Fuhrer, K., Gonin, M., 
and Schultz, J. A.; Anal. Chem., 76, 2187–2195 (2004) 
13. Harvey, S. R., MacPhee, C. E., and Barran, P. E.; Methods, 54, 454–461 (2011) 
14. Zhong, Y., Hyung, S. J., and Ruotolo, B. T.; Expert Rev Proteomics, 9, 47–58 (2012) 
15. Valentine, S. J., Plasencia, M. D., Liu, X., Krishnan, M., Naylor, S., Udseth, H. R., 
Smith, R. D., and Clemmer, D. E.; J. Proteome Res., 5, 2977–2984 (2006) 
55 
 
16. Pagel, K. and Harvey, D. J.; Anal. Chem., 85, 5138–5145 (2013) 
17. Paglia, G., Kliman, M., Claude, E., Geromanos, S., and Astarita, G.; Anal. Bioanal. 
Chem., 407, 4995–5007 (2015) 
18. Kliman, M., May, J. C., and McLean, J. A.; Biochim. Biophys. Acta - Mol. Cell Biol. 
Lipids, 1811, 935–945 (2011) 
19. Ellis, H. W., Pai, R. Y., McDaniel, E. W., Mason, E. A., and Viehland, L. A.; At. data 
Nucl. data tables, 17, 177–210 (1976) 
20. Mason, E. A. and McDaniel, E. W.; Transport Properties of Ions in Gases (1988), 
Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA 
21. Dwivedi, P., Schultz, A. J., and Hill, H. H.; Int. J. Mass Spectrom., 298, 78–90 (2010) 
22. Lermyte, F., Konijnenberg, A., Williams, J. P., Brown, J. M., Valkenborg, D., and 
Sobott, F.; J. Am. Soc. Mass Spectrom., 25, 343–350 (2014) 
23. Malkar, A., Devenport, N. A., Martin, H. J., Patel, P., Turner, M. A., Watson, P., 
Maughan, R. J., Reid, H. J., Sharp, B. L., Thomas, C. L. P., Reynolds, J. C., and 
Creaser, C. S.; Metabolomics, 9, 1192–1201 (2013) 
24. O’Donnell, R. M., Sun, X., and Harrington, P. de B.; TrAC - Trends Anal. Chem., 27, 
44–53 (2008) 
25. Damen, C. W. N., Chen, W., Chakraborty, A. B., van Oosterhout, M., Mazzeo, J. R., 
Gebler, J. C., Schellens, J. H. M., Rosing, H., and Beijnen, J. H.; J. Am. Soc. Mass 
Spectrom., 20, 2021–2033 (2009) 
26. Ewing, R. G., Atkinson, D. A., Eiceman, G. A., and Ewing, G. J.; Talanta, 54, 515–
529 (2001) 
27. Reid Asbury, G., Klasmeier, J., and Hill, H. H.; Talanta, 50, 1291–1298 (2000) 
28. Hill, A. R., Edgar, M., Chatzigeorgiou, M., Reynolds, J. C., Kelly, P. F., and Creaser, 
C. S.; Eur. J. Mass Spectrom., 21, 265–274 (2015) 
29. Eiceman, G. A. and Stone, J. A.; Anal. Chem., 76, 390–397 (2004) 
30. Cumeras, R., Figueras, E., Davis, C. E., Baumbach, J. I., and Gràcia, I.; Analyst, 140, 
1376–1390 (2015) 
31. Márquez-Sillero, I., Aguilera-Herrador, E., Cárdenas, S., and Valcárcel, M.; TrAC 
56 
 
Trends Anal. Chem., 30, 677–690 (2011) 
32. Armenta, S., Alcala, M., and Blanco, M.; Anal. Chim. Acta, 703, 114–123 (2011) 
33. Li, F., Xie, Z., Schmidt, H., Sielemann, S., and Baumbach, J.; Spectrochim. Acta Part 
B At. Spectrosc., 57, 1563–1574 (2002) 
34. Ujma, J., Giles, K., Morris, M., and Barran, P. E.; Anal. Chem., 88, 9469–9478 (2016) 
35. Eiceman, G. A. and Z, K.; Ion mobility spectrometry (2005), 2nd Edition, Boca Raton: 
CRC Press  
36. May, J. C. and McLean, J. A.; Anal. Chem., 87, 1422–1436 (2015) 
37. Agilent Technologies; 6560 Ion Mobility Q-TOF LC/MS, (2017) Available at: 
http://www.agilent.com/en-us/products/mass-spectrometry/lc-ms-instruments/6560-
ion-mobility-q-tof-lc-ms. (Accessed: 1st May 2017) 
38. Merenbloom, S. I., Koeniger, S. L., Valentine, S. J., Plasencia, M. D., and Clemmer, 
D. E.; Anal. Chem., 78, 2802–2809 (2006) 
39. Smiths Detection; Ionscan 500DT, Available at: 
http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=115:ions
can-500dt&Itemid=1427&lang=en#.WQ8uIPnyubw. (Accessed: 1st May 2017) 
40. Smiths Detection; Ionscan 600, Available at: 
http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=495:ions
can-600&Itemid=1427&lang=en#.WQ8umPnyubw. (Accessed: 1st May 2017) 
41. Merenbloom, S. I., Glaskin, R. S., Henson, Z. B., and Clemmer, D. E.; Anal. Chem., 
81, 1482–1487 (2009) 
42. Bruker Corp.; Ion Mobility Spectrometry, Available at: 
https://www.bruker.com/products/cbrne-detection/ims.html. (Accessed: 1st May 2017) 
43. L3 Security & Detection Systems; Explosives & Drug Trace Detection, Available at: 
http://www.sds.l-3com.com/products/explosives-drug-detection.htm. (Accessed: 1st 
May 2017) 
44. G.A.S. Gesellschaft für analytische Sensorsysteme mbH; Products, Available at: 
http://www.gas-dortmund.de/Products/1_354.html. (Accessed: 1st May 2017) 
45. Excellims; Products, Available at: http://www.excellims.com/products/. (Accessed: 1st 
57 
 
May 2017) 
46. AIRSENSE Analytics GmbH; Products, Available at: 
http://www.airsense.com/en/products. (Accessed: 20th July 2005) 
47. Autoclear LLC.; Products / Trace Detection, Available at: http://a-clear.com/products-
page/trace-detection-scintrex. (Accessed: 20th July 2005) 
48. B & S Analytik GmbH; Products, Available at: http://www.bs-
analytik.de/produkte.htm. (Accessed: 1st May 2017) 
49. Giles, K., Pringle, S. D., Worthington, K. R., Little, D., Wildgoose, J. L., and 
Bateman, R. H.; Rapid Commun. Mass Spectrom., 18, 2401–2414 (2004) 
50. Pringle, S. D., Giles, K., Wildgoose, J. L., Williams, J. P., Slade, S. E., Thalassinos, 
K., Bateman, R. H., Bowers, M. T., and Scrivens, J. H.; Int. J. Mass Spectrom., 261, 1–
12 (2007) 
51. Giles, K., Wildgoose, J. L., Langridge, D. J., and Campuzano, I.; Int. J. Mass 
Spectrom., 298, 10–16 (2010) 
52. Waters; Synapt (2017), Available at: 
http://www.waters.com/waters/en_GB/SYNAPT/nav.htm?cid=10131968&locale=en_
GB. (Accessed: 1st May 2017) 
53. Shvartsburg, A. A. and Jarrold, M. F.; Chem. Phys. Lett., 261, 86–91 (1996) 
54. Mesleh, M. F., Hunter, J. M., Shvartsburg, A. A., Schatz, G. C., and Jarrold, M. F.; J. 
Phys. Chem., 100, 16082–16086 (1996) 
55. Siu, C. K., Guo, Y., Saminathan, I. S., Hopkinson, A. C., and Siu, K. W. M.; J. Phys. 
Chem. B, 114, 1204–1212 (2010) 
56. Bleiholder, C., Wyttenbach, T., and Bowers, M. T.; Int. J. Mass Spectrom., 308, 1–10 
(2011) 
57. Bleiholder, C., Contreras, S., Do, T. D., and Bowers, M. T.; Int. J. Mass Spectrom., 
345–347, 89–96 (2013) 
58. Anderson, S. E., Bleiholder, C., Brocker, E. R., Stang, P. J., and Bowers, M. T.; Int. J. 
Mass Spectrom., 330–332, 78–84 (2012) 
59. Bleiholder, C., Contreras, S., and Bowers, M. T.; Int. J. Mass Spectrom., 354–355, 
58 
 
275–280 (2013) 
60. Gorshkov, M. P.; Inventor’s certificate of USSR No. 966583, G01N27/62 (1982) 
61. Buryakov, I. a.; J. Anal. Chem., 66, 1095–1102 (2011) 
62. Kolakowski, B. M. and Mester, Z.; Analyst, 132, 842–864 (2007) 
63. Purves, R. W., Guevremont, R., Day, S., Pipich, C. W., and Matyjaszczyk, M. S.; Rev. 
Sci. Instrum., 69, 4094 (1998) 
64. Shvartsburg, A. A. and Smith, R. D.; J. Am. Soc. Mass Spectrom., 19, 1286–1295 
(2008) 
65. Guevremont, R. and Purves, R. W.; J. Am. Soc. Mass Spectrom., 10, 492–501 (1999) 
66. Wilks, A., Hart, M., Koehl, A., Somerville, J., Boyle, B., and Ruiz-Alonso, D.; Int. J. 
Ion Mobil. Spectrom., 15, 199–222 (2012) 
67. Papanastasiou, D., Wollnik, H., Rico, G., Tadjimukhamedov, F., Mueller, W., and 
Eiceman, G. A.; J. Phys. Chem. A, 112, 3638–3645 (2008) 
68. Guevremont, R.; J. Chromatogr. A, 1058, 3–19 (2004) 
69. Krylov, E., Nazarov, E. G., Miller, R. A., Tadjikov, B., and Eiceman, G. A.; J. Phys. 
Chem. A, 106, 5437–5444 (2002) 
70. Purves, R. W. and Guevremont, R.; Anal. Chem., 71, 2346–57 (1999) 
71. Krylov, E. V., Nazarov, E. G., and Miller, R. A.; Int. J. Mass Spectrom., 266, 76–85 
(2007) 
72. Nazarov, E. G., Coy, S. L., Krylov, E. V, Miller, R. A., and Eiceman, G. A.; Anal 
Chem, 78, 7697–7706 (2006) 
73. Schneider, B. B., Nazarov, E. G., Londry, F., Vouros, P., and Covey, T. R.; Mass 
Spectrom. Rev., 35, 687–737 (2016) 
74. Schneider, B. B., Covey, T. R., Coy, S. L., Krylov, E. V., and Nazarov, E. G.; Anal 
Chem, 82, 1867–1880 (2010) 
75. Schneider, B. B., Nazarov, E. G., and Covey, T. R.; Int. J. Ion Mobil. Spectrom., 15, 
141–150 (2012) 
76. Rorrer, L. C. and Yost, R. A.; Int. J. Mass Spectrom., 378, 336–346 (2015) 
59 
 
77. Levin, D. S., Miller, R. a, Nazarov, E. G., and Vouros, P.; Anal. Chem., 78, 5443–52 
(2006) 
78. Krylova, N., Krylov, E., Eiceman, G. A., and Stone, J. A.; J. Phys. Chem. A, 107, 
3648–3654 (2003) 
79. Kafle, A., Coy, S. L., Wong, B. M., Fornace, A. J., Glick, J. J., and Vouros, P.; J. Am. 
Soc. Mass Spectrom., 25, 1098–1113 (2014) 
80. Purves, R. W., Barnett, D. A., Ells, B., and Guevremont, R.; J. Am. Soc. Mass 
Spectrom., 12, 894–901 (2001) 
81. Shvartsburg, A. A., Li, F., Tang, K., and Smith, R. D.; Anal. Chem., 79, 1523–1528 
(2007) 
82. Creese, A. J., Smart, J., and Cooper, H. J.; Anal. Chem., 85, 4836–4843 (2013) 
83. Shvartsburg, A. A., Creese, A. J., Smith, R. D., and Cooper, H. J.; Anal. Chem., 82, 
8327–8334 (2010) 
84. Shvartsburg, A. A., Tang, K., and Smith, R. D.; Anal. Chem., 82, 32–35 (2010) 
85. Shvartsburg, A. A., Bryskiewicz, T., Purves, R. W., Tang, K., Guevremont, R., and 
Smith, R. D.; J. Phys. Chem. B, 110, 21966–21980 (2006) 
86. Shvartsburg, A. A.; Anal. Chem., 86, 10608–10615 (2014) 
87. Shvartsburg, A. A., Noskov, S. Y., Purves, R. W., and Smith, R. D.; Proc. Natl. Acad. 
Sci., 106, 6495–6500 (2009) 
88. Shvartsburg, A. A., Noskov, S. Y., Purves, R. W., and Smith, R. D.; i, (2015) 
89. Shvartsburg, A. a and Smith, R. D.; Anal. Chem., 84, 7297–7300 (2012) 
90. Robinson, E. W., Sellon, R. E., and Williams, E. R.; Int. J. Mass Spectrom., 259, 87–
95 (2007) 
91. Robinson, E. W., Shvartsburg, A. A., Tang, K., and Smith, R. D.; Anal. Chem., 80, 
7508–7515 (2008) 
92. Arthur, K. L., Eiceman, G. A., Reynolds, J. C., and Creaser, C. S.; J. Am. Soc. Mass 
Spectrom., 27, 800–809 (2016) 
93. Elistratov,  a a, Shibkov, S. V, and Nikolaev, E. N.; Eur. J. Mass Spectrom., 12, 143–
51 (2006) 
60 
 
94. Spangler, G. E.; Int. J. Ion Mobil. Spectrom., 15, 109–121 (2012) 
95. Auerbach, D., Aspenleiter, J., and Volmer, D. A.; J. Am. Soc. Mass Spectrom., 25, 
1610–1621 (2014) 
96. Tang, F., Li, H., Wang, X. H., Yang, J., Zhang, L., and Wang, F.; Sci. China-
Technological Sci., 54, 1407–1414 (2011) 
97. Prasad, S., Tang, K., Manura, D., Papanastasiou, D., and Smith, R. D.; Anal. Chem., 
81, 8749–8757 (2009) 
98. Carnahan, B., Day, S., Kouznetsov, V., and Tarassov, A.; in Proceeding of fourth 
international workshop on IMS (1995) 
99. Carnahan, B., Day, S., Kouznetsov, V., and Tarassov, A.; SPIE, 2937, 106–119 (1996) 
100. Guevremont, R. and Purves, R. W.; Rev. Sci. Instrum., 70, 1370–1383 (1999) 
101. Kapron, J. T., Jemal, M., Duncan, G., Kolakowski, B., and Purves, R.; Rapid Commun. 
Mass Spectrom., 19, 1979–1983 (2005) 
102. Barnett, D. A., Belford, M., Dunyach, J. J., and Purves, R. W.; J. Am. Soc. Mass 
Spectrom., 18, 1653–1663 (2007) 
103. Buryakov, I. A., Krylov, E. V., Makas, A. L., Nazarov, E. G., Pervukhin, V. V., and 
Rasulev, U. K.; J Anal Chem, 48, 156–165 (1993) 
104. Nazarov, E. G., Miller, R. A., Eiceman, G. A., and Krylov, E. V.; Int. J. Ion Mobil. 
Spectrom., 5, 76–81 (2002) 
105. Eiceman, G. A., Nazarov, E. G., and Miller, R. A.; Int. J. Ion Mobil. Spectrom., 3, 15–
27 (2000) 
106. Miller, R. A., Eiceman, G. A., Nazarov, E. G., and King, A. T.; Sensors Actuators, B 
Chem., 67, 300–306 (2000) 
107. Spangler, G. E.; F. Anal. Chem. Tech., 4, 255–267 (2000) 
108. Schneider, B. B., Covey, T. R., Coy, S. L., Krylov, E. V., and Nazarov, E. G.; Int. J. 
Mass Spectrom., 298, 45–54 (2010) 
109. Krylov, E. V., Coy, S. L., Vandermey, J., Schneider, B. B., Covey, T. R., and Nazarov, 
E. G.; Rev. Sci. Instrum., 81, 24101-1-24101–11 (2010) 
110. Owlstone Medical Ltd; Owlstone Medical (2017), Available at: 
61 
 
https://www.owlstonemedical.com/. (Accessed: 1st May 2017)   
111. Shvartsburg, A. A., Mashkevich, S. V, and Smith, R. D.; Society, 2663–2673 (2006) 
112. Shvartsburg, A. A. and Smith, R. D.; J. Am. Soc. Mass Spectrom., 18, 1672–1681 
(2007) 
113. Shvartsburg, A. A. and Smith, R. D.; Anal. Chem., 85, 6967–6973 (2013) 
114. Rorrer, L. C. and Yost, R. A.; Int. J. Mass Spectrom., 300, 173–181 (2011) 
115. Isenberg, S. L., Armistead, P. M., and Glish, G. L.; J. Am. Soc. Mass Spectrom., 25, 
1592–1599 (2014) 
116. Hall, A. B., Coy, S. L., Nazarov, E. G., and Vouros, P.; J. Forensic Sci., 57, 750–756 
(2012) 
117. Hall, A. B., Coy, S. L., Kafle, A., Glick, J., Nazarov, E., and Vouros, P.; J. Am. Soc. 
Mass Spectrom., 24, 1428–1436 (2013) 
118. Kafle, A., Klaene, J., Hall, A. B., Glick, J., Coy, S. L., and Vouros, P.; Rapid Commun. 
Mass Spectrom., 27, 1473–1480 (2013) 
119. Brown, L. J., Toutoungi, D. E., Devenport, N. A., Reynolds, J. C., Kaur-Atwal, G., 
Boyle, P., and Creaser, C. S.; Anal. Chem., 82, 9827–9834 (2010) 
120. Brown, L. J., Smith, R. W., Toutoungi, D. E., Reynolds, J. C., Bristow, A. W. T., Ray, 
A., Sage, A., Wilson, I. D., Weston, D. J., Boyle, B., and Creaser, C. S.; Anal. Chem., 
84, 4095–4103 (2012) 
121. Brown, L. J., Smith, R. W., Toutoungi, D. E., Reynolds, J. C., Bristow, A., Ray, A., 
Sage, A., Weston, D., Wilson, I., Boyle, B., Creaser, C. S., Bristow, A. W. T., Weston, 
D. J., Medicines, D. I., and Park, A.; (2012) 
122. Smith, R. W., Reynolds, J. C., Lee, S.-L., and Creaser, C. S.; Anal. Methods, 5, 3799–
3802 (2013) 
123. Smith, R. W., Toutoungi, D. E., Reynolds, J. C., Bristow, A. W. T., Ray, A., Sage, A., 
Wilson, I. D., Weston, D. J., Boyle, B., and Creaser, C. S.; J. Chromatogr. A, 1278, 
76–81 (2013) 
124. Smith, R. W., Cox, L. B., Yudin, A., Reynolds, J. C., and Creaser, C. S.; Anal. 
Methods, 7, 34–39 (2015) 
62 
 
125. Guevremont, R., Barnett, D. A., Purves, R. W., and Vandermey, J.; Anal. Chem., 72, 
4577–4584 (2000) 
126. Thermo Fisher Corporation; Thermo Fisher FAIMS Operator’s Manual (2006), 
Revision A, Available at: http://tools.thermofisher.com/content/sfs/manuals/FAIMS-
operators-manual.pdf. (Accessed: 1st May 2017) 
127. An, X., Eiceman, G. A., and Stone, J. A.; Int. J. Ion Mobil. Spectrom., 13, 25–36 
(2010) 
128. Krylov, E. V.; Int. J. Mass Spectrom., 225, 39–51 (2003) 
129. Shvartsburg, A. a, Smith, R. D., Wilks, A., Koehl, A., Ruiz-Alonso, D., and Boyle, B.; 
Anal. Chem., 81, 6489–6495 (2009) 
130. Shvartsburg, A. A., Tang, K., Smith, R. D., Holden, M., Rush, M., Thompson, A., and 
Toutoungi, D.; Anal. Chem., 81, 8048–8053 (2009) 
131. Shvartsburg, A. A., Prior, D. C., Tang, K., and Smith, R. D.; Anal. Chem., 82, 7649–
7655 (2010) 
132. Owlstone Medical Ltd; ultraFAIMS (2017), Available at: 
https://www.owlstonemedical.com/products/ultraFaims/. (Accessed: 1st May 2017) 
133. Paschen, F.; Ann. Phys., 273, 69–96 (1889) 
134. Kendler, S., Lambertus, G. R., Dunietz, B. D., Coy, S. L., Nazarov, E. G., Miller, R. 
A., and Sacks, R. D.; Int. J. Mass Spectrom., 263, 137–147 (2007) 
135. Shvartsburg, A. A., Li, F., Tang, K., and Smith, R. D.; Anal. Chem., 78, 3706–3714 
(2006) 
136. Krylov, E.; Int. J. Ion Mobil. Spectrom., 15, 85–90 (2012) 
137. Krylov, E. V., Coy, S. L., and Nazarov, E. G.; Int. J. Mass Spectrom., 279, 119–125 
(2009) 
138. Ceremuga, M., Szyposzy, M., and Sikora, T.; Open J. Phys. Chem., 3, 170–176 (2013) 
139. Karpas, Z., Berant, Z., and Shahal, O.; J. Am. Chem. Soc., 111, 6015–6018 (1989) 
140. Barnett, D. A., Ells, B., Guevremont, R., Purves, R. W., and Viehland, L. A.; J. Am. 
Soc. Mass Spectrom., 11, 1125–1133 (2000) 
141. Shvartsburg, A. A. and Smith, R. D.; Anal Chem, 83, 9159–9166 (2011) 
63 
 
142. Gabryelski, W. and Froese, K. L.; J. Am. Soc. Mass Spectrom., 14, 265–277 (2003) 
143. Maccarone, A. T., Duldig, J., Mitchell, T. W., Blanksby, S. J., Duchoslav, E., and 
Campbell, J. L.; J. Lipid Res., 55, 1668–1677 (2014) 
144. Owlstone Medical Ltd; ultraFAIMS-MS for High Throuput Screening and 
Quantification of Vitamin D Metabolite Stereoisomers, 1–4 (2017), Available at: 
https://www.owlstonemedical.com/media/uploads/files/VitD_v3.pdf. (Accessed: 1st 
September 2017) 
145. Shvartsburg, A. A., Isaac, G., Leveque, N., Smith, R. D., and Metz, T. O.; J Am Soc 
Mass Spectr., 22, 1146–1155 (2011) 
146. Levin, D. S., Vouros, P., Miller, R. A., and Nazarov, E. G.; J. Am. Soc. Mass 
Spectrom., 18, 502–511 (2007) 
147. Thompson, J. J.; Rays of positive electricity and their application to chemical analyses 
(1993) London: Longmans, Green and Co. 
148. Dempster, A. J.; Phys. Rev., 11, 316–325 (1918) 
149. Aston, F. W.; Philos. Mag. Ser. 6, 38, 707–714 (1919) 
150. Ardrey, R. E.; Liquid Chromatography – Mass Spectrometry: An Introduction (2003) 
1st Edition, Chichester: John Wiley & Sons Ltd. 
151. McMaster, M. C.; HPLC: A Practical User’s Guide (2007), 2nd Edition, Chichester: 
John Wiley & Sons Ltd. 
152. Swartz, M. E.; J. Liq. Chromatogr. Relat. Technol., 28, 1253–1263 (2005) 
153. Churchwell, M. I., Twaddle, N. C., Meeker, L. R., and Doerge, D. R.; J. Chromatogr. 
B Anal. Technol. Biomed. Life Sci., 825, 134–143 (2005) 
154. Alpert, A. J.; J. Chromatogr. A, 499, 177–196 (1990) 
155. Yoshida, T.; J. Biochem. Biophys. Methods, 60, 265–280 (2004) 
156. Valette, J. C., Demesmay, C., Rocca, J. L., and Verdon, E.; Chromatographia, 59, 55–
60 (2004) 
157. Buszewski, B. and Noga, S.; Anal. Bioanal. Chem., 402, 231–247 (2012) 
158. Dole, M., Mack, L. L., Hines, R. L., Mobley, R. C., Ferguson, L. D., Alice, M. B., 
Malcolm Dole, L. L. M., Marck, L. L., Hines, L., Mobley, R. C., Ferguson, L. D., and 
64 
 
Alice, M. B.; J Chem.Phys., 49, 2240–2249 (1968) 
159. Yamashita, M. and Fenn, J. B.; J Phys.Chem., 88, 4451–4459 (1984) 
160. Fenn, J. B., Mann, M., Meng, C. K. A. I., Wong, S. F., and Whitehouse, C. M.; 
Science, 246, 64–71 (1989) 
161. Kebarle, P. and Verkerk, U. H.; Mass Spectrom. Rev., 28, 898–917 (2009) 
162. Hoffmann, E. D. and Stroobant, V.; Electrospray in Mass Spectrometry: Principles 
and Applications, 43–55 (2007), Chichester: John Wiley & Sons Ltd. 
163. Taylor, G.; Proc. R. Soc. A Math Phys. Eng. Sci., 280, 383–397 (1964) 
164. Gomez, A. and Tang, K.; Phys. Fluids, 6, 404–414 (1994) 
165. Kebarle, P. and Peschke, M.; Anal. Chim. Acta, 406, 11–35 (2000) 
166. Tang, K. and Smith, R. D.; Int. J. Mass Spectrom., 185, 97–105 (1999) 
167. Wilm, M. S. and Mann, M.; Int. J. Mass Spectrom. Ion Process., 136, 167–180 (1994) 
168. Wilm, M. and Mann, M.; Anal. Chem, 68, 1–8 (1996) 
169. Juraschek, R., Dülcks, T., and Karas, M.; J. Am. Soc. Mass Spectrom., 10, 300–308 
(1999) 
170. Stephens, W. E.; Phys. Rev., 69, 691 (1946) 
171. Cameron, A. E. and Eggers, D. F.; Rev. Sci. Instrum., 19, 605–607 (1948) 
172. Wiley, W. C. and McLaren, I. H.; Rev. Sci. Instrum., 26, 1150–1157 (1955) 
173. Boesl, U.; Mass Spectrom. Rev., 36, 86–109 (2017) 
174. Hoffmann, E. D. and Stroobant, V.; Time-of-Flight Analysers in Mass Spectrometry: 
Principles and Applications, 126–143 (2007), Chichester: John Wiley & Sons Ltd. 
175. Mamyrin, B. A., Karataev, V. I., Shmikk, D. V, and Zagulin, V. A.; Sov. Phys. - JETP, 
37, 45–48 (1973) 
176. Radionova, A., Filippov, I., and Derrick, P. J.; Mass Spectrom. Rev., 35, 738–757 
(2016) 
177. Guilhaus, M.; J. Mass Spectrom., 30, 1519–1532 (1995) 
178. Guilhaus, M., Selby, D., and Mlynski, V.; Mass Spectrom. Rev., 19, 65–107 (2000) 
65 
 
179. Hoffmann, E. D. and Stroobant, V.; Quadrupole Analysers in Mass Spectrometry: 
Principles and Applications, 88–100 (2007), Chichester: John Wiley & Sons Ltd. 
180. McLuckey, S. A.; J. Am. Soc. Mass Spectrom., 3, 599–614 (1992) 
181. Bure, C. and Lange, C.; Curr. Org. Chem., 7, 1613–1624 (2003) 
182. Hoffmann, E. D. and Stroobant, V.; Detectors and Computers in Mass Spectrometry: 
Principles and Applications, 175–187 (2007), Chichester: John Wiley & Sons Ltd. 
183. Verenchikov, A. N., Krylov, E. V., Louppou, V. B., Makas, A. L., Pervukhin, V. V., 
and Shkurov, V. A.; Analysis of ionic compositions of solutions using an ion gas 
analyzer in Chemical analysis of environment, 127–133 (1991), Novosibirsk: Nauka 
184. Ells, B., Barnett, D. A., Purves, R. W., and Guevremont, R.; J. Environ. Monit., 2, 
393–397 (2000) 
185. Swearingen, K. E. and Moritz, R. L.; Expert Rev Proteomics, 33, 395–401 (2015) 
186. Owlstone Medical Ltd; The rise and rise of ion mobility spectrometry, (2017) 
Available at: https://www.owlstonemedical.com/about/blog/2017/mar/2/rising-ion-
mobility-publications/. (Accessed: 1st May 2017) 
187. Mabrouki, R., Kelly, R. T., Prior, D. C., Shvartsburg, A. a, Tang, K., and Smith, R. D.; 
J. Am. Soc. Mass Spectrom., 20, 1768–74 (2009) 
188. Shvartsburg, A. a, Li, F., Tang, K., and Smith, R. D.; Anal. Chem., 78, 3706–3714 
(2006) 
189. McCooeye, M. and Mester, Z.; Rapid Commun. Mass Spectrom., 20, 1801–1808 
(2006) 
190. Christakoudi, S., Cowan, D. and Taylor, N.; Steroids, 75, 34–52 (2010)  
191. Gomes, R., Meredith, W., Snape, C. and Sephton, M.; J. Pharm. Biomed. Anal., 49, 
1133–1140 (2009) 
192. Beach, D. G. and Gabryelski, W.; Anal. Chem., 85, 2127–2134 (2013) 
193. McCooeye, M., Ding, L., Gardner, G. J., Fraser, C. A., Lam, J., Sturgeon, R. E., and 
Mester, Z.; Anal. Chem., 75, 2538–2542 (2003) 
194. Kapron, J., Kelavkar, U., Hutzley, J., and McNally, J.; Adv. Pharm. Anal., Special Is, 
40–42 (2007) 
66 
 
195. Guddat, S., Thevis, M., Kapron, J., Thomas, A., and Schänzera, W.; Drug Test. Anal., 
1, 545–553 (2009) 
196. Venne, K., Bonneil, E., Eng, K., and Thibault, P.; Anal. Chem., 77, 2176–2186 (2005) 
197. Canterbury, J. D., Yi, X., Hoopmann, M. R., and MacCoss, M. J.; Anal. Chem., 80, 
6888–6897 (2008) 
198. Creese, A. J., Shimwell, N. J., Larkins, K. P. B., Heath, J. K., and Cooper, H. J.; J. Am. 
Soc. Mass Spectrom., 24, 431–443 (2013) 
199. Berger, D.; Med. Lab. Obs., 31, 28–30, 32, 34–40 (1999) 
200. Nicholson, J. and Lindon, J.; Nature, 455, 1054–1056 (2008) 
201. Purves, R.; Anal. Bioanal. Chem., 405, 35–42 (2013) 
202. Campbell, L., Le Blanc, Y.; Bioanalysis, 7, 853–856 (2015) 
203. Hatsis, P. and Kapron, J. T.; Rapid Commun. Mass Spectrom., 22, 735–738 (2008) 
204. Koester, C. J. and Moulik, A.; Anal. Chem., 77, 3737–3754 (2005) 
205. Pavlacka, M., Bajerova, P., Kortankova, K., Blaha, J., Zastera, M., Mazl, R., and 
Ventura, K.; Int. J. Ion Mobil. Spectrom., 19, 31–39 (2016) 
206. Guo, D., Wang, Y., Li, L., Wang, X., and Luoa, J.; J. Mass Spectrom., 50, 198–205 
(2015) 
207. Zhang, A., Sun, H., Yan, G., Wang, P., Han, Y., and Wang, X.; Cancer Lett., 345, 17–
20 (2014) 
208. Yoshizawa, J. M., Schafer, C. A., Schafer, J. J., Farrell, J. J., Paster, B. J., and Wong, 
D. T. W.; Clin. Microbiol. Rev., 26, 781–791 (2013) 
209. Chiappin, S., Antonelli, G., Gatti, R., and Palo, E. F. De; Clin. Chim. Acta, 383, 30–40 
(2007) 
210. Humphrey, S. P. and Williamson, R. T.; J. Prosthet. Dent., 85, 162–169 (2001) 
211. Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C., Bjorndahl, T. 
C., Krishnamurthy, R., Saleem, F., Liu, P., Dame, Z. T., Poelzer, J., Huynh, J., Yallou, 
F. S., Psychogios, N., Dong, E., Bogumil, R., Roehring, C., and Wishart, D. S.; PLoS 
One, 8, 1-28 (2013) 
212. Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS); Document GP-
67 
 
16A2 21, (2001) 
213. Arasaradnam, R. P., Mcfarlane, M. J., Ryan-Fisher, C., Westenbrink, E., Hodges, P., 
Thomas, M. G., Chambers, S., O’Connell, N., Bailey, C., Harmston, C., Nwokolo, C. 
U., Bardhan, K. D., and Covington, J. A.; PLoS One, 9, 1-9 (2014) 
214. Arasaradnam, R. P., McFarlane, M., Daulton, E., Skinner, J., O’Connell, N., Wurie, S., 
Chambers, S., Nwokolo, C., Bardhan, K., Savage, R., and Covington, J.; Dig. Liver 
Dis., 48, 148–153 (2016) 
215. Covington, J. A., Westenbrink, E. W., Ouaret, N., Harbord, R., Bailey, C., O’Connell, 
N., Cullis, J., Williams, N., Nwokolo, C. U., Bardhan, K. D., and Arasaradnam, R. P.; 
Sensors (Basel)., 13, 11899–11912 (2013) 
216. Covington, J. a., van. der Schee, M. P., Edge,  a. S. L., Boyle, B., Savage, R. S., and 
Arasaradnam, R. P.; Analyst, 6775–6781 (2015) 
217. Beach, D. G. and Gabryelski, W.; Anal. Chem., 83, 9107–9113 (2011) 
218. Bowman, A. P., Abzalimov, R. R., and Shvartsburg, A. A.; J. Am. Soc. Mass 
Spectrom., 28, 1562–1561 (2017) 
219. Swearingen, K. E., Hoopmann, M. R., Johnson, R. S., Saleem, R. A., Aitchison, J. D., 
and Moritz, R. L.; Mol. Cell. Proteomics, 11, M111.014985-M111.014985 (2012) 
220. Bridon, G., Bonneil, E., Muratore-schroeder, T., and Caron-lizotte, O.; J. Proteome 
Res., 11, 927–940 (2012) 
221. Swearingen, K. E., Winget, J. M., Hoopmann, M. R., Kusebauch, U., and Moritz, R. 
L.; Anal. Chem., 87, 12230–12237 (2015) 
222. Zhao, H., Cunningham, D. L., Creese, A. J., Heath, J. K., and Cooper, H. J.; J. 
Proteome Res., 14, 5077–5087 (2015) 
223. Saba, J., Bonneil, E., Pomiès, C., Eng, K., and Thibault, P.; J. Proteome Res., 8, 3355–
3366 (2009) 
224. Hatsis, P., Brockman, A. H., and Wu, J.-T.; Rapid Commun. Mass Spectrom., 21, 
2295–2300 (2007) 
225. Klaassen, T., Szwandt, S., Kapron, J. T., and Roemer, A.; Rapid Commun. Mass 
Spectrom., 23, 2301–2306 (2009) 
68 
 
226. Fu, Y., Xia, Y. Q., Flarakos, J., Tse, F. L. S., Miller, J. D., Jones, E. B., and Li, W.; 
Anal. Chem., 88, 3655–3661 (2016) 
227. Xia, Y. Q., Wu, S. T., and Jemal, M.; Anal. Chem., 80, 7137–7143 (2008) 
228. Kapron, J., Wu, J., Mauriala, T., Clark, P., Purves, R. W., and Bateman, K. P.; Rapid 
Commun. Mass Spectrom., 20, 1504–1510 (2006) 
229. Wu, S. T., Xia, Y. Q., and Jemal, M.; Rapid Commun. Mass Spectrom., 21, 3667–3676 
(2007) 
230. Beach, D. G., Melanson, J. E., and Purves, R. W.; Anal. Bioanal. Chem., 407, 2473–
2484 (2015) 
231. Ray, J. A., Kushnir, M. M., Yost, R. A., Rockwood, A. L., and Wayne Meikle, A.; 
Clin. Chim. Acta, 438, 330–336 (2014) 
 
  
69 
 
 Chapter Two 
2. Analysis of supramolecular complexes of 3-methylxanthine 
using ion mobility spectrometry combined with mass 
spectrometry 
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2.1. Chapter two overview 
Miniaturised field asymmetric waveform ion mobility spectrometry (FAIMS), combined with 
mass spectrometry (MS), has been applied to the study of self-assembling, non-covalent 
supramolecular complexes of 3-methylxanthine (3-MX) in the gas phase. 3-MX forms stable 
tetrameric complexes around an alkali metal (Na+, K+) or ammonium cation, to generate a 
diverse array of complexes with single and multiple charge states. Complexes of (3-MX)n 
observed include: singly charged complexes where n = 1-8 and 12 and doubly charged 
complexes where n = 12-24. The most intense ions are those associated with multiples of 
tetrameric units, where n = 4, 8, 12, 16, 20, 24. The effect of dispersion field on the ion 
intensities of the self-assembled complexes indicates some fragmentation of higher order 
complexes within the FAIMS electrodes (in-FAIMS dissociation), as well as in-source 
collision induced dissociation within the mass spectrometer. FAIMS-MS enables charge state 
separation of supramolecular complexes of 3-MX and is shown to be capable of separating 
species with overlapping mass-to-charge ratios. FAIMS selected transmission also results in 
an improvement in signal-to-noise ratio for low intensity complexes and enables the 
visualisation of species undetectable without FAIMS. These complexes were also explored 
using travelling wave ion mobility spectrometry (TWIMS) and drift tube ion mobility 
spectrometry (DTIMS) combined with mass spectrometry and tandem mass spectrometry to 
further explore the structures of the complexes and measure rotationally averaged collision 
cross section (CCS) values that have been compared with theoretically calculated values.  
2.2. Introduction 
Self-assembling supramolecular complexes of simple molecules are of interest in a wide 
variety of fields,1 including structural biology,2 self-assembling membranes,3 therapeutic 
delivery systems,4 nanostructures,5–7 electrochemistry8 and supramolecular technology.9 3-
Methylxanthine (3-MX) is an example of a small molecule that can form stable non-
covalently bound supramolecular complexes in the gas phase.10 3-MX has been shown to 
self-assemble in the presence of alkali metals and ammonium ions to form clusters around a 
stabilising cation, as shown in Figure 2.1; the 3-MX purine base contains both hydrogen bond 
donor (NH(1) and O(2)) and acceptor (NH(7) and O(6)) groups.11–13 
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Figure 2.1 Proposed structure of 3-MX non-covalently bound tetramer ([(3-MX)4+Cat]+) with 
stabilising cation (cat+ = NH4+, Na+, K+)10,12,13 
3-MX is a purine derivative and a metabolite of caffeine and theophylline,14,15 and has been 
monitored biologically in urine and plasma by liquid chromatographic methods.16–19 Guanine 
is a related purine base structure that self-assembles into tetrad structures in biological 
systems (G-quadruplexes) to form complexes that have been well characterised, theoretically 
and experimentally.2,20–24 Other related purine bases, such as xanthine and uric acid 
derivatives, have shown to similarly self-assemble into non-covalently bound tetrameric 
species.11,25,26 G-quadruplexes are of significant interest due to their formation in vivo at 
telomeres and their potential application as anticancer drug targets. Purine bases such as 
xanthine and uric acid are an intermediate and the end product respectively of purine 
metabolism, which are of interest in the analysis of metabolites as elevated levels can be 
indicative of a number of diseases and conditions.25 3-MX has been studied by electrospray 
(ESI)-MS and nuclear magnetic resonance (NMR) by Szolomájer et al.10; mass spectral data 
for a single tetrameric complex of 3-MX (or tetrad) and an octameric species composed of 
two parallel tetrads were reported.  
The work presented in this thesis show the combination of field asymmetric waveform ion 
mobility spectrometry (FAIMS, Section 1.3), drift tube ion mobility spectrometry (DTIMS, 
Section 1.2.1) and travelling wave ion mobility spectrometry (TWIMS, Section 1.2.2) with 
orthogonal acceleration time-of-flight (TOF)-MS to provide complementary ion mobility and 
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mass spectral information. These techniques have been used to investigate the structure of 
non-covalently bound, supramolecular complexes of (3-MX)n. Singly charged complexes up 
to n = 12, doubly charged complexes up to n = 24, and a range of intermediate complexes are 
observed. The differences in ion mobility under both low and high electric field conditions 
using FAIMS-MS analysis provided noise reduction, structural elucidation and separation of 
isobaric complexes of differing charge states. CCS experimental measurements were 
calculated using two different ion mobility techniques combined with mass spectrometry, to 
allow for comparison of CCS values calculated using a calibration (TWIMS) and a direct 
CCS measurement (DTIMS) of 3-MX complexes. Four theoretical models were used to 
calculate the CCS: the projection approximation (PA), projected superposition approximation 
(PSA), the exact hard spheres scattering (EHSS) method and the trajectory method (TM).27–33 
2.3. Experimental 
2.3.1. Sample preparation 
HPLC grade methanol, water, and analytical grade sodium hydroxide and ammonium acetate 
were purchased from Fisher Scientific (Loughborough, UK). 3-MX, formic acid and peptides 
utilised for collision cross section (CCS) calibration: (Glycine)2, (Alanine)3, (Lysine)4, 
(Phenylalanine)5 and bradykinin were all purchased from Sigma-Aldrich (Gillingham, UK). 
3-MX (0.5 mM) solutions in 60:40 v/v MeOH:water were prepared with two different 
modifiers (1 mM each): sodium hydroxide and ammonium acetate to promote adduct 
clusters. Standard solutions of 3-MX were analysed by direct syringe infusion. A calibration 
solution for TWIM-MS analysis consisting of (Glycine)2, (Alanine)3, (Lysine)4, 
(Phenylalanine)5 and bradykinin (1 mg mL
-1 each) was prepared in aqueous 0.1 % FA 
solution. All standard solutions were analysed by direct syringe infusion. 
2.3.2. Instrumentation 
ESI-MS and ESI-FAIMS-MS instrumentation 
Direct infusion ESI-MS experiments were carried out using an Agilent 6230 TOF MS 
(Agilent Technologies, UK) operated in positive ionisation mode using a 10 µL min-1 sample 
infusion rate from a syringe pump. The ESI nebuliser pressure was set to 30 psig with a 
sheath gas (N2) flow of 10 L min
-1 at 200°C, with the nozzle voltage set to 2000 V. The 
capillary voltage was set to 3500 V and the drying gas (N2) flow to 8 L min
-1 at 150°C. The 
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MS scan rate was 10 scans s-1 in the mass range m/z 90-2200, with a fragmentor voltage of 
150 V. 
ESI-FAIMS-MS analyses were carried out using the Agilent 6230 TOF MS (Agilent 
Technologies, UK) modified with a prototype miniaturised chip-based FAIMS (Owlstone 
Ltd., Cambridge, UK), which has been described in detail elsewhere (Sections 1.3.3 and 
1.5.1).34–36 The FAIMS device was located behind the modified spray shield of the Jet Stream 
ESI source, in front of the mass spectrometer inlet capillary, and consists of multiple parallel 
planar electrode channels (100 µm electrode gap) with a short trench length (78.1 mm) and 
ion path length (700 µm). ESI-FAIMS-MS experiments were performed by direct syringe 
infusion of 3-MX solutions and by scanning of the FAIMS dispersion field (DF) and 
compensation field (CF) to investigate the transmission of singly, doubly and multiply 
charged 3-MX clusters through the FAIMS device. The DF was stepped from 194 to 323 Td 
(12 steps) and the CF was scanned from -2 to +5 Td, at a rate of 0.1 Td s-1 (140 steps), to 
perform a two-dimensional scan of the FAIMS parameters. 
TWIMS-MS and DTIMS-MS instrumentation 
IM-MS analyses were carried out using travelling wave ion mobility spectrometry (TWIMS) 
and drift tube ion mobility spectrometry (DTIMS) combined with MS. The IM-MS data 
acquired were processed using Microsoft Excel (2010), MassLynx V4.1 and Driftscope 
software (Waters, Manchester, UK). 
TWIMS-MS analyses were carried out using a hybrid quadrupole/ ion mobility/ TOF 
spectrometer (Waters Synapt HDMS, Waters Corporation, Manchester, UK). The ESI source 
was operated in positive ionisation mode with direct syringe infusion of the sample at a rate 
of 10 µL min-1; the capillary voltage was set to 3 kV and the cone voltage to 20 V. The 
source and desolvation gas (N2) flow rates were set to 23 L h
-1 and 400 L h-1, with 
temperatures set to 120°C and 200°C respectively. The tri-wave drift cell conditions were 
travelling wave heights of 7.5-12 V and 8-14 V, wave velocity of 300 m s-1, with a pusher 
pulse of 64 µs and the drift gas (N2) set to 24 mL min
-1. TWIMS-MS/MS data were obtained 
with the quadrupole set to transmit m/z 687.2 ([(3-MX)4+Na]
+) or m/z 1351.4 ([(3-
MX)8+Na]
+) or m/z 2037.6 ([(3-MX)12+2Na-H]
+) with a collision energy of 14 eV applied in 
the trap region for MS/MS analysis. The experimental CCS using TWIMS-MS were 
measured in N2 in the tri-wave drift cell. The calibration standards (of known CCS in He) 
were used to create a calibration curve after correction for the non-linear electric field of the 
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TWIMS system (see Section 1.3.3).37 Experimental TWIMS-MS CCS measurements were 
carried out using a calibration mixture consisting of polypeptides: (Gly)2, (Ala)3, (Lys)4, 
(Phe)5 and bradykinin, which were recorded under the same conditions as [(3-MX)+Na]
+, [(3-
MX)4+Na]
+, [(3-MX)8+Na]
+ and [(3-MX)12+2Na-H]
+. 
DTIMS-MS experiments were performed in collaboration with Professor Perdita Barran and 
Dr Chris Nortcliffe from the University of Manchester. CCS measurements in He were 
performed on an in-house modified Waters Micromass Q-TOF mass spectrometer with an 
orthogonal nESI source. The instrument has a 5 cm copper drift cell which is filled with 
helium to a pressure of ~4 Torr.38 Experiments were performed at six electrical potentials 
between 60 V and 25 V at 5 V increments. Arrival-time distributions were recorded 
synchronously for all ions over ten mobility separations. Rotationally averaged experimental 
CCS measurements, in helium, were obtained by plotting experimental arrival times against 
pressure/temperature (as described in Section 1.2.3).39,40 
The theoretical CCS values for the 3-MX monomer, tetramer and octamer were based upon 
the molecular structure of the 3-MX monomer from the published x-ray crystallographic 
data.13 The density functional theory calculations were performed by Dr Mark Edgar, from 
Loughborough University, using the B3LYP/6-311G** and B-LYP-D/6-311G** basis sets 
using GUASSIAN0941 or the Firefly QC42 package which is partially based on the GAMESS 
(US) source code.43 This produced energetically relaxed structures which were used in a 
separate software package called MOBCAL developed by Shvartsburg and Jarrold,27,28 using 
models to calculate theoretical CCS. In the work presented here the Fortran77 MOBCAL 
code was compiled using the Force 2.0 FORTRAN Compiler and Editor (version 2.0.9p). 
The CCS of the 3-MX singly charged tetrameric and monomeric sodium adduct complexes 
were calculated using three different models in MOBCAL, the projection approximation 
(PA), the exact hard spheres scattering (EHSS) and the trajectory method (TM). 27–29 A fourth 
method recently developed method was also compared called the projected superposition 
approximation (PSA).30–33 Further information about these methods are described in Section 
1.2.4. 
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2.4. Results and discussion 
2.4.1. ESI-MS mass spectra 
The self-assembly of 3-MX results in a complex ESI mass spectrum when a solution of 3-
MX is infused in 60:40 v/v methanol:water with 1 mM ammonium acetate (Figure 2.2). A 
range of non-covalent clusters with different cations are observed in the gas phase, in 
agreement with Szolomájer et al.10 When ammonium acetate is added as a solvent modifier, 
abundant peaks correspond to tetrameric species with alkali metal and ammonium cations 
(Figure 2.2 (a)); for example [(3-MX)4+NH4]
+ (m/z 682), [(3-MX)4+Na]
+ (m/z 687) and [(3-
MX)4+K]
+ (m/z 703). The mass spectrum is characterised by many singly (Figure 2.2 (a)), 
doubly (Figure 2.2 (b) – (d)) and multiply (Figure 2.2 (d)) charged species, making it difficult 
to identify which species are present because of the overlapping isotopic patterns.  
The use of sodium hydroxide as a solvent modifier results in a simplified mass spectrum 
dominated by singly charged sodiated adducts as shown in Figure 2.2 (e), The base peak in 
the spectrum is the [(3-MX)4+Na]
+ ion at m/z 687.19, with the second most intense response 
corresponding to the [(3-MX)8+Na]
+ ion at m/z 1351.39. Monomer, dimer and trimer sodiated 
complexes are observed with lower intensities at m/z 189.04, 355.09 and 521.14 respectively, 
suggesting that the tetrameric based complexes are more stable than non-tetrameric 
structures. Complexes of (3-MX)n observed in the presence of sodium ions include: singly 
charged tetrameric complexes [(3-MX)n+xNa-yH]
+ (x – y = 1 for x = 1-5, y = 0-4) where n = 
4, 8, and 12; doubly charged tetrameric complexes [(3-MX)n+xNa-yH]
2+ (x – y = 2 for x = 2-
10, y = 0-8) where n = 12, 16, 20, and 24; and a range of triply charged complexes 
corresponding to n = 32 in the region m/z 1815-1850; for example [(3-MX)32+6Na-3H]
3+. 
Intermediate non-tetrameric complexes of low intensity are also observed that correspond to 
singly charged complexes where n = 1-3 and 5-7, and doubly charged non-tetrameric 
complexes where n = 13-15 and 17-23. The focus of this study was on the 3-MX monomer 
and singly charged tetrameric complexes of 3-MX with sodium: [(3-MX)+Na]+ (m/z 189.04), 
[(3-MX)4+Na]
+ (m/z 687.18), [(3-MX)8+Na]
+ (m/z 1351.38) and [(3-MX)12+2Na-H]
+ (m/z 
2037.55). 
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Figure 2.2 (a) Mass spectrum of 3-MX in 60:40 MeOH:H2O with 1 mM ammonium acetate with 
FAIMS off, inserts show zoomed in regions of the spectra; (b) a mixture of singly and doubly 
charged species in the region m/z 2010-2060; (c) doubly charged species in the region m/z 1012-
1040; (d) doubly and multiply charged species in the region m/z 1680-1760; (e) mass spectrum of 
3-MX in 60:40 MeOH:H2O with 1 mM sodium hydroxide with FAIMS off 
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2.4.2. ESI-FAIMS-MS analysis of non-covalent supramolecular complexes 
The sodiated 3-MX clusters present in the ESI-MS spectrum (Figure 2.2) were also observed 
using ESI-FAIMS-MS. This demonstrates that supramolecular complexes of 3-MX may be 
transmitted through the FAIMS device in the presence of the alternating high and low electric 
fields and at a temperature of 150°C (standalone FAIMS is routinely used at much lower 
temperatures, i.e. atmospheric temperature).44 The hyphenation of FAIMS with MS allows 
ions of a single m/z to be selected as the CF is scanned at a fixed DF giving the characteristic 
FAIMS CF spectrum of each ion. Alternatively, a FAIMS three-dimensional representation 
of DF, CF and intensity can be obtained by sweeping the DF (194-323 Td, in steps of 10 Td) 
and CF (-2-5 Td, in steps of 0.05 Td) to generate a heat map (or contour plot), where DF is 
plotted against CF and the intensity is represented by a colour scale.45 The ESI-FAIMS-MS 
heat maps are plotted for mass-selected ions in order to provide a way to observe the 
behaviour of selected ions transmitted through the FAIMS device, and aid in the selection of 
parameters to resolve ions of interest.45  
The 3-MX monomeric species is the building block of all of the complexes in the mass 
spectrum for 3-MX (Figure 2.2). Figure 2.3 shows the FAIMS characteristics of the 3-MX 
monomer ([(3-MX)+Na]+, m/z 189.04) at three different fragmentor voltages, which is 
applied in the intermediate pressure region of the MS interface, with the FAIMS scanned 
between DF 180-300 Td (steps of 10 Td) and CF -2-5 Td (steps of 0.05 Td). The monomer 
ion observed at DF 200 Td and fragmentor voltage of 150 V (Figure 2.3 (a) black solid line, 
and Figure 2.3 (b)), is an intense peak centred around CF -0.05 Td can be observed at DF 
values up to 260 Td, with a secondary peak centred around CF 0.65 Td at DF 200 Td in 
Figure 2.3 (a). This secondary peak is observed to reduce in intensity as the fragmentor 
voltage is lowered from 150 V to 100 V (Figure 2.3 (a) grey dotted line, and Figure 2.3 (c)), 
and then to 50 V (Figure 2.3 (a) grey solid line, and Figure 2.3 (d)). The peak is not present in 
the CF spectrum at DF 200 Td and little remains in the heat map at 50 V. The overlaid CF 
spectra for the 3-MX dimer ([(3-MX)2+Na]
+, m/z 355.09), in Figure 2.3 (b) black dotted line, 
is also centred around CF 0.65 Td at DF 200 Td, showing a strong correlation to the 
secondary peak in the CF spectra of the 3-MX monomer. This suggests that the dimer was 
transmitted through the FAIMS electrodes intact and fragmented in the MS interface by in-
source collision induced dissociation (in-source CID) at 150 V post-FAIMS separation, 
resulting in the two peaks evident in the CF spectra and the FAIMS heat maps for m/z 
189.04.35,46 This is further supported by the mass spectra (Figure 2.4) extracted at the 
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optimum FAIMS transmission conditions for the two peaks (DF 200 Td, CF -0.05 Td and 
0.65 Td) at each of the three fragmentor voltages, showing the m/z 189 ion of the 3-MX 
monomer present in the mass spectra at CF 0.65 Td at 150 V, which decreases at 100 V and 
is not present at 50 V. In each of the heat maps for the 3-MX monomer (Figure 2.3 (b), (c) 
and (d)), the intensity reduces sharply as the DF increases above 240 Td resulting from a 
greater number and velocity of collisions due to field heating at higher DFs.47,48 
 
Figure 2.3 ESI-FAIMS-MS analysis of [(3-MX)+Na]+ (m/z 189.04) at three different MS 
fragmentor voltages; (a) overlaid CF spectra at DF 200 Td where the black solid line = [(3-
MX)+Na]+ at 150 V, grey dotted line = [(3-MX)+Na]+ at 100 V, grey solid line = [(3-MX)+Na]+ at 
50 V, black dotted line = [(3-MX)2+Na]+ (m/z 355.09) at 150 V; three dimensional heat maps of 
DF vs CF (where intensity (%) is represented on the colour scale) of m/z 189.04 at (b) 150 V, (c) 
100 V, and (d) 50 V 
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Figure 2.4 Mass Spectra extracted in the region m/z 170-420 at three MS fragmentor voltages at 
two different FAIMS conditions: DF 216 Td, CF -0.05 Td at (a) 150 V, (b) 100 V and (c) 50 V; 
and DF 216 Td, CF 0.65 Td at (d) 150 V, (e) 100 V and (f) 50 V 
The change in CF for transmission of the (3-MX)n (n = 4, 8, 12) tetrameric complexes, in 
Figure 2.5 (a), follows a trend with increased distance from 0 Td in the order: [(3-
MX)12+2Na-H]
+ (1.15 Td) <  [(3-MX)8+Na]
+ (1.70 Td) < [(3-MX)4+Na]
+ (2.05 Td); i.e. the 
difference in CF from 0 Td decreases as the size of the complex increases. The increased 
distance from 0 Td can be attributed to increased differences in mobility between electric 
field extremes. The overlap of the CF spectra and near even distribution of this trend suggests 
an incremental effect of the FAIMS conditions of the tetrameric based structures of these 
singly charged complexes of 3-MX, possibly indicating an influence of structure and size, 
and suggests a relationship with the number of layers in the stacked assembly.5,10 
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Figure 2.5 (a) CF spectra at DF 323 Td for singly charged sodium doped tetrameric 3-Mx 
complexes: black solid line = [(3-MX)4+Na]+ (m/z 687.18), black dotted line = [(3-MX)8+Na]+ 
(m/z 1351.38), grey solid line = [(3-MX)12+2Na-H]+ (m/z 2037.55); three dimensional heat maps 
of DF vs CF (where intensity (%) is represented on the colour scale) of (b) [(3-Mx)4+Na]+ (m/z 
687.18) and (c) [(3-MX)12+2Na-H]+ (m/z 2037.55)  
The single tetramer structure ([(3-MX)4+Na]
+, m/z 687.18) was observed to be stable through 
the FAIMS device at all DFs up to 300 Td (Figure 2.5 (a) solid black line and (b)), indicated 
by the symmetrical profile that retains a constant peak width, with a slight fall in intensity at 
the higher DFs up to 323 Td. In contrast, the [(3-MX)12+2Na-H]
+ (m/z 2037.55) ion has a 
broad, unsymmetrical profile at all DFs (Figure 2.5 (c)) compared to the single tetramer 
complex (Figure 2.5 (b)). This unsymmetrical broadening of the [(3-MX)12+2Na-H]
+ profile 
(Figure 2.5 (c)) at DFs above 270 Td, could be due to a combination of factors such as: signal 
instability due to the low intensity of the ion; a higher probability of a distribution of 
conformations for this larger complex; or the dissociation of higher complexes during 
transmission through the FAIMS electrodes. Evidence for in-FAIMS dissociation is provided 
in the mass spectra, shown in Figure 2.6, extracted at DF 323 Td and CF 2.70 Td, 
corresponding to the high CF tailing edge of the asymmetrical peak of the [(3-MX)12+2Na-
H]+ ion (Figure 2.5 (a)). In addition to the singly charged m/z 2037.55 ion in the mass 
spectrum (Figure 2.6 (b)), abundant species include higher ordered doubly charged ions of n 
= 16 and 20 in the regions m/z 1362 – 1395 and m/z 1694 – 1716 respectively. This suggests 
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that the electric field strengths experienced by ions in the FAIMS (up to 60 kV cm-1) may 
cause higher ordered and doubly charged complexes, such as n = 16, 20 and 24 (formed in 
the ESI source) to dissociate to yield singly charged m/z 2037.55 ions during transmission 
through the FAIMS electrodes (the relative fragility of the structures can be observed via a 
tandem MS analysis shown in Figure 2.7).  
 
Figure 2.6 (a) CF spectra at DF 323 Td for [(3-MX)12+2Na-H]+ (m/z 2037.55) and mass spectra 
extracted at DF 323 Td and CF 2.70 Td in the m/z regions: (b) m/z 100-2200, (c) m/z 1350-1405 
and (d) m/z 1690-1735 
 
Figure 2.7 Plot of the collision induced dissociation of [(3-MX)8+Na]+ using MS/MS on Synapt 
G1: m/z 1351 isolated on the quadrupole and then the trap CE ramped from 2 to 40 V in 2 V 
increments 
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The singly charged octameric complex, [(3-MX)8+Na]
+ (Figure 2.8 (a)), is observed to have a 
very stable and symmetrical profile even up to the highest DF values, similar to the single 
tetramer structure [(3-MX)4+Na]
+ (Figure 2.5 (b)), but the reduction in ion intensity as the DF 
increases, expected due to increased field heating and scattering of ions through the FAIMS 
device at higher DFs, is not observed. The CF for maximum transmission of [(3-MX)8+Na]
+ 
increases from 0.35 Td (DF 194 Td) to 1.70 Td (DF 323 Td), an increase of 1.35 Td. In 
contrast, a doubly charged complex [(3-MX)16+3Na-H]
2+ (Figure 2.8 (b)), whilst having a 
symmetrical profile, is much more affected by the electric fields with the CF for maximum 
transmission increasing from 0.65 Td (DF 194 Td) to 2.85 Td (DF 323 Td), an increase of 
2.20 Td, and the intensity starts to decrease significantly at DF 260 Td and above. The 
intensities of [(3-MX)8+Na]
+ and [(3-MX)16+3Na-H]
2+ at DF values in the range 180-300 Td 
at the lowest fragmentor voltage of 50 V (Figure 2.9), show the expected decrease in the 
intensity for the doubly charged [(3-MX)16+3Na-H]
2+ ion at higher DFs as seen from Figure 
2.8 (h). However, the intensity of [(3-MX)8+Na]
+ ion shows an unexpected overall increase 
as the DF increases. This increase in the intensity of the singly charged 3-MX octameric 
complex is evidence that the higher ordered and more highly charged species, such as the 
doubly charged [(3-MX)16+3Na-H]
2+, may dissociate in the FAIMS device into the smaller 
singly charged complexes, such as [(3-MX)8+Na]
+. 
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Figure 2.8 Overlapping charge state separation of 3-MX (+Na+) complexes at fragmentor 
voltage of 150 V: three-dimensional heat maps of DF vs CF (with intensity (%) represented on 
the colour scale) of (a) m/z 1351.38 ([(3-MX)8+Na]+) and (b) m/z 1362.38 ([(3-MX)16+3Na-H]2+); 
(c) mass spectrum with no FAIMS; (d) FAIMS CF scan at DF 323 Td, selected ion responses for 
m/z 1373.37; (e) FAIMS selected mass spectrum of singly charged species at DF 323 Td, CF 1.7 
Td; and (f) FAIMS selected mass spectrum of doubly charged species at DF 323 Td, CF 2.85 Td; 
(g) three-dimensional heat map of m/z vs. CF (at DF 323 Td, with intensity (%) represented on 
the colour scale) showing the FAIMS separation of two isobaric species at m/z 1373.37, [(3-
MX)8+2Na-H]+ and [(3-MX)16+4Na-2H]2+, and their isotopic patterns; (f) three-dimensional heat 
map of DF vs CF (with intensity (%) represented on the colour scale) of m/z 1373.37 ([(3-
MX)8+2Na-H]+ and [(3-MX)16+4Na-2H]2+  
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Figure 2.9 Plot of singly charged [(3-MX)8+Na]+ and [(3-MX)16+3Na-H]+ of max intensity for 
each species vs the DF, showing the changes in absolute max intensity as the DF increases 
 
The isotope pattern provides a source of identification for singly or multiply charged species 
in mass spectrometry, but will not separate isobaric ions of different charge states. However, 
ESI-FAIMS-MS allows for the separation of ions based upon compound-dependent 
differences in high and low field mobility as a result of charge state.34,35,49 FAIMS separation 
may therefore be used to suppress or enhance the transmission of singly or multiply charged 
ions selectively. The significance of this becomes apparent for overlapping isotopic patterns 
of singly and doubly charged species, such as (3-MX)8 and (3-MX)16 in the range m/z 1300-
1400 in Figure 2.8 (c), which cannot be resolved by the reflectron TOF mass analyser alone. 
However, the singly charged [(3-MX)8+2Na-H]
+ ion (m/z 1373.37) is resolved from the 
corresponding doubly charged [(3-MX)16+4Na-2H]
2+ ion with the same m/z by FAIMS 
(Figure 2.8 (d)). FAIMS-selected transmission of the appropriate charge state is shown in 
Figure 2.8 (e) and (f) at CF 1.70 Td and 2.85 Td respectively (DF 323 Td), resulting in the 
ESI-FAIMS-MS separation of overlapping singly and doubly charged isobaric 3-MX species 
in the mass spectrum. The most abundant octameric species with a single sodium cation ([(3-
MX)8+Na]
+) at m/z 1351.39 also demonstrates the ability of FAIMS to increase the signal-to-
noise ratio (S:N), by 2.8 times in Figure 2.8 (e) compared to the FAIMS off mass spectrum in 
Figure 2.8 (c), and also the ability to filter out this highly abundant singly charged species to 
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reveal that there is no evidence of a [(3-MX)16+2Na]
2+ complex which would have the same 
m/z (Figure 2.8 (f)). A 2-3 fold enhancement of the S:N was observed for all of the 
complexes in Figure 2.8 (e) and (f), compared to Figure 2.8 (c), as a result of the removal of 
background noise from the doubly and singly charged species for Figure 2.8 (e) and (f) 
respectively.  
In this study of 3-MX complexes, a second type of heat map of m/z vs. CF at a particular DF 
(instead of DF vs. CF at a particular m/z, as shown in Figure 2.3 and Figure 2.5) provides an 
alternative view of selected ions. Figure 2.8 (g) is an example of such a plot, for m/z vs. CF at 
DF 323 Td in the region m/z 1373-1376, which shows the FAIMS separation of the two 
isobaric species of m/z 1373.37 which correspond to the singly and doubly charged species 
[(3-MX)8+2Na-H]
+ and [(3-MX)16+4Na-2H]
2+. These isobaric singly and doubly charged 
species at m/z 1373.37 can also be plotted as a heat map of DF vs. CF at all DFs, Figure 2.8 
(h) which shows an intense peak corresponding to the singly charged [(3-MX)8+2Na-H]
+ and 
a secondary peak that begins to separate from the main intense peak at DF 240 Td and above. 
This heat map can be compared to those which are either singly or doubly charged with no 
corresponding peak present, such as those of m/z 1351.38 and 1362.38 (Figure 2.8 (a) and 
(b)), demonstrating the similar profiles of the singly and doubly charged complexes. 
The ESI-mass spectrum of 3-MX with sodium hydroxide as the solvent modifier (Figure 2.2 
(e)) is dominated by tetrameric complexes and the transmission of some lower abundance 
non-tetrameric 3-MX isobaric species can be masked by these prominent ions (Figure 2.10). 
For example, in the mass spectrum of 3-MX in the region m/z 1016-1026 without FAIMS 
applied (Figure 2.10 (a)), the peak at m/z 1019.3 could correspond to [(3-MX)6+Na]
+ or [(3-
MX)12+2Na]
2+, though the isotope pattern suggests that only the doubly charged tetrameric 
species is present. However, comparison of the FAIMS peaks for the first two isotopes of this 
species (Figure 2.10 (b)) at m/z 1019.28 and 1019.78 shows a small shoulder is observed at 
the low CF edge of the peak for m/z 1019.28. Careful selection of the FAIMS DF and CF 
makes it possible to filter out the (35 times) more abundant doubly charged species in order 
to selectively transmit the singly charged [(3-MX)6+Na]
+ ion (Figure 2.10 (c)); without 
FAIMS separation it was not possible to determine the presence of this hexameric complex of 
3-MX, whilst the tetrameric doubly charged [(3-MX)12+2Na]
2+ dominates the mass spectrum. 
Also, by selecting the FAIMS at the maximum CF for transmission for m/z 1019.3 ([(3-
MX)12+2Na]
2+) at DF 216 Td, the S:N is doubled by reducing background noise in the mass 
spectrum (Figure 2.10 (d)). 
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Figure 2.10 ESI-FAIMS-MS analysis of m/z 1019.28: (a) mass spectrum with no FAIMS 
applied; (b) FAIMS CF scan at DF 216 Td for m/z 1019.28 (solid line) and m/z 1019.78 (dotted 
line); (c) FAIMS selection of singly charged species (DF 216 Td, CF 0.25 Td); and (d) FAIMS 
selection of doubly charged species (DF 216 Td, CF 1.10 Td)  
 
The ability of FAIMS to investigate self-assembling supramolecular complexes of 3-MX 
doped with sodium has been demonstrated. However, ESI-FAIMS-MS analysis can also be 
used to investigate complexes of 3-MX with different stabilising cations NH4
+, Na+ and K+ 
(Figure 2.11) whose FAIMS conditions have been shown to vary dependent on cation. A 
combination of these varying FAIMS conditions and charge state separation has been utilised 
to identify hetero-cationised complexes of 3-MX (Figure 2.12). In the region m/z 1340-1450, 
a range of both singly and doubly charged complexes with different stabilising cations can be 
identified using ESI-FAIMS-MS that were previously hidden using ESI-MS alone. Figure 
2.12 shows an example of how FAIMS can be used to separate these isobaric compounds of 
different charge state by examining the FAIMS CF spectra for m/z 1370.4 (Figure 2.12 (a)). 
The mass spectral peak for m/z 1370.4 without FAIMS applied (Figure 2.12 (b)) is an overlap 
of the more abundant [(3-MX)8+K]
+ isotope peaks and a hidden doubly charged ion. Careful 
selection of the CF maxima of the two peaks in the FAIMS spectra (Figure 2.12 (a)) and 
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extraction of the mass spectra (Figure 2.12 (c) and (d)) allows for the separation of the 
isobaric abundant singly charged complex, [(3-MX)8+K]
+, and the doubly charged hetero-
cationic complex, corresponding to [(3-MX)16+2Na+K-H]
2+.  
 
Figure 2.11 CF FAIMS spectra at DF 323 Td of the 3-MX tetramer complex with three different 
cations: grey solid line = [(3-MX)4+NH4]+, black solid line = [(3-MX)4+Na]+ and black dotted 
line = [(3-MX)4+K]+  
 
Figure 2.12 ESI-FAIMS-MS analysis of a hetero-cation [(3-MX)16+2Na+K-H]2+ of m/z 1370.36: 
(a) FAIMS CF scan at DF 323 Td; (b) mass spectrum with no FAIMS applied; (c) FAIMS 
selection at CF 1.65 Td; (d) FAIMS selection at CF 2.75 Td 
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Complexes with multiple cations, both homo- and hetero-cationised complexes, appear to be 
stable with sodium cations even with ammonium acetate as the modifier. Singly charged 
octameric homo-cation complexes of 3-MX with up to five Na+ were observed (DF 323 Td, 
CF 1.65 Td), while only [(3-MX)8+NH4]
+ and [(3-MX)8+K]
+ were observed for NH4
+ and 
K+. Furthermore, the hetero-cation complexes with Na+ + K+ were more abundant than the 
NH4
+ + Na+ and NH4
+ + K+ complexes, with a range of Na+ + K+ complexes observed in the 
region m/z 1340-1450, for example [(3-MX)8+3Na+K-3H]
+ (DF 323 Td, CF 1.65 Td) and 
[(3-MX)16+2Na+2K-2H]
2+ (DF 226 Td, CF 0.85 Td). Hetero-cation complexes with all three 
cations were also observed, with very low intensities, that correspond to: [(3-
MX)8+NH4+Na+K-2H]
+ (m/z 1406.36; DF 323 Td, CF 2.75 Td), [(3-MX)16+NH4+2Na+K-
2H]2+ (m/z 1378.87; DF 313 Td, CF 2.60 Td), [(3-MX)16+3NH4+Na+2K-4H]
2+ (m/z 1403.88; 
DF 216 Td, CF 0.80 Td), and [(3-MX)16+NH4+3Na+2K-4H]
2+ (m/z 1408.84; DF 302 Td, CF 
2.30 Td). 
2.4.3. Comparison of experimental CCS to theoretical CCS 
The gas phase ion mobilities of sodium doped 3-MX complexes have also been analysed by 
IM-MS via direct syringe infusion of 3-MX (0.5 mM). The focus of the IM-MS analysis was 
on the singly-charged tetrameric sodium adducts and the monomeric sodium adduct as the 
building block of the complexes. The resulting TWIMS-MS EICs for [(3-MX)4+Na]
+, [(3-
MX)8+Na]
+ and [(3-MX)12+2Na-H]
+, shown in Figure 2.13, demonstrate the separation of the 
3-MX tetrameric complexes. As the m/z of the singly charged complexes increase the 
observed bin number increases from 80 for [(3-MX)4+Na]
+, 125 for [(3-MX)8+Na]
+ and to 
170 for [(3-MX)12+2Na-H]
+. This is in contrast to the FAIMS-MS analysis (Figure 2.5) 
where the CF for transmission of the tetrameric clusters decreases as the size (m/z) of the 
cluster increases.  
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Figure 2.13 Ion mobility spectra of [(3-MX)+Na]+ singly charged tetrameric complexes, at a 
TWIMS wave height range of 8-14 V 
 
CCS values for the sodiated 3-MX adducts of interest were calculated theoretically using 
modelled lowest energy conformations to provide x, y and z coordinates for each atom in the 
structure: five monomeric structures were modelled (Figure 2.14 (a)), one structure for the 
tetramer (Figure 2.14 (b)), and two octameric structures (Figure 2.14 (c)). These x, y and z 
coordinates were modelled using DFT in GUASSIAN09 and Firefly QC by Dr Mark Edgar 
(Loughborough University). The x, y and z coordinates were then inputted into MOBCAL to 
calculate the CCS using the PA, EHS, TM and PSA models (described in Section 1.2.4). The 
calculated theoretical CCS values for each model are reported in Table 2.1, along with the 
experimentally measured values using DTIMS-MS and TWIMS-MS. The dodecameric 
species was not modelled theoretically due to the computational cost, and was also not 
measured on the DTIMS as it was not observed (possibly due to differences between the 
nano-ESI source on the DTIMS-MS and the ESI source used on the TWIMS-MS).  
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Figure 2.14 Structures of 3-MX theoretically modelled: (a) 3-MX monomeric structures; (b) tetrameric structure of 3-MX; (c) 3-MX octameric 
structures50 
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Table 2.1 Comparison of theoretically calculates CCS values with experimentally measured 
CCS values 
3-MX Complex m/z 
Modelled CCS values (Å2) 
Experimental CCS 
measurements (Å2)† 
Figure 
2.14 
MOBCAL 
PSA 
Server 
TWIMS DTIMS 
PA EHSS TM PSA 
[(3-MX)+Na]+ 189.04 
a i 
a ii 
a iii 
a iv 
a v 
78 
78 
78 
74 
75 
81 
81 
81 
77 
77 
73 
73 
73 
70 
72 
71 
71 
71 
68 
68 
79 ± 4 65 ± 4 
[(3-MX)4+Na]+ 687.18 b 185 197 185 181 180 ± 2 180 ± 4 
[(3-MX)8+Na]+ 1351.38 
c i 
c ii 
254 
258 
285 
293 
272 
278 
260 
273 
258 ± 2 236 ± 3 
[(3-MX)12+2Na-H]+ 2037.55 Not modelled 338 ± 1 
Not 
observed 
† Values quoted as ± 3 times the standard deviation 
 
Comparison of the experimentally measured CCS and the modelled values, shows that 
DTIMS-MS values for the monomer and the octamer are smaller than expected from the 
modelled data. The TWIMS-MS experimental CCS values are in good agreement with the 
modelled data using the PA method. The PSA method is also in good agreement for the 
TWIMS-MS determined tetramer and the octamer (Figure 2.14 (c) (i)), however the 
monomer is experimentally larger than the modelled values using PSA. The PSA values for 
the DTIMS-MS monomer are in agreement with the monomeric structures shown in Figure 
2.14 (a) (iv and v) and with the DTIMS-MS determined tetramer. The observation of the 
modelled data agreeing more with the TWIMS-MS data is unexpected as TWIMS, which 
uses a calibration to measure CCS, has previously been shown to overestimate CCS values in 
comparison to DTIMS measured values which are directly measured.37 The CCS values 
modelled using EHSS compared to the experimental values of the complexes appear to have 
overestimated in comparison to the other modelling methods, which was expected as EHSS 
has been shown to overestimate CCS compared to PA and TM based upon systematic 
exaggeration of scattering of atoms.51  
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TWIMS analysis combined with tandem MS (Figure 2.15) allowed for further structural 
analysis of the fragmentation of these tetrameric 3-MX complexes in the gas phase. Pre-
selection of the m/z 1351.4 ([(3-MX)8+Na]
+) using the quadrupole of the IM-MS instrument, 
and increasing the collision energy in the trap region of the Synapt (Section 1.2.2) to 14 eV, 
the octameric complex can be fragmented. The m/z and the ion mobility profiles of the 
fragments of the octamer both provide evidence of the structural relationships of the 
tetrameric (4n) complexes and the intermediate structures, including dimer and trimer. The 
IM-MS/MS data for the octamer indicates the breakdown of the octamer into the tetrameric 
and dimeric 3-MX structures, with intermediate complexes also. As the m/z (size) of the 
fragment decreases (with decreasing number of 3-MX in the complex) the mobility increases 
and the complex is observed at faster arrival times (lower bin numbers).  
 
Figure 2.15 Tandem MS of [(3-MX)8+Na]+: (a) ion mobility profiles with a TWIMS wave height 
range of 8-14 V with the trap CE at 14 V; (b) product ion mass spectrum showing the fragments 
of [(3-MX)8+Na]+ 
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2.5. Conclusions 
Miniaturised chip-based FAIMS combined with TOF MS has been applied to the study of 
self-assembling supramolecular non-covalent complexes of 3-MX. Non-covalently bound 
supramolecular complexes are shown to be able to successfully traverse the FAIMS device, 
but at high DFs there is evidence for in-FAIMS dissociation of higher ordered complexes 
may be observed. Singly charged 3-MX complexes of a tetrameric structure were shown to 
have different CF values for maximum transmission, with CF decreasing with increasing 
complex size. FAIMS selection prior to mass analysis allows the separation of charge states 
of 3-MX complexes. Singly charged tetrameric complexes were found to be stable through 
the FAIMS device, even up to the highest DF values, whilst the doubly charged tetrameric 
species show a clear decline in intensity at higher CF values as the DF increases compared to 
the singly charged 3-MX complexes. FAIMS pre-selection allows complexes that were 
previously concealed by more abundant overlapping isobaric species to be observed, further 
highlighting the complexity and depth of information that ESI-FAIMS-MS analysis can 
unravel in the study of these supramolecular complexes. ESI-FAIMS-MS has also been 
applied to an array of supramolecular non-covalent complexes of 3-MX with multiple cations 
present, and shown to aid in the identification of hetero-cation complexes. FAIMS-MS has 
shown the potential to aid in the deconvolution of complicated mass spectra of 
supramolecular non-covalent complexes. Hyphenation of FAIMS-MS and IM-MS has been 
used for a structural analysis of 3-MX complexes. Structural information can be inferred from 
the fragmentation of higher-order 3-MX complexes via collisionally induced dissociation 
using the Agilent TOF MS and tandem MS combined with IMS using a Waters HDMS 
Synapt can be used to obtain ion mobility spectra of 3-MX complex fragments. TWIMS-MS 
and DTIMS-MS analysis has been used to determine the CCS of selected singly charged 3-
MX complexes, and compared to computationally modelled CCS values. 
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 Chapter Three  
3. The determination of salivary oxypurines before and after 
exercise by combined liquid chromatography-field 
asymmetric waveform ion mobility spectrometry-time-of-
flight mass spectrometry 
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3.1. Chapter three overview 
A method combining field asymmetric waveform ion mobility spectrometry with liquid 
chromatography-mass spectrometry (LC-FAIMS-MS) has been developed for the analysis of 
the oxypurine compounds hypoxanthine (HX) and xanthine (XA) in saliva. Separation of the 
oxypurines from interfering matrix components was investigated using FAIMS-MS. The 
selected FAIMS parameters were then applied to the rapid LC-FAIMS-MS analysis of HX 
and XA using a short chromatographic separation method (7 min). A comparison of the LC-
MS method with and without FAIMS applied, resulted in improved discrimination from 
saliva matrix interferences and improved chromatographic peak integration for both HX and 
XA using a FAIMS separation. A quantitative evaluation of the LC-FAIMS-MS method was 
performed giving limits of detection of 2.0 ng mL-1 for HX and 1.8 ng mL-1 for XA, and 
limits of quantification of 6.6 ng mL-1 for HX and 6.0 ng mL-1 for XA. The developed LC-
FAIMS-MS method was applied to the targeted analysis of the oxypurine metabolites in 
saliva collected from healthy male athletes (n = 11) both pre- and post-exercise designed to 
induce oxidative stress; post-exercise collection time-points included immediately after 
exercise, one hour and twenty-four hours’ post-exercise. The salivary concentrations of both 
HX and XA were lower after physical exercise, compared to the pre-exercise (rest) 
concentrations and returned to approximately pre-exercise levels after twenty-four hours. The 
method reported has the potential for monitoring the salivary oxypurines, HX and XA, as 
biomarkers of oxidative stress and in other clinical applications.  
3.2. Introduction 
Exhaustive exercise and overtraining can have major health implications for athletes, and 
exercise induced oxidative stress and inflammation can be associated with many known 
diseases.1,2 The identification of biomarkers of oxidative stress could therefore lead to the 
early identification and effective treatment of diseases and chronic inflammation.3 Exercise 
induced muscle fatigue or muscular stress has previously been related to oxidative stress, 
ATP depletion, muscle damage or immunological compromise.4,5  
The oxypurine compounds hypoxanthine (HX) and xanthine (XA) are naturally occurring 
purine derivatives (Figure 3.1), which are derived from the degradation of purine nucleotides 
(adenine and guanine). They have been positively correlated with ATP consumption and the 
formation of free radicals and reactive oxygen species.6,7 HX is also produced by the action 
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of xanthine oxidase on XA, or from the reduction of XA by xanthine oxidoreductase (XOR). 
In the purine catabolism, XOR catalyses the oxidative hydroxylation of HX to XA and 
subsequently of XA to uric acid (UA). UA acts as a potent antioxidant and free radical 
scavenger associated with oxidative stress and other diseases.8–10 XOR therefore has 
important functions as a cellular defence enzyme against oxidative stress.11 HX and XA are 
usually analysed in plasma, serum or urine, and it has been reported that plasma and or 
urinary levels of these oxypurines can changes as a result of oxidative stress.12,13 In a study of 
twenty healthy males performing exercise to exhaustion, serum HX and XA levels were 
found to significantly increase post exercise, leading to the proposal of oxypurines as 
biomarkers of oxidative stress and muscle fatigue.5 Similar results were also observed in the 
analysis of HX and XA in plasma where an increase in concentrations of both HX and XA 
were observed post-exercise, with a peak increase in the levels of HX post exercise of nearly 
nine times the resting level.14 HX has been suggested as an indicator of the effectiveness of a 
training regime,15 and as a potential biomarker to normalise for metabolomic changes due to 
exercise although further research is required.16,17  
 
Figure 3.1 Structures of (a) hypoxanthine (HX) and (b) xanthine (XA) 
 
HX and XA have been detected in plasma, serum or urine using a variety of methods 
including high performance liquid chromatography (HPLC) and capillary 
electrophoresis.8,9,18 These oxypurines have also been detected in saliva,8,9,18–20 which is 
known to change in response to a variety of different physiological states.21 However, saliva 
is a complex biofluid which can require careful sample preparation and/or extended analysis 
times to separate HX and XA from co-eluting matrix interferences. This results in the 
relatively long analysis times (15-60 min) reported for the liquid chromatography-mass 
spectrometry (LC-MS) analysis of HX, XA and structurally related purine compounds in 
saliva and other biofluids.19,22–25 
101 
 
The performance of liquid chromatographic separation can be improved by the use of ultra-
high performance liquid chromatography (UHPLC) and high resolution mass spectrometry 
(HRMS), using time-of-flight (TOF) or Orbitrap mass analysers, or by tandem MS. However, 
even the highest resolution mass analysers cannot separate isobaric analytes and matrix 
interferences. An alternative approach to enhancing the selectivity and performance of LC-
MS analyses is the incorporation of a rapid gas-phase ion separation technique such as ion 
mobility spectrometry (IMS) in combination with LC-MS using either drift tube IMS or field 
asymmetric waveform ion mobility spectrometry (FAIMS), also known as differential ion 
mobility spectrometry. FAIMS separates ions based on differences in the mobility of ions in 
low and high electric fields, which is a separation mechanism that is highly orthogonal to LC 
and MS. The combination of a miniaturised FAIMS device with LC-MS has been shown to 
improve selectivity and limits of detection and quantification without loss of linear dynamic 
range, whilst reducing interfering chemical noise in the analysis of complex biofluids.26–28 
Here, we report the development of a rapid LC-FAIMS-MS method requiring minimal 
sample pre-treatment, for the analysis of salivary oxypurines (HX and XA). The method has 
been applied to the analysis of saliva samples collected from male cyclists pre- and post-
exhaustive exercise. 
3.3. Experimental 
3.3.1. Chemicals 
HPLC grade acetonitrile (ACN) and HPLC grade water (H2O) were both purchased from 
Fisher Scientific (Loughborough, UK). HX, XA, 1-methylxanthine-(methyl-13C,d3) (1-MXd3) 
and formic acid (FA) were all purchased from Sigma Aldrich (Dorset, UK). Individual 
standard solutions of HX (1 µg mL-1), XA (1 µg mL-1) and 1-MXd3 (0.5 µg mL
-1) were 
prepared in H2O:ACN v/v 95:5 with 0.1% FA for FAIMS-MS analysis. A solution of 1-
MXd3 (0.3 µg mL
-1) was prepared in H2O:ACN v/v 92.5:7.5 with 0.15% FA for spiking into 
saliva for LC-FAIMS-MS analysis of saliva samples. Calibration standard solutions of HX 
and XA were prepared in H2O:ACN v/v 92.5:7.5 with 0.15% FA for spiking into a pooled 
saliva extract during sample preparation to give final concentrations (post-spiking) of HX and 
XA of 20, 40, 60, 80 and 100 ng mL-1, and 200 ng mL-1 of 1-MXd3, along with an extract 
spiked only with 1-MXd3. 
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3.3.2. Saliva sample collection 
Saliva samples were collected from trained male cyclists (n = 11) aged between 18-45. Prior 
to the exercise performance test, participants were asked to arrive in a euhydrated and fasted 
state (from 10 pm the day prior to the test) and to refrain from caffeinated and alcoholic 
beverages for twenty-four hours prior to the test. Ethical approval for the study was obtained 
from the local ethical advisory committee (Ethical Advisory Committee, Loughborough 
University) with reference numbers: R14-P72, G10-P24 and G10-P23. Saliva was collected 
from participants pre-exercise, immediately post-exercise, one-hour post-exercise and 
twenty-four hours post exercise. The exhaustive exercise consisted of cycling on an exercise 
bike sub maximally at 70% of their maximum power output (determined via a pre-testing 
session to measure maximum power output) for 45 minutes and then to cycle the greatest 
distance possible for a further 15 minutes. The one hour cycling exercise protocol was 
designed to induce oxidative stress. 
Saliva was collected by a passive drool method where participants were asked to sit 
comfortably with their head tilted forward, to allow saliva to pool in the front of the 
mouth.29,30 Saliva was dribbled from the mouth into a glass collection vial (30 mL, 
Chromacol, UK) at regular intervals. This process was continued for at least 5-10 minutes to 
provide 1.5 – 2 mL of saliva. Saliva collected from all participants was re-aliquoted into 600 
µL aliquots into microcentrifuge tubes (2 mL LoBind Eppendorf, Sigma Aldrich, UK). 600 
µL from all participants was pooled together and re-aliquoted as 600 µL aliquots to be used 
for method development and quality control (QC). Samples were aliquoted over ice prior to 
storage to minimise freeze-thaw cycles and stored at -80°C to arrest biological activity. 
3.3.3. Saliva sample pre-treatment 
Saliva samples stored at -80°C were thawed at room temperature for 20 min. Each sample 
was vortexed for 30 s followed by centrifugation at 10,000 g for 10 min at ambient 
temperature. An aliquot of the supernatant (250 µL) was transferred to a fresh 
microcentrifuge tube and diluted with 500 µL of an internal standard solution (1-MXd3 (0.3 
µg mL-1) in H2O:ACN v/v 92.5:7.5 with 0.15% FA) to prepare the sample at the starting 
mobile phase conditions (H2O:ACN v/v 95:5 with 0.1% FA), with a final internal standard 
concentration of 0.2 µg mL-1. The diluted supernatant was vortexed for 30 s to ensure 
homogeneity and transferred to an autosampler vial (2 mL) for LC-FAIMS-MS analysis. 
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3.3.4. Instrumentation 
 Analysis was performed using an Agilent 1200 series HPLC interfaced to an Agilent 6230 
TOF mass spectrometer fitted with a modified Jet Stream electrospray ionisation (ESI) source 
(Agilent Technologies, Santa Clara, USA) to accommodate the FAIMS. The miniaturised 
chip-based ultraFAIMS device (Owlstone Medical Ltd), described in detail elsewhere,31 was 
located in front of the transfer capillary of the MS behind a modified spray shield within the 
ESI source. The electrodes of the FAIMS chip are arranged as multiple parallel channels, 
with a trench length of 78.1 mm, a 100 µm electrode gap and a path length of 700 µm. 
Nitrogen (N2) was used as the carrier gas for the FAIMS and the MS drying gas. Samples 
were introduced into the ESI source either by direct syringe infusion at a flow rate of 10 µL 
min-1 (for initial FAIMS optimisation by FAIMS-MS) or by the LC. Chromatographic 
separations were performed on an Agilent Poroshell 120 EC-C18 reversed phase column of 
dimensions 2.1 x 75 mm, 2.7 µm (Agilent Technologies, Santa Clara, USA), with a 5 mm 
guard column of the same phase attached in series prior to the analytical column. 
3.3.5. HPLC conditions 
Mobile phase A consisted of 0.1% aqueous formic acid (v/v) and mobile phase B was 0.1% 
formic acid in ACN. The mobile phase flow rate was set to 0.3 mL min-1 and the column was 
maintained at 40°C. Saliva samples were analysed with an injection volume of 10 µL by the 
chromatographic gradient programme: 5% B (0 min), increased to 8% B (0-2 min) for the 
retention of the oxypurine compounds, followed by a column clean-up and equilibration 
phase by increasing from 8% B to 95% B (2-3 min), hold (3-4 min), then returning to initial 
conditions of 5% B (4-5 min) and hold (5-7 min). 
3.3.6. MS conditions 
The TOF-MS was operated in positive ion mode with a scan rate of 10 scans s-1 for FAIMS-
MS analysis, and at 2 scans s-1 for LC-FAIMS-MS analysis. For all analyses the MS 
parameters were as follows: m/z range 50-1200, nebulizer pressure was set to 35 psig with a 
sheath gas (N2) flow of 11 L min
-1 at 350°C, with a nozzle voltage of 2000 V. The capillary 
voltage was set to 4000 V, the fragmentor voltage was set to 150 V and the drying gas (N2) 
flow set to 10 L min-1 at 150°C. 
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3.3.7. Optimisation of FAIMS conditions 
FAIMS-MS analyses of HX and XA were performed using a two-dimensional FAIMS scan 
(or sweep) in the dispersion field (DF) range from 180-300 Td, in steps of 10 Td, and 
compensation field (CF) range from -2-5 Td, in steps of 0.05 Td (where 1 Td = 10-17 V cm2). 
The DF and CF selected for the LC-FAIMS-MS analysis of saliva were optimised as DF 230 
Td and CF 0.90 Td with the TOF-MS operated in positive ion mode. 
3.3.8. Analytical protocol for LC-FAIMS-MS salivary analysis 
The sample list for analysis was randomised using Microsoft Excel. A series of five 
consecutive injections of a pooled saliva extract were run prior to sample analysis to 
condition the chromatographic column. A pooled saliva extract was analysed after every five 
saliva samples as a QC sample. Method blanks demonstrated no carry-over between saliva 
sample runs. 
3.3.9. Data processing 
Data were acquired using the FAIMS Control software in combination with the MassHunter 
Acquisition software. MassHunter Qualitative Analysis software version B.05.00 (Agilent 
Technologies, Santa Clara, USA) was used for processing raw LC-MS and LC-FAIMS-MS 
data. A modified prototype version of the MassHunter Qualitative Analysis software was 
used for processing raw FAIMS-MS data, with a mass extraction window of m/z ± 0.02. 
Microsoft Excel and PowerPoint 2010 (Microsoft, Seattle, USA), and OriginLab 2015 
(Academic version, b9.2.272) were used to produce figures in this report. 
3.4. Results and discussion 
3.4.1. LC-FAIMS-MS method development for the analysis of HX and XA 
A short chromatographic method (7 min) was developed for HX, XA and 1-MXd3 with the 
analytes eluting in 2 min and the remainder of the chromatographic method used to wash-out 
the saliva matrix and re-equilibrate the column. The retention times for the extracted ion 
chromatograms (EICs) of the [M+H]+ ions for HX (m/z 137.0458, 100 ng mL-1), XA (m/z 
153.0407, 100 ng mL-1) and 1-MXd3 (m/z 171.0791, 200 ng mL
-1) are 0.88 min (Figure 3.2 
(a)), 0.95 min (Figure 3.2 (b)) and 1.62 min respectively. In the EICs for m/z 137.0458 and 
m/z 153.0407 for an unspiked pooled saliva extract (Figure 3.2 (c) and (d)), co-eluting matrix 
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interferences are observed, with HX (Figure 3.2 (c)) unresolved from these interferences and 
XA is not baseline resolved (Figure 3.2 (d)). 
 
Figure 3.2 EICs from the LC-MS analysis for m/z 137.0458 ((a) and (c)) and m/z 153.0407 ((b) 
and (d)), for a mixed standard solution of HX and XA ((a) and (b) respectively) and for an 
unspiked pooled saliva extract ((c) and (d)) 
 
Selection of optimal FAIMS conditions for the targeted analysis of HX and XA in saliva by 
LC-FAIMS-MS was determined by the removal of co-eluting matrix interferences to improve 
the signal-to-noise ratio (S:N), peak area, peak height and peak shape compared to LC-MS 
alone. The oxypurine compounds and the internal standard (1-MXd3) were first analysed as 
individual standard solutions along with an unspiked pooled saliva extract (post sample 
preparation). The samples were directly infused into the ESI source and analysed by FAIMS-
MS, in order to select FAIMS DF and CF parameters to be further tested using LC-FAIMS-
MS. FAIMS-MS analysis was performed by scanning the DF from 180 to 300 Td in 10 Td 
steps and the CF from -2 to 5 Td in 0.05 Td steps. Figure 3.3 (a) shows ions from the saliva 
extract are observed in the CF range from -2 to 3 Td at DF 230 Td, with the highest intensity 
at 2 Td. The selected CF responses for HX and XA in Figure 3.3 (a) are in the CF range 0 to 
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1.5 Td overlapping the CF TIC of the saliva extract. Three DF and three CFs were selected 
where HX and XA could be transmitted by the FAIMS along with the internal standard 1-
MXd3: CF 0.7 Td at DF 220 Td (Figure 3.3 (b)), CF 0.9 Td at DF 230 Td (Figure 3.3 (c)), and 
CF 1.1 Td at DF 240 Td (Figure 3.3 (d)). 
 
Figure 3.3 (a) Normalised intensity FAIMS-MS CF spectra for TIC of saliva response (black) 
and the normalised intensity EICs of the [M+H]+ ions of HX (red), XA (blue) and 1-MXd3 
(green) at DF 230 Td; FAIMS-MS CF spectra (absolute intensities) for the EICs of the [M+H]+ 
ions of HX (red), XA (blue) and 1-MXd3 (green) at (b) DF 220 Td, (c) DF 230 Td, and (d) DF 240 
Td 
 
The three FAIMS conditions selected, CF 0.7 Td at DF 220 Td, CF 0.9 Td at DF 230 Td and 
CF 1.1 Td at DF 240 Td, were applied to the LC-FAIMS-MS analysis of an unspiked saliva 
extract in order to determine the optimum DF/CF combination for the transmission of HX, 
XA and 1-MXd3. EICs for HX (m/z 137.0458 ± 0.02, 0.91 min) and XA (m/z 153.0407 ± 
0.02, 0.96 min) are shown in Figure 3.4. Each of the three FAIMS conditions resulted in a 
reduction of the co-eluting interferences in the EICs for HX (Figure 3.4 (b) to (d)) and XA 
(Figure 3.4 (f) to (h)) compared to LC-MS (Figure 3.4 (a) and (e)). The S:N ratio of both HX 
and XA was increased in comparison to LC-MS for all three FAIMS conditions by an 
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average of 230% for HX and 255% for XA. CF 1.1 Td at DF 240 Td resulted in the largest 
reduction of co-eluting matrix interferences, but also had the largest reduction in the peak 
intensity at the highest DF. CF 0.7 Td at DF 220 Td had the highest peak intensity, but the 
least reduction in the co-eluting matrix interferences. CF 0.9 Td at DF 230 Td was therefore 
selected as the FAIMS condition for the analysis as a compromise between peak intensity and 
separation of co-eluting matrix interferences. 
 
Figure 3.4 EICs for an unspiked saliva extract containing HX (m/z 137.0458) using (a) LC-MS, 
and (b) LC-FAIMS-MS at CF 0.7 Td and DF 220 Td, (c) LC-FAIMS-MS at CF 0.9 Td and DF 
230 Td, and (d) LC-FAIMS-MS at CF 1.1 Td and DF 240 Td. EICs for XA (m/z 153.0407) using 
(e) LC-MS, and (f) LC-FAIMS-MS at CF 0.7 Td and DF 220 Td, (g) LC-FAIMS-MS at CF 0.9 
Td and DF 230 Td, and (h) LC-FAIMS-MS at CF 1.1 Td and DF 240 Td 
 
The LC-MS chromatographic method was developed to minimise the run time for HX and 
XA, but this resulted in a significant overlap of the HX peak with salivary matrix 
components. The observed co-elution of HX with matrix components could be reduced by 
changing the chromatographic gradient to separate the metabolite from the saliva matrix, at 
the cost of increased chromatographic run time. Options to improve the selectivity of HX 
without increasing chromatographic run time include the selection of a narrower mass 
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extraction window using HRMS or the application of FAIMS separation combined with LC-
MS.28 A direct comparison of both techniques to improve selectivity for HX without 
increasing the run time is shown in Figure 3.5. The LC-MS and LC-FAIMS-MS EICs for the 
[HX+H]+ ion (m/z 137.0458) for the analysis of HX in an unspiked pooled saliva sample, 
with a high resolution mass window of m/z 137.0458 ± 0.02 is shown in Figure 3.5 (a). The 
absolute intensity of the HX peak, with FAIMS switched off, is reduced by a factor of two if 
the mass extraction window is narrowed from ± 0.02 (Figure 3.5 (a)) to m/z 137.0458 ± 0.008 
(Figure 3.5 (b)), but there is no further discrimination against the co-eluting saliva matrix 
interference. In contrast, the application of FAIMS separation shows a significant reduction 
in the co-eluting chemical noise from the saliva matrix (Figure 3.5 (c) and (d)) whilst 
maintaining the rapid elution time. The removal of chemical noise from the saliva matrix 
resulted in improved peak integration and S:N even though the absolute intensity of the HX 
peak was reduced due to ion losses in the FAIMS device. Comparison of the two mass 
extraction windows with FAIMS on, m/z 137.0458 ± 0.02 (Figure 3.5 (c)) and m/z 137.0458 
± 0.008 (Figure 3.5 (d)), resulted in a reduction of sensitivity without a significant increase in 
S:N. Therefore, the ± 0.02 mass extraction window was selected for subsequent LC-FAIMS-
MS analyses. The mass spectrum from the HX peak with the FAIMS off showed HX with a 
mass error of -9.6 ppm (m/z 137.0471). Whereas with FAIMS applied (LC-FAIMS-MS) the 
observed mass error was -0.82 ppm (m/z 137.0459), as a result of discrimination against 
isobaric co-eluting saliva matrix interferences. 
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Figure 3.5 EICs (m/z 137.0458) for HX from an unspiked saliva sample analysed by LC-MS 
(FAIMS off) using a mass extraction window of (a) m/z 137.0458 ± 0.02 and (b) 137.0458 ± 0.008, 
and by LC-FAIMS-MS (DF 230 Td, CF 0.9 Td) using a mass extraction window of (c) m/z 
137.0458 ± 0.02 and (d) m/z 137.0458 ± 0.008 
 
Table 3.1 compares the quantitative performance of the LC-MS and LC-FAIMS-MS methods 
for the determination of HX and XA using standard additions spiked into a pooled saliva 
sample. From Table 3.1, the limit of detection (LOD; S:N 3:1)) for HX was reduced from 3.8 
ng mL-1 (FAIMS off) to 2.0 ng mL-1 (FAIMS on), and the limit of quantification (LOQ; S:N 
10:1) was also reduced from 12.6 ng mL-1 (FAIMS off) to 6.6 ng mL-1 (FAIMS on), based on 
the extracted ion peak areas of HX (m/z 137.0458 ± 0.02) using LC-FAIMS-MS. The LOD 
and LOQ for XA were similar at 1.9 ng mL-1 and 6.2 ng mL-1 (FAIMS off) and 1.8 ng mL-1 
and 6.0 ng mL-1 (FAIMS on), based on the extracted ion peak areas of XA (m/z 153.0407 ± 
0.02) using LC-FAIMS-MS. The intra-day reproducibility of the LC-FAIMS-MS system was 
compared with LC-MS by analysing HX and XA spiked into saliva (100 ng mL-1, Table 3.1) 
in both FAIMS on and FAIMS off modes. Relative standard deviations (%) sufficient for 
good quantitation were obtained with both LC-MS and LC-FAIMS-MS (1.7% - 6.6%). These 
data for HX demonstrate the FAIMS device can enhance quantitative performance compared 
to high resolution LC- MS. 
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Table 3.1 A comparison of LOD, LOQ and R2 for standards of HX and XA spiked into pooled 
saliva (20-100 ng mL-1) and intra-day reproducibility for the determination of HX and XA 
standards (100 ng mL-1, n = 3); LOD and LOQ based upon the S:N of the lowest concentration 
standard spiked into saliva 
 HX LC-MS XA LC-MS HX LC-FAIMS-MS XA LC-FAIMS-MS 
LOD (ng mL-1) 3.8 1.9 2.0 1.8 
LOQ (ng mL-1) 12.6 6.2 6.6 6.0 
R2 0.9983 0.9679 0.9916 0.9893 
Intra-day (% RSD) 2.6 4.8 1.7 6.6 
 
3.4.2. LC-FAIMS-MS determination of salivary hypoxanthine and xanthine pre- and 
post-oxidative stress 
The LC-FAIMS-MS method developed for the analysis of HX and XA was applied to the 
analysis of saliva samples collected from cyclists pre-exercise, immediately post-exercise, 
one-hour post exercise and twenty-four hours post exercise. A large biological variance 
between participants was observed in the pre-exercise samples with concentrations in the 
range 3.1 to 242.9 ng mL-1 for salivary HX and 22.4 to 1183.1 ng mL-1 for salivary XA 
(Table 3.2). These XA and HX concentrations are within ranges previously reported in saliva, 
although at the lower end of the range for HX.19,20,29 Figure 3.6 shows box and whisker plots 
of HX and XA concentrations for male participants pre- and post-exercise. Despite the 
biological variance in the salivary HX and XA levels pre-exercise, the same overall trend 
towards lower concentrations immediately after exercise and for the next hour post-exercise 
is observed, with the levels of HX and XA returning to approximately pre-exercise levels in 
the twenty-four hours’ post-exercise samples. The observation of lower HX and XA levels in 
saliva after the physical exercise (Figure 3.6) is the opposite trend to previously reported 
plasma concentrations of HX, which increased immediately post-exhaustive physical 
exercise.5,14 Lower levels of HX and XA (Figure 3.6) may be due to changes in enzymatic 
activity in saliva after exercise.30,31 However, significant inter-day variations in salivary 
levels of HX and XA (and UA) have been reported by Kochańska et al., which may explain 
the variations in HX and XA concentrations observed in this study.20 Markelj et al. reported 
the analysis of urine and saliva by LC-MS, which showed that concentrations of HX and XA 
were significantly lower, relative to the concentration of UA, in saliva than in urine,18 
although salivary UA has been shown to have a linear correlation with serum UA 
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concentrations.32 Further work is required to understand the relative levels of HX, XA and 
UA in saliva as a result of oxidative stress. 
Table 3.2 Salivary HX and XA concentrations at sampling time points pre- and post-exercise; 
where (-) indicates a sample was not collected at that time-point 
Sample 
ID 
 HX concentration (ng mL-1)  XA concentration (ng mL-1) 
 
Pre Post 
1-hour 
Post 
24-hour 
Post 
 
Pre Post 
1-hour 
Post 
24-hour 
Post 
S001A  (-) 19.4 (-) 73.4  (-) 109.0 (-) 304.3 
S001B  44.9 11.9 25.6 31.6  223.2 106.3 142.1 169.6 
S002A  20.7 13.2 10.0 26.4  64.2 51.2 46.5 83.2 
S002B  6.3 24.2 4.7 25.5  37.0 77.7 31.4 57.8 
S003A  16.7 34.1 10.1 41.6  107.6 119.0 73.2 176.7 
S003B  50.9 26.1 13.5 31.2  207.3 110.1 58.1 180.4 
S004A  242.9 116.6 62.0 133.6  599.4 248.6 96.9 202.8 
S004B  105.9 60.3 38.4 180.8  332.4 161.9 67.9 351.3 
S005A  8.8 6.4 <2.0 3.3  74.7 51.0 11.4 15.4 
S005B  3.5 8.8 8.1 <2.0  22.4 43.5 <1.8 11.9 
S006A  41.6 (-) 7.6 16.1  244.1 (-) 47.5 69.1 
S006B  24.6 21.9 6.9 17.5  190.6 168.3 65.0 100.6 
S007A  (-) 12.2 6.4 21.2  (-) 23.3 <1.8 31.2 
S007B  46.6 <2.0 <2.0 5.3  136.6 5.5 <1.8 8.3 
S009A  81.0 25.5 23.3 129.2  295.1 70.0 190.9 618.4 
S009B  121.8 41.1 13.6 <2.0  1183.1 157.0 241.2 215.6 
S010A  <2.0 <2.0 <2.0 18.7  <1.8 <1.8 <1.8 428.6 
S010B  3.1 <2.0 <2.0 <2.0  328.9 65.8 31.5 141.4 
S011A  18.4 21.0 5.0 10.1  36.1 69.1 11.1 12.7 
S011B  36.0 14.6 7.9 20.1  45.1 40.0 18.7 18.6 
S012A  22.7 <2.0 <2.0 80.8  317.2 3.1 62.8 325.1 
S012B  23.1 11.0 2.3 12.7  86.1 26.4 42.8 77.1 
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Figure 3.6 Box and whisker plots for male participants (n=11), of the detected peak areas 
divided by the internal standard (IS, 1-MXd3) peak area for (a) HX and (b) XA at four sampling 
time points: pre-exercise (Pre), immediately post-exercise (Post). One-hour post-exercise (1-
hour Post) and twenty-four hours’ post-exercise (24-hour Post) 
 
3.5. Conclusion 
A rapid (7 min) method combining miniaturised FAIMS with LC-MS and non-invasive 
sampling has been developed for the determination of HX and XA in saliva. Using LC-
FAIMS-MS, improved chromatographic peak integration was possible, in comparison to LC-
MS, due to the reduction in the co-eluting chemical interferences from the saliva matrix. This 
also resulted in improved mass spectrometric observed mass error using HRMS, aiding in the 
qualitative identification and quantitation of the purine based derivatives, HX and XA. Saliva 
samples analysed from healthy male athletes showed a decrease in salivary oxypurines 
immediately post-exercise and one-hour post-exercise, in comparison to levels determined 
pre-exercise and twenty-four hours’ post-exercise, which suggests that both HX and XA 
113 
 
could be used as biomarkers of oxidative stress. The combination of LC-FAIMS-MS with the 
non-invasive sampling collection technique for saliva has potential as a rapid and high-
throughput screening technique for oxidative stress, based on the determination of oxypurine 
metabolite biomarkers, as well as in other clinical applications. 
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 Chapter Four 
4. Rapid analysis of anabolic steroid metabolites in urine by 
combining field asymmetric waveform ion mobility 
spectrometry with liquid chromatography and mass 
spectrometry 
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4.1. Chapter four overview 
The combination of field asymmetric waveform ion mobility spectrometry with liquid 
chromatography-mass spectrometry (LC-FAIMS-MS) has been developed for the analysis of 
glucuronide and sulfate metabolites of seven anabolic-androgenic steroids (AAS) in urine. 
Separation by FAIMS-MS was investigated in positive ion mode for selected cationic adducts 
(H+, NH4
+, Na+, K+, Cs+). LC-FAIMS-MS analysis of the doubly sodiated adducts ([M+2Na-
H]+) of isobaric and co-eluting steroid metabolites allowed their rapid (8 min) qualitative and 
quantitative determination in spiked urine using hydrophilic interaction liquid 
chromatography prior to FAIMS-MS separation, with discrimination >95% achieved between 
the steroids investigated. A quantitative evaluation of the LC-FAIMS-MS method was 
performed giving limits of detection in the range 1-6 ng mL-1 and limits of quantification in 
the range 3-20 ng mL-1, with reproducibility (%RSD <10%; n = 6) and linearity (R2> 0.99). 
The LC-FAIMS-MS method demonstrates increases in signal-to-noise ratios for the doubly 
sodiated steroid metabolites in unspiked urine (>250%) by the reduction of isobaric 
interferences from the matrix. An alternative or additional tool for identification of the steroid 
metabolites is based on the observations of different patterns of sodium acetate clusters that 
are characteristic for each metabolite. 
4.2. Introduction 
The use of anabolic steroids in the world of sports for performance enhancement sees 
professional athletes attempting to enhance their natural athletic potential. In 1999, the World 
Anti-Doping Agency (WADA) was formed to assist sport organisations in combating this 
abuse.1 The goal of doping control was to preserve the ‘spirit of sport’ characterised by 
several values such as ethics, fair play and health.2 WADA became responsible for the 
publication of prohibited drugs used in sport and the establishment of international standards 
for testing these drugs. Testosterone and its derivatives are the most widely used anabolic 
steroids by athletes due to their physiological effect on muscle development and 
maintenance. In 2004, WADA specified that urine samples with a testosterone (T)/ 
epitestosterone (ET, 17α-epimer) ratio above a threshold of 4.0 are indicative of exogenous 
abuse and should be submitted to confirmatory analysis. Samples with suspiciously high 
levels of steroids detected preliminarily using GC-MS can be submitted for analysis by GC-
combustion isotope ratio-MS (GC/C/IRMS) in order to ascertain whether the suspiciously 
high levels of steroid present are endogenous or exogenous. GC/C/IRMS is the method of 
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choice as it can distinguish between natural and synthetic steroids based upon the 13C to 12C 
isotopic ratio (δ13‰) where δ13 around (-22 to -24)‰ is typical for endogenous steroids as a 
result of biosynthesis and (-27 to -29)‰ is typical for exogenous steroids (however, it is 
essential to consider diet and country of origin).3  
The determination of anabolic steroids such as T/ET in urine samples, either as free drugs or 
their glucuronide or sulfate metabolites, has conventionally used mass spectrometry-based 
techniques including gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-mass spectrometry (LC-MS).2,4 GC-MS remains the most widely used 
method for targeted quantitative analysis of endogenous anabolic-androgenic steroids 
(EAAS) and their ratios.5 The detection of EAAS is complicated by their natural presence in 
the body, which means the simple presence of these steroids and/or their metabolites cannot 
be used to prove administration. Population derived thresholds of steroid concentrations for 
detecting EAAS administration are limited in their sensitivity due to the large inter-individual 
variations, differences in the relative concentrations of the steroids to each other, the 
influence of urinary dilution, and the effect of confounding factors. For example, a study of 
over 3000 individuals found that in males (with concentrations typically higher than females) 
the mean concentrations for androsterone and etiocholanolone were 2640 ng mL-1 (max. 
20,700 ng mL-1) and 1850 ng mL-1 (max. 11,400 ng mL-1) respectively.6 For testosterone and 
epitestosterone the concentrations were much lower, 37.4 ng mL-1 (max. 249 ng mL-1) and 
28.9 ng mL-1 (max. 391 ng mL-1). 
GC-MS may be the current method of choice for EEAS analysis, however, shortcomings of 
GC-MS are the need for laborious derivatisation of the steroids prior to analysis,7 and long 
analysis times to resolve isobaric species. LC-MS does not usually require a derivatization 
step and can be used to enhance the speed of analysis with shorter chromatographic run times 
compared to GC-MS.7 LC-MS using ESI offers a rapid and sensitive method for the direct 
analysis of steroid metabolites due to the acidic moiety of the glucuronide (negative ion 
mode) and the proton affinity of the keto-functional group (positive ion mode). The need for 
sample preparation is reduced in LC-MS, however its routine use for quantitative analysis has 
been hampered by the formation of multiple adducts (H+, Na+ and NH4
+) in the ionisation 
source, reducing the sensitivity of the analyte signal. Further specificity and sensitivity can be 
achieved by combining both chromatographic methodologies, GC or LC, with tandem mass 
spectrometry (MS/MS) in targeted analysis.8,9 However, limitations of this approach include 
the inability to separate co-eluting isobaric interferences by MS, and the identification of 
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isobaric steroids with similar fragmentation patterns using MS/MS. The effects of co-eluting 
species and isobars (same m/z values) result in non-Gaussian chromatographic peaks as well 
as impure mass spectra, which is a major drawback in chromatographic and mass 
spectrometric based techniques. The difficulty in detecting low concentrations (< ng mL-1) of 
T/ET using chromatography-MS has triggered the introduction of ion mobility spectrometry 
(IMS) with both MS and chromatography.10  
Ion mobility spectrometry (IMS) is a separation technique that has been shown to be a 
powerful tool for distinguishing isomers of many different biological classes, including 
metabolites,10,11 peptides,12 lipids,13 and carbohydrates14,15 (Section 1.1). IMS has also been 
demonstrated to reduce chemical noise due to isobaric interferences in biological matrices 
when combined with LC-MS (and MS/MS).10,16,17 Recent work on steroid analysis by 
Chouinard et al,11 resulted in the separation of dimeric adducts of steroid isomers and epimers 
by DTIMS-MS where initially no separation of the protonated monomers was achieved; 
resolution of the steroid isomers and epimers was achieved however to accomplish this 
multiple different cation adducts were utilised in two different buffer gases (N2 and CO2) 
which would significantly limit the through-put of analysis for drug detection in biological 
matrices.  
FAIMS has a high degree of orthogonality to both MS and LC, and has been shown to 
separate steroid isomers and isobars, whilst also increasing signal-to-noise ratios (S:N) for 
targeted compounds by removing isobaric interferences from biological matrices, such as 
plasma and urine.18–20 However, some of these reported studies required derivatisation prior 
to IMS or FAIMS analysis to achieve separation of the steroid isomers of interest.16,20 This 
chapter describes the development of an LC-FAIMS-MS method for the determination of 
seven steroid metabolites of interest to anti-doping in human urine.21 The steroids targeted 
(Figure 4.1) include isobaric steroid sulfates: testosterone sulfate (TS), epitestosterone sulfate 
(ETS), and dehydroepiandrosterone sulfate (DHEAS); and two pairs of isobaric steroid 
glucuronides: testosterone glucuronide (TG), epitestosterone glucuronide (ETG) and 
androsterone glucuronide (ADG), etiocholanolone glucuronide (ECG). These pairs of steroid 
glucuronides and the trio of steroid sulfate metabolites are exact mass isomers which cannot 
be separated by even the highest resolution mass spectrometry. The data presented here 
includes a FAIMS-MS investigation into the separation of the steroid isomers in positive ion 
mode. The LC-FAIMS-MS method for the determination of the steroid metabolites uses a 
HILIC separation with an analysis time of 8 minutes. This application also demonstrates the 
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ability of FAIMS to scan within the timeframe of a chromatographic peak,22 to achieve 
isobaric separation without limiting throughput in the analysis of biological matrices.  
 
Figure 4.1 Structures of the targeted steroid metabolites (a) testosterone and epitestosterone 
glucuronides (TG/ETG), (b) etiocholanolone and androsterone glucuronides (ECG/ADG), and 
(c) testosterone, dehydroepiandrosterone and epitestosterone sulfates (TS/DHEAS/ETS)23 
 
4.3. Experimental 
4.3.1. Chemicals 
HPLC grade acetonitrile (ACN), HPLC grade water (H2O), ammonium acetate, and sodium 
acetate were all purchased from Fisher Scientific (Loughborough, UK). Acetic acid was 
purchased from Sigma Aldrich (Dorset, UK), and caesium chloride was obtained from 
Riedel-de Haën (Seelze, Germany). TG (50 µg mL-1), ETG (100 µg mL-1), ECG (87 µg mL-
1), ADG (100 µg mL-1), TS (77 µg mL-1), ETS (76 µg mL-1) and DHEAS (solid) solutions in 
methanol, were supplied by the Drug Control Centre (King’s College London, London, UK). 
Anonymised urine samples were also supplied by the Drug Control Centre (King’s College 
London, London, UK) with the urinary supernatants then stored at -20°C prior to analysis. 
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4.3.2. Sample preparation 
Standard solutions of the steroid compounds for FAIMS-MS (2 µg mL-1) and LC-FAIMS-
MS analysis were prepared by dilution in the starting LC mobile phase ACN:H2O 98:2 v/v 
with 10 mM ammonium acetate and 0.1% acetic acid, with the addition of sodium acetate 
(3.69 µg mL-1) for FAIMS-MS analysis. Standard solutions for LC-FAIMS-MS and LC-MS 
analysis were prepared without the addition of sodium acetate. For spiking urine aliquots, the 
steroid standards were diluted in H2O and spiked (1 µg mL
-1) into a pooled urine sample prior 
to sample clean-up. Investigations into the steroid metabolite FAIMS separation in the 
starting mobile phase were performed with the addition of sodium acetate (3.69 µg mL-1) or 
caesium chloride (0.34 µg mL-1). 
Aliquots of urine (500 µL), stored at -80°C, were thawed for twenty minutes. The urine was 
diluted with H2O (500 µL), or for spiked aliquots a mixture of all seven steroids diluted in 
H2O was added (1 µg mL
-1, 500 µL), and the diluted urine (1 mL) was centrifuged for 10 min 
at 10,000 g. A solid phase extraction (SPE) sample clean-up was employed, using a C18 
cartridge (60 mg, Phenomenex, Macclesfield, UK) conditioned with ACN (1 mL) and 
equilibrated with H2O (1 mL). The diluted urine (1 mL) was loaded onto the SPE cartridge. 
The cartridge was washed with 14:86 v/v ACN:H2O (1 mL) before elution using ACN (2 
mL). The eluent was evaporated to near dryness (~10 µL) at 30°C using a Turbovap LV 
concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA) and reconstituted in 
50 µL 98:2 v/v ACN:H2O with 10 mM ammonium acetate and 0.1% acetic acid. The urine 
extract was transferred to a polypropylene micro-insert (Agilent Technologies, Santa Clara, 
USA) in an autosampler vial (2 mL) for LC-FAIMS-MS and LC-MS analysis. 
4.3.3. Instrumentation 
LC-FAIMS-MS and LC-MS analyses of steroid metabolites were performed using an Agilent 
1200 series HPLC coupled with an Agilent 6230 time-of-flight (TOF) mass spectrometer 
fitted with a JetStream electrospray ionisation (ESI) source operated in positive ion mode 
(Agilent Technologies, Santa Clara, USA). The miniaturized FAIMS device (ultraFAIMS, 
Owlstone Ltd.), with an electrode gap of 100 µm, a short trench length (78.1 mm) and ion 
path length (700 µm), which has been previously described elsewhere (Sections 1.3.3 and 
1.5),24,25 was located in front of the inlet capillary of the mass spectrometer behind a modified 
spray shield in the ESI source. LC-MS analyses were performed with the FAIMS device in 
place and no electric fields applied. FAIMS-MS analyses were performed by direct infusion, 
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via a syringe pump (11-plus, Harvard Apparatus, Cambridge, UK), operated at a rate of 10 
µL min-1.  
HPLC separation for LC-FAIMS-MS and LC-MS was carried out on an Agilent Poroshell 
120 hydrophilic interaction liquid chromatography (HILIC) column (4.6 x 50 mm, 2.7 µm), 
maintained at 35°C, with a 5 mm HILIC guard column (Agilent Technologies, Santa Clara, 
USA) and a 5 µL sample injection volume (autosampler maintained at 6°C). A gradient 
chromatographic method utilized mobile phase A consisting of H2O with 10 mM ammonium 
acetate and 0.1% acetic acid and mobile phase B consisting of 98:2 v/v ACN:H2O with 10 
mM ammonium acetate and 0.1% acetic acid. The chromatographic method was as follows: 
hold at 100% B from 0 to 0.5 min, decrease to 92% B at 1.5 min, decrease further to 82% B 
at 2.5 min and hold for 1 min, before increasing back up to 100% B at 6 min and holding for 
2 min, for a total run time of 8 min and operated at a flow rate of 0.275 mL min-1. A solution 
of 205 µg mL-1 sodium acetate (in 90:10 v/v ACN:H2O) was infused into the LC mobile 
phase post-column at a flow rate of 5 µL min-1 in order to promote the formation of doubly 
sodiated adducts of the steroid metabolites in the ESI source (post LC separation, prior to 
FAIMS and MS separation), for a total flow rate into the ESI source of 0.28 mL min-1.  
The scan rate of the TOF MS was 10 scans s-1 for FAIMS-MS analysis and 2 scans s-1 for 
LC-FAIMS-MS and LC-MS analysis in the m/z range 80-1500 Da. The MS nebulizer 
pressure was set to 50 psig with a sheath gas (N2) flow of 11 L min
-1 at 250°C, with a nozzle 
voltage of 2000 V. The capillary voltage was set to 3500 V, the fragmentor voltage was set to 
200 V and the drying gas (N2) flow set to 7 L min
-1 at 150°C, which also provides N2 as the 
carrier gas in the FAIMS device. FAIMS-MS analyses were performed using a two-
dimensional FAIMS scan (or sweep) in the DF range from 180-300 Td (in steps of 10 Td) 
and CF range from -2-5 Td (in steps of 0.05 Td). The FAIMS parameters were optimized for 
the seven metabolites and LC-FAIMS-MS analyses were performed at three conditions (each 
at DF 260 Td) of CF 1.35 Td for DHEAS, TS and TG, CF 2.05 Td for ETS, ETG and ECG, 
and CF 2.70 Td for ADG (where 1 Td = 10-17 V cm2). The data were acquired in three 
analysis runs with the FAIMS at held static at one condition per run, however it is possible to 
acquire the data in one analysis by alternating between the FAIMS conditions, to allow for 
the determination of all seven steroid metabolites in a single run, an example of which is 
shown in Section 4.4.5. Data were acquired using Agilent MassHunter Acquisition B.05.00 
and prototype FAIMS Control software, and processed using Agilent MassHunter Qualitative 
Analysis B.05.00. Microsoft Excel and OriginLab 2015 (Academic version b9.2.272). 
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4.4. Results and discussion 
4.4.1. FAIMS-MS investigation of steroid metabolites  
Preliminary FAIMS-MS analysis of TG/ETG, in 50:50 v/v MeOH:H2O with 0.1% formic 
acid, showed no significant separation of the deprotonated isobaric steroid metabolites in 
negative ion mode up to the highest dispersion fields the device can reach, such as DF 300 Td 
shown in Figure 4.2 (a). However, there was a partial resolution observed in positive ion 
mode for the protonated and sodiated adducts (Figure 4.2 (b and c)). Initial results of the 
DHEAS/ETS/TS and ADG/ECG, showed partial separation of ETS from DHEAS/TS and 
also showed partial separation of ADG and ECG. Further FAIMS-MS analysis was 
performed in ACN:H2O 98:2 v/v with the selection of HILIC for chromatographic analysis.  
 
Figure 4.2 Initial FAIMS spectra of TG/ETG separation in both (a) negative ion mode 
(deprotonated), and (b and c) positive ion mode (protonated and sodiated adducts respectively) 
at DF 300 Td, showing no separation in negative ion mode and partial separation in positive ion 
mode 
 
Therefore, a FAIMS-MS investigation into the separation of the seven steroid metabolites 
was conducted in positive ion mode to study the effects of different cations (H+, NH4
+, Na+, 
K+, Cs+) on the FAIMS separation. Figure 4.3 is a summary of the variation of CF with the 
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applied DF for the cationised steroid metabolites following direct infusion into the FAIMS-
MS, where the CF values plotted are for the apex of the FAIMS peak at each DF (peak 
widths not shown); note that not all of the adduct ions were observed for each of the steroids. 
The FAIMS characteristics of the steroid ions result from differences between the complex 
non-linear relationship for ion mobility and field strength at high fields, compared to the 
field-independent ion mobility under low field conditions. Differential ion mobility is 
influenced by cationisation, so the appropriate choice of cation may result in the separation of 
isobaric ions where the protonated and deprotonated molecules are not resolved.11,26,27  
Separation of TG/ETG (Figure 4.3, dark blue/green) was observed for the protonated, 
sodiated and caesium adducts, with the best resolution obtained for the doubly sodiated 
adducts, [TG+2Na-H]+ and [ETG+2Na-H]+. Separation of ADG/ECG (Figure 4.3, red/grey) 
was only achieved for the sodiated and doubly sodiated adducts. The [ADG+Na]+ adduct was 
transmitted at lower CF values compared to [ECG+Na]+ for all DFs, but for the doubly 
sodiated adducts the order is reversed with the [ADG+2Na-H]+ adduct observed at higher 
CFs than [ECG+2Na-H]+. This results in better resolution of the doubly sodiated adducts in 
comparison to the singly sodiated ions, with peak widths of ~ 1 Td allowing the ions to be 
transmitted at 2.05 Td (ECG) and 2.70 Td (ADG) without overlap. The sulfated steroid 
metabolites were generally detected as dications, except for the protonated forms of TS/ETS, 
which showed no separation (Figure 4.3, purple/light blue), and only small differences 
between the separation with the different metal cations were observed. In each case, the ETS 
(Figure 4.3, light blue) was separated from TS/DHEAS (Figure 4.3, purple/orange), with the 
greatest resolution observed for the [M+Na+K-H]+ adducts. TS/DHEAS were not separated 
by FAIMS for any combination of cations.  
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Figure 4.3 FAIMS-MS analysis of steroid metabolite adducts; plotted are the CF values for the apex of the FAIMS peak at each DF (10 Td steps) for 
ADG (red), DHEAS (orange), ECG (grey), ETG (green), ETS (light blue), TG (dark blue) and TS (purple) 
126 
 
The doubly sodiated adducts ([M+2Na-H]+) were selected for the LC-FAIMS-MS analysis, 
because of the separation of the steroid isobars, with post-column addition of sodium acetate 
to promote the formation of sodiated adducts. A sodium concentration of 0.20 mg mL-1 
provided the optimum sensitivity for the [M+2Na-H]+ ions, suppressing other adducts 
without promoting the formation of higher sodiated clusters.  For the combination of FAIMS 
with LC-MS, the FAIMS DF and CF separations of the doubly sodiated adducts were further 
investigated and optimized (Figure 4.4 (a)). As a compromise between separation and signal 
intensity, DF 260 Td was chosen from the FAIMS-MS analysis (Figure 4.4 (b)) to be used for 
all subsequent LC-FAIMS-MS analyses (Figure 4.4 (b)). Three optimum FAIMS CFs were 
selected (Figure 4.4 (b)) to transmit the steroid metabolites ([M+2Na-H]+): CF 1.35 Td for 
DHEAS, TS and TG; CF 2.05 Td for ETS, ETG and ECG; and CF 2.70 Td for ADG. This 
choice of FAIMS settings allowed the selective transmission of each of the glucuronide 
isobars in a mixture of the seven steroid standards. DHEAS and TS were not separated by 
FAIMS (same CF for transmission) or MS (same m/z), so it was necessary to achieve 
chromatographic separation of the DHEAS and TS in the LC-FAIMS-MS analysis. The 
relationship between the structures of steroid ions and their low field ion mobility has been 
reported for the separation of TG/ETG using TWIMS, and the resolution of the sodiated 
dimers of androsterone epimers by static field DTIMS.10,11 However, relating structure to CF 
in FAIMS is more complicated due to the non-linear relationship between ion mobility and 
field strength at high fields. This is dependent upon several factors including the effective 
temperature (determined by the carrier gas temperature and frictional heating), interactions 
between the ion and buffer gas and structural changes as the field is increased. Therefore, 
modelling the CF values for these steroid metabolites was not attempted in this study. 
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Figure 4.4 (a) FAIMS-MS DF vs. CF waterfall plot for disodiated adduct of the seven targeted 
steroid metabolites in 98:2 v/v ACN:H2O with 10 mM ammonium acetate and 0.1% acetic acid 
with 45 µM of sodium acetate; (b) CF spectra at DF 260 Td with three optimised CFs 1.35 Td, 
2.05 Td and 2.70 Td 
 
4.4.2. Determination of steroid metabolites using LC-FAIMS-MS 
Reversed-phase (C18) and HILIC chromatography were both investigated for the separation 
of the steroid metabolites. The glucuronides were chromatographically resolved using a 
reversed phase method, however DHEAS and TS were not resolved. The glucuronides were 
also separated by FAIMS, but DHEAS and TS were not, so the only combination found to be 
capable of separating all seven metabolites was HILIC-FAIMS-MS. A fast HILIC method (8 
min) was selected due to the rapid elution of the three steroid sulfates (Figure 4.5 (a)), where 
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TS/ETS co-elute (m/z 413.14, retention times 2.20/2.22 min respectively), but are 
chromatographically separated from DHEAS (m/z 413.14, retention time 1.93 min), as shown 
in Figure 4.5 (a) (FAIMS off). As TS/ETS are separated by CF in the FAIMS, the 
combination of LC-FAIMS-MS allows separation of each of the steroid sulfates (Figure 4.5 
(a), CFs 1.35 Td and 2.05 Td). In LC-MS (Figure 4.5, FAIMS off) the glucuronides TG/ETG 
(m/z 509.21, 7.23/7.09 min respectively) and ADG/ECG (m/z 511.23, 6.99/7.07 min 
respectively) co-elute, as shown in Figure 4.5 (b) and (c) respectively; therefore, all of the 
steroid metabolites could not be identified and quantified using LC-MS alone. TG/ETG and 
ADG/ECG are selectively transmitted using the FAIMS at CFs 1.35 Td and 2.05 Td for 
TG/ETG (Figure 4.5 (b)) and CFs 2.05 Td and 2.70 Td for ECG/ADG (Figure 4.5 (c)).  
 
Figure 4.5 Extracted ion chromatograms for the seven steroids spiked (1 µg mL-1) into urine 
with LC-MS (FAIMS off) shown in black and LC-FAIMS-MS chromatograms (at DF 260 Td) 
with the optimum CFs extracted for each steroid: CF 1.35 Td (purple) for DHEAS (a) and TS 
(a) (m/z 413.14) and TG (b) (m/z 509.21); CF 2.05 Td (pink) for ETS (a) (m/z 413.14), ETG (b) 
(m/z 509.21) and ECG (c) (m/z 511.23); and CF 2.70 Td (grey) for ADG (c) (m/z 511.23) 
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LC-FAIMS-MS allows a high level of discrimination (>95%) for the steroid metabolites 
spiked into urine (Table 4.1) where discrimination was calculated from the peak areas of the 
spiked standards (1 µg mL-1) run individually and as a mixture using LC-FAIMS-MS at the 
three chosen CFs (DF 260 Td). Intra-day reproducibility of LC-FAIMS-MS of spiked 
standards (1 µg mL-1) was found to be comparable to LC-MS (%RSD <10%) with no internal 
standard used, as shown in Table 4.1 (note that for the LC-MS of TS/ETS and ADG/ECG, 
individual %RSDs could not be determined due to co-elution). Therefore, a three-
dimensional separation of all seven of the targeted steroid metabolites as a mixture was 
achieved only through the incorporation of FAIMS with LC-MS with a total analysis time of 
<10 minutes (Figure 4.6). 
 
Table 4.1 Discrimination (%) between steroid metabolites, calculated as 
[Areaindividual/Areamixed]x100, and relative standard deviation (%) for LC-MS and LC-FAIMS-
MS analysis of spiked urine replicate aliquots (n = 6) 
Steroid ([M+2Na-H]+) 
Discrimination 
(%) 
Relative standard deviation (%, n = 6) 
LC-MS LC-FAIMS-MS 
DHEAS 97.0 5.6 4.3 
TS 99.5 
4.9 
5.1 
ETS 96.2 2.8 
ADG 95.1 
12.8 
5.8 
ECG 97.2 3.6 
ETG 96.0 12.2 4.9 
TG 95.1 8.7 9.1 
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Figure 4.6 Summary of the three-dimensional separation achieved for seven targeted steroid 
metabolites using LC-FAIMS-MS, where isobaric steroids are coloured: m/z 413.14 is purple, 
m/z 509.21 is pink, and m/z 511.23 is grey 
 
Table 4.2 shows the quantitative characteristics of the LC-FAIMS-MS method for the 
determination of standards of the seven steroids. Good linearity (R2 > 0.99) was observed in a 
six point calibration across the range 31-1000 ng mL-1 for each of the targeted doubly 
sodiated ions ([M+2Na-H]+) of the steroid metabolites with calculated limits of detection 
(LOD, S:N 3:1) in the range 1-6 ng mL-1 and limits of quantification (LOQ, S:N 10:1) in the 
range 3-20 ng mL-1. Internal standards were not used in not used in this LC-FAIMS-MS 
method development, but could be incorporated in routine assays. These data demonstrate the 
stability of the miniaturized FAIMS and ion source configuration used in this study, although 
the CFs for ion transmission would require optimization for other FAIMS chip and ion source 
configurations. Using LC-MS alone without the FAIMS, some of the steroid metabolites 
could not be quantified using this chromatographic method without a significantly increased 
chromatographic run time due to the co-elution of the isobaric steroid metabolites. 
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Table 4.2 Summary of the quantitative responses for the steroid metabolites using LC-FAIMS-
MS 
Steroid ([M+2Na-H]+) LOD (ng mL-1) LOQ (ng mL-1) R2 Linear 
DHEAS 1.1 3.8 0.9975 
TS 1.3 4.2 0.9955 
ETS 1.1 3.7 0.9919 
ADG 6.1 20.3 0.9900 
ECG 2.8 9.3 0.9927 
ETG 3.7 12.3 0.9927 
TG 1.0 3.4 0.9926 
 
4.4.3. Analysis of unspiked urine 
LC-FAIMS-MS in comparison to LC-MS has been shown previously to increase linear 
dynamic ranges and lower LODs and LOQs due to S:N improvements of components of 
interest resulting from a reduction in chemical noise.28 This was demonstrated for the targeted 
steroid metabolites in unspiked human urine. Figure 4.7 demonstrates the quantitative 
determination of ADG (0.23 µg mL-1, grey) and ECG (0.17 µg mL-1, pink) in urine by LC-
FAIMS-MS in comparison to the indistinguishable isobars in LC-MS (black). Using LC-
FAIMS-MS the two isobars are individually identified and S:N improvements of >250% are 
observed (ADG S:N 1450, ECG S:N 4510) compared to the unresolved ADG/ECG peaks in 
LC-MS (S:N 180). Increases in the S:N for components using LC-FAIMS-MS is 
advantageous as they can lead to lower LODs and LOQs, enhancing the response of targeted 
components by reducing noise and removing isobaric interferences from the matrix. 
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Figure 4.7 EICs (m/z 511.23, DF 260 Td) for unspiked urine with LC-MS (black) and LC-
FAIMS-MS at CF 2.05 Td (pink, ECG) and at CF 2.70 Td (grey, ADG); S:N improvement of 
>250% are observed 
 
4.4.4. Cluster patterns in FAIMS-MS and LC-FAIMS-MS – a new tool to aid in 
identification 
The addition of sodium acetate to promote the formation of the doubly sodiated adducts of 
the steroid metabolites also results in the formation of singly charged clusters of the [M+2Na-
H]+ adducts with sodium acetate of the formula [M+2Na-H]++(NaOAc)n. These were 
observed in the mass spectra in MS and FAIMS-MS modes, and the mass spectra extracted 
from the chromatographic peak retention times for each steroid in LC-MS and LC-FAIMS-
MS. Using MS alone, each of the steroid metabolites forms clusters with the sodium acetate 
ranging from one sodium acetate up to a cluster of thirteen (in the m/z range analysed). Using 
FAIMS-MS analysis of the standards, EICs of these cluster ions could be extracted and the 
FAIMS spectra overlaid (Figure 4.8). These overlaid extracted cluster FAIMS 
chromatograms showed unique patterns of separation in the CF dimension (at the selected DF 
for analysis) for clusters of each of the steroid metabolites. As the clusters with sodium 
acetate for each of the steroid isobaric pairs and trio were also isobaric, if they were analysed 
as a mixture using MS alone, they would be indistinguishable, as shown in Figure 4.9 (a), 
Figure 4.10 (a), and Figure 4.11 (a).  
133 
 
 
Figure 4.8 FAIMS-MS spectra (EICs) of the doubly sodiated steroid metabolites and the clusters of increasing numbers of NaOAc, of the form 
[M+2Na-H]++(NaOAc)n, overlaid; the dashed orange line indicates the CF for transmission of the doubly sodiated ion (with no NaOAC), and the 
dark orange line indicates the unique cluster pattern of FAIMS CF shift with an increasing number of NaOAc in the cluster EICs 
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Figure 4.9 Cluster patterns observed in the mass spectra for the doubly sodiated [M+2Na-H]+ ions of DHEAS, TS and ETS (m/z 413.1369) analysed 
individually using (a) MS, (b) FAIMS-MS (DF 260 Td, CF 1.35 Td for DHEAS/TS and CF 2.05 Td for ETS) and (c) LC-FAIMS-MS, and analyses as 
a mixture for (d) LC-FAIMS-MS 
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Figure 4.10 Cluster patterns observed in the mass spectra for the doubly sodiated [M+2Na-H]+ ions of TG and ETG (m/z 509.2122) analysed 
individually using (a) MS, (b) FAIMS-MS (DF 260 Td, CF 1.35 Td for TG and CF 2.05 Td for ETG) and (c) LC-FAIMS-MS, and analyses as a 
mixture for (d) LC-FAIMS-MS 
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Figure 4.11 Cluster patterns observed in the mass spectra for the doubly sodiated [M+2Na-H]+ ions of ADG and ECG (m/z 511.2278) analysed 
individually using (a) MS, (b) FAIMS-MS (DF 260 Td, CF 2.05 Td for ECG and CF 2.70 Td for ADG) and (c) LC-FAIMS-MS, and analyses as a 
mixture for (d) LC-FAIMS-MS 
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Using FAIMS-MS to analyse the mass spectrum with selection of the CF for transmission of 
the steroid metabolites as in Section 4.4.1 above, results in an array of different cluster 
patterns observed for both the sulfates (Figure 4.9 (b)) and the glucuronides (Figure 4.10 (b) 
and Figure 4.11 (b)). Each of the steroid metabolites has a unique cluster pattern at the CF for 
transmission chosen for separation in Section 4.4.1. The explanation as to why each steroid 
metabolite has a unique cluster pattern, as plotted in the graphs, can be observed by looking 
at the extracted FAIMS spectra for each cluster ion ([M+2Na-H]++(NaOAc)n) for each 
steroid as shown in Figure 4.8. The dark orange lines in Figure 4.8 indicate the pattern that 
the CF shifts for each increasing cluster ion up to n = 13, showing that the overlaid CF 
spectra for each steroid and its clusters creates a unique pattern for each steroid ion. The 
dashed orange line indicates the CF chosen for transmission of each steroid and where the 
mass spectra was extracted for each steroid in Figure 4.9 (b), Figure 4.10 (b) and Figure 4.11 
(b), which shows that even though all of the clusters were observed in the FAIMS the 
differences in the CF spectra give a unique pattern in the FAIMS at the selected CF/DF for 
transmission and therefore a unique combination of the cluster ions are observed and the 
intensities also differ in the extracted mass spectra. Therefore, the different cluster patterns 
observed for each steroid metabolite arise from the transmission of the clusters through the 
FAIMS device. This demonstrates a new and powerful form of separation and identification 
utilising FAIMS in combination with MS.  
Further differences in the cluster pattern intensities can be observed in LC-FAIMS-MS 
(Figure 4.9 (c and d), Figure 4.10 (c and d) and Figure 4.11 (c and d)) in comparison to 
FAIMS-MS. For example, at the CF for transmission of ADG (CF 2.70 Td, DF 260 Td) in 
the LC-FAIMS-MS (Figure 4.11 (c and d) and Figure 4.8) none of the cluster ions with 
NaOAc are observed as they all traverse the device at lower CF values, therefore the only ion 
observed is the doubly sodiated ion of ADG ([ADG+2Na-H]+). However, the lower-ordered 
clusters (up to n = 4) for ECG are transmitted through the device at CF 2.05 Td (DF 260 Td). 
The cluster patterns of each of the sulfate ions in the LC-FAIMS-MS (Figure 4.9 (c and d)) 
are highly diverse with clusters for DHEAS observed across the mass spectrum, higher 
ordered clusters for TS observed and lower ordered clusters for ETS observed; therefore, 
creating unique cluster patterns at the CFs for transmission of each ion. In tandem MS, a 
fragmentation pattern can be used to confirm the identity of a species.29,30 Proposed here is 
the that FAIMS cluster patterns, could be used as an additional unique qualifying 
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identification tool to confirm the identity of each of the steroid metabolites utilising the 
FAIMS pre-selection, either by FAIMS-MS or LC-FAIMS-MS. 
4.4.5. Targeted multi-compensation field scanning LC-FAIMS-MS analysis 
The analysis of the steroid metabolites at the three optimal CFs for transmission of the 
isobars, was performed in the previous sections with the FAIMS CF (and DF) kept static 
during the chromatographic run, with three chromatographic analyses required to separate all 
seven of the targeted steroids. An alternative approach which can be employed is a targeted 
multi-compensation field by scanning through the three optimal CF conditions identified 
from the FAIMS-MS analyses of the steroids in a single chromatographic run. This was 
achieved by utilising a scanning LC-FAIMS-MS approach, which is described in detail in 
Chapter 5 of this thesis for non-targeted metabolic profiling,22 but modified to target specific 
CFs instead of scanning across the full CF range. In order to apply this multi-CF scan 
approach during the chromatographic run, a one-dimensional scan was applied where the DF 
was kept constant at DF 260 Td and the CF was scanned at 1.35, 2.05 and 2.75 Td (3 
conditions, 0.7 Td step size) with the MS scan rate set to 2 scan s-1. The single multi-CF data 
file acquired from the analysis of a standard mixture of all seven targeted steroid compounds 
can be both m/z and CF extracted, as shown for the [M+2Na-H]+ adducts of the steroid 
metabolites in Figure 4.12. Separation and discrimination of the isobars using this approach 
achieved within a single 8 min analysis is shown in Figure 4.12.  
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Figure 4.12 Mass and CF extracted ion chromatograms for the seven steroid standards (1 µg 
mL-1) using the targeted multi-CF one analysis LC-FAIMS-MS approach in a single 
chromatographic run (at DF 260 Td): CF 1.35 Td (purple) for DHEAS (a) and TS (a) (m/z 
413.14) and TG (b) (m/z 509.21); CF 2.05 Td (pink) for ETS (a) (m/z 413.14), ETG (b) (509.21) 
and ECG (c) (m/z 511.23); and CF 2.75 Td (green) for ADG (c) (m/z 511.23) 
 
4.5. Conclusion 
The combination of a miniaturized FAIMS separation with LC-MS using a HILIC column 
has enabled the determination of seven anabolic steroid metabolites in human urine. A short 
chromatographic run time (8 min) was made possible by FAIMS separation of co-eluting 
isobaric steroid metabolites. A reduction in chemical noise from the urine matrix and 
improved S:N is also observed. The LC-FAIMS-MS method showed good qualitative and 
quantitative responses for the steroid metabolites, with an additional identification tool using 
cluster patterns made possible using FAIMS. Higher sensitivity for the naturally low-
abundant steroid metabolites could be achieved by combining the LC-FAIMS-MS with 
tandem mass spectrometry, for example a triple quadrupole mass spectrometer.  
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 Chapter Five 
5. Increasing peak capacity in non-targeted omics application 
by combining full scan field asymmetric waveform ion 
mobility spectrometry with liquid chromatography-mass 
spectrometry 
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5.1. Chapter five overview 
The incorporation of full scan field asymmetric waveform ion mobility spectrometry 
(FAIMS) combined with liquid chromatography and mass spectrometry (LC-FAIMS-MS) 
has been investigated to enhance peak capacity for omics applications. The miniaturized 
FAIMS device is capable of rapid compensation field (CF) scanning and has been 
incorporated into an ultra-high performance liquid chromatography (UHPLC) and time-of-
flight (TOF) mass spectrometry analysis, allowing the acquisition of both full scan FAIMS 
and MS nested data sets within the timescale of a UHPLC peak. Proof-of-principle for the 
potential of scanning LC-FAIMS-MS in omics applications, is demonstrated for the non-
targeted profiling of human urine using hydrophilic interaction chromatography (HILIC). The 
high level of orthogonality between FAIMS and MS provides additional unique compound 
identifiers, with detection of features based on retention time, FAIMS dispersion field (DF) 
and CF, and mass-to-charge ratio (m/z). Extracted FAIMS full scan data can be matched to 
standards to aid in the identification of unknown analytes. The peak capacity for features 
detected using LC-FAIMS-MS was increased 3-fold compared to LC-MS alone, due to a 
combination of the reduction of chemical noise and separation of co-eluting isobaric species 
across the whole analytical space. The use of FAIMS selection with in source collision 
induced dissociation (FISCID) reduces sample complexity associated with overlapping 
fragmentation patterns and provides structural information on the selected precursor ions 
using a single mass analyser. 
5.2. Introduction 
The identification of unknown analytes in biological matrices remains a significant challenge, 
whether the focus is on small molecules, metabolites, proteins, lipids or components of 
cellular extracts. Conventional mass spectrometric based approaches for non-targeted 
analyses typically utilize chromatographic techniques, such as LC or gas chromatography, 
combined with MS or tandem MS (MS/MS).1–3 However, sample matrix complexity can lead 
to molecular features being missed or remaining hidden within the dataset, due to 
components being unresolved from the chemical noise and/or co-eluting isobaric species. 
Improvements in limits of detection and peak capacity can be achieved using complex sample 
preparation techniques and/or lengthy chromatographic run times. However, these 
approaches may not always be successful and are usually employed in targeted analyses 
where the analytes of interest are known. Moreover, these targeted optimization approaches 
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may not be applicable in a non-targeted analysis, where the aim is to profile the whole 
metabolome or proteome and detect small perturbations within a complex matrix under 
specified conditions.4  
Alternative techniques include drift tube ion mobility spectrometry (IMS), which separates 
components based on difference in their mobilities as they drift through a buffer gas, such as 
drift tube ion mobility spectrometry (DTIMS) and travelling wave ion mobility spectrometry 
(TWIMS). IM has been used in non-targeted IM-MS5–7 and LC-IM-MS methods for the 
acquisition of nested data sets in metabolomic8,9 and proteomic applications.10,11 However, 
although useful, for improving confidence in structural assignments by increasing 
measurement dynamic range and component resolution, particularly in proteomic 
applications,11 the drift time through the mobility device typically increases with mass in m/z 
vs drift time plots, reducing the orthogonality of the two techniques.8,11  
FAIMS, also known as differential mobility spectrometry (DMS) or differential ion mobility 
spectrometry (DIMS),12,13 is an atmospheric pressure, gas-phase separation technique, which 
separates ions based upon non-linear compound-dependent differences in their mobilities in 
alternating high and low electric fields, as described in detail in Section 1.3. FAIMS therefore 
differs from DTIMS, which separates ions based on ion drift velocity in a buffer gas under 
low electric field strengths (Section 1.1).14 FAIMS combined with LC-MS, described in 
Section 1.5, can be used to increase selectivity and lower detection limits by reducing 
chemical noise and removing interferences, which can be advantageous when dealing with 
complex biological matrices.15–17 
FAIMS-MS has previously been used in non-targeted omics applications, showing increased 
peak capacities compared to high resolution MS alone.18,19 Beach et al showed that even with 
minimal sample preparation increases in peak capacity could be achieved through the 
combination of FAIMS with MS by improving the identification of low abundance species by 
removing chemical interference from the matrix.18 The combination of other FAIMS and 
DMS devices with mass spectrometry has been previously shown to increase peak capacity 
and resolve isobars in metabolomics and proteomic applications.18,20 However, the slow scan 
speeds of most commercially available FAIMS devices, resulting from long ion residence and 
dwell times (50-200 ms), means that the acquisition of scan data over the full CF range is 
incompatible with typical LC peak elution times, particularly for fast UHPLC analyses. The 
incorporation of FAIMS into LC-MS for omics workflows has therefore been limited to 
stepping between a small number of selected CFs in a single run, usually between 3-6 CFs 
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per scan,21,22 or scanning over a reduced FAIMS CF scan range; the fastest reported time for 
a partial CF scan being ~2-3 seconds.23 Both of these approaches may result in missing data 
for ions not transmitted through the device at the CF for transmission of the ions,24,25 which is 
an effect that would only be increased with the elution time of the narrow peak widths (~5-10 
s) associated with UHPLC separations. Other approaches to overcoming the slow scanning 
speeds of FAIMS devices have been to extend chromatographic run times to increase peak 
width and therefore increase the number of CF scans per chromatographic peak; or to 
perform multiple chromatographic analyses, each at a different static CF, which can improve 
peak capacity, but significantly increases the total analysis time.26,27 There is, therefore, a 
need for a fast scanning of the full FAIMS CF spectrum within the timescale of a UHPLC 
peak, in order to acquire LC-FAIMS-MS datasets whilst maintaining a high throughput for 
analyses, necessary to process large datasets with the aim towards identifying robust 
biomarkers.  
Fast scanning of the full CF range in cycle times compatible with UHPLC chromatographic 
peak widths is obtained using the miniaturised chip-based FAIMS device which has short ion 
residence times (50-100 µs).28–30 Described in this chapter is the hyphenation of UHPLC with 
full scan FAIMS and TOF-MS for the acquisition of non-targeted nested scanning LC-
FAIMS-MS data sets. Here, the FAIMS is scanned across a full scan CF range in 1 s (limited 
by the TOF scanning rate, not the FAIMS). The potential of this approach to be applied to 
omics applications is demonstrated for the molecular profiling analysis of human urine 
showing a three-fold increase in peak capacity without a corresponding increase in analysis 
time compared to LC-MS alone. A reduction in chemical noise and the separation of 
interferences and isobaric ions is demonstrated using a short (10 min) high-throughput 
chromatographic method. 
5.3. Experimental 
5.3.1. Chemicals 
HPLC grade acetonitrile (ACN), water and ammonium acetate were purchased from Fisher 
Scientific (Loughborough, UK). Acetic acid, creatinine and theophylline were purchased 
from Sigma Aldrich (Dorset, UK). A pooled human urine sample was aliquoted into 500 µL 
aliquots and stored at -80°C until analysed.  
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5.3.2. Sample preparation 
Sample preparation for samples for LC-FAIMS-MS analysis 
A protein precipitation method previously reported was adapted and used in this study.9,31 
Aliquots of urine (500 µL), stored at -80°C, were thawed at room temperature for 20 min. 
The thawed urine sample was vortexed for 30 s followed by ultra sonication for 1 min to 
ensure sample homogeneity, prior to the addition of cold (4°C) ACN (1 mL) to the urine 
aliquot.32 The mixture was vortexed for 30 s, followed by ultra sonication for 1 min and 
allowed to stand for 5 min prior to centrifugation at 12200 rpm for 10 min at ambient 
temperature. The supernatant was removed and analysed by LC-FAIMS-MS and LC-MS. 
Sample preparation for FAIMS-MS and TWIMS-MS analysis 
A urine aliquot (500 µL) was removed from the -80°C freezer and thawed for 20 min at room 
temperature. The aliquot was diluted 1:1 with water and centrifuged at 12200 rpm for 10 min 
at ambient temperature. The extract was loaded onto a pre-conditioned (with ACN (1 mL) 
and water (1 mL)) 200 mg C18CU solid phase extraction (SPE) cartridge (Caliper Life 
Sciences, Seer Green, UK), washed with ACN:water (14:86 v/v, 1 mL) and eluted with ACN 
(3 mL). The SPE eluent was then evaporated to near dryness (using N2) and reconstituted in 
500 µL ACN:water (98:2 v/v) with 10 mM ammonium acetate and 0.1% acetic acid. 
5.3.3. Instrumentation 
LC-FAIMS-MS instrumentation and parameters 
LC-FAIMS-MS analyses were performed using an Agilent 1200 series LC interfaced to an 
Agilent 6230 TOF-MS (Agilent Technologies, Santa Clara, USA) fitted with a prototype 
chip-based miniaturized FAIMS device (ultraFAIMS, Owlstone Ltd., Cambridge, UK), 
which has been described in detail elsewhere (Section 1.3.3).33 The miniaturised multi-
channel FAIMS device (100 µm electrode gap), with a short trench length (78.1 mm) and ion 
path length (700 µm), was located in front of the MS inlet transfer capillary and behind a 
modified spray shield in the Jet Stream electrospray (ESI) source. LC-MS analyses were 
performed with the FAIMS device in place with no applied electric fields.  
The Jet Stream ESI source was operated in positive ion mode in the mass range m/z 80-1500. 
The MS nebulizer pressure was set to 50 psig with a sheath gas (N2) flow of 11 L min
-1 at 
250°C and a nozzle voltage of 2000 V. The capillary voltage was set to 3500 V, the 
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fragmentor voltage was set to 200 V and the drying gas (N2) flow set to 7 L min
-1 at 150°C. 
The MS scan rate was 12 scans s-1 for LC-FAIMS-MS and LC-MS analysis. 
Urine extracts (5 µL) were injected onto a Poroshell 120 hydrophilic interaction liquid 
chromatography (HILIC) column, with dimensions 4.6 x 50 mm x 2.7 µm (Agilent 
Technologies, Santa Clara, USA), maintained at 35°C and operated at a flow rate of 0.5 mL 
min-1. A gradient chromatographic method utilized mobile phase A consisting of water with 
10 mM ammonium acetate and 0.1% acetic acid, and mobile phase B consisting of 
ACN:water (98:2 v/v) with 10 mM ammonium acetate and 0.1% acetic acid. The 
chromatographic method was as follows: hold at 100% B from 0-0.25 min, decrease to 62% 
B from 0.25-5 min, increase to 100% B from 5-5.5 min and hold for a further 4.5 min for re-
equilibration, giving a total chromatographic run time of 10 min. 
The FAIMS CF was scanned from -0.9 to 4.0 Td with DF 240 Td at 1 scan s-1. Each FAIMS 
scan, in LC-FAIMS-MS mode, consisted of eleven 0.49 Td CF steps and an interscan re-
initialization step. The FAIMS was controlled via a prototype software ‘FAIMS Control’ 
(Agilent Technologies, Santa Clara, USA) which allowed the synchronization of the FAIMS 
scans with TOF pushes, and was used in combination with the MassHunter Acquisition 
software (B.05.00, Agilent Technologies, Santa Clara, USA) which controlled the LC and the 
MS. 
FAIMS-MS and TWIMS-MS instrumentation and parameters 
FAIMS-MS analysis was performed on the Agilent 6230 TOF-MS fitted with the 
miniaturised FAIMS device, with the MS nebulizer pressure was set to 50 psig with a sheath 
gas (N2) flow of 11 L min
-1 at 250°C, with a nozzle voltage of 2000 V. The capillary voltage 
was set to 3500 V, the fragmentor voltage was set to 200 V and the drying gas (N2) flow set 
to 7 L min-1 at 150°C. The MS scan rate was set to 10 scans s-1 in the mass range m/z 80-1500 
in positive ion mode. A two-dimensional FAIMS scan (or sweep) was performed between DF 
180 to 280 Td (10 Td steps) and CF -2 to 5 Td (0.05 Td steps).  
TWIMS-MS was performed on a Synapt G2-S high-resolution MS (Waters Corp., Milford, 
MA, USA). The MS ESI source was operated in positive ion mode, with capillary voltage set 
to 2 kV and sampling cone set to 30 V. The source and desolvation temperatures were set to 
120°C and 300°C respectively, gas flow (N2) rates were set to 30 L h
-1 and 600 L h-1 
respectively and the nebulizer pressure was set to 7 bar. The tri-wave drift cell conditions 
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were set to a wave velocity of 300 m s-1 with the wave height ramped from 10 V to 40 V 
(ramped over the full IMS cycle). 
Both FAIMS-MS and TWIMS-MS were performed by direct infusion into the ESI source of 
the urine extract, performed using a syringe pump operated at a sample infusion rate of 10 µL 
min-1.  
5.3.4. Scanning LC-FAIMS-MS synchronisation 
Synchronization of the start of the FAIMS scan with the start of the LC-MS acquisition was 
achieved via the use of a contact closure board installed on the binary LC pump (Figure 5.1) 
connected to an in-house constructed contact closure interface, which initiated the FAIMS 
scanning at the start of the LC run. The contact closure interface was constructed from a 
computer mouse printed circuit board, which was interfaced with the computer using a USB 
connector and the contact closure board of the LC pump; such that, when the contact closure 
relay closed the left mouse button was actuated (Figure 5.1). The contact closure was 
programmed into the chromatographic method at 0.01 min to trigger the start of the FAIMS 
scan, with the control computer mouse pointer placed over the FAIMS Control software scan 
execute button. This contact closure ensures that the FAIMS always began scanning at the 
same time point in every chromatographic run and allowed for the alignment and 
deconvolution of CF values in data analysis. 
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Figure 5.1 Schematic diagram of the connections to allow for synchronisation of the FAIMS 
scan with the LC and MS, showing the contact closure interface from the binary pump of the 
LC to the computer to trigger the start of the FAIMS scan34 
 
5.3.5. Data analysis 
FAIMS-MS and TWIMS-MS comparison 
Data processing software that can process both FAIMS-MS and TWIMS-MS raw data does 
not exist at the time of writing of this thesis. Therefore, in order to compare the results for the 
same urine extract analysed using both FAIMS-MS and TWIMS-MS the data from both 
techniques were exported as CSV files, from MassHunter (Agilent Technologies, Santa 
Clara, USA) and Driftscope (Waters, Manchester, UK) respectively, for importation into 
OriginLab 2015 (Academic version, b9.2.272). Comparative heat plots of the FAIMS-MS 
and TWIMS-MS analytical space were then generated for comparison on the same intensity 
(colour) scale.  
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LC-FAIMS-MS feature determination 
The data from the LC-FAIMS-MS analysis were acquired in the Agilent proprietary output 
format (.d) containing all of the data as acquired spectra labelled by retention time. The data 
were automatically saved in MS/MS or MS2 format35 with the FAIMS applied, and was 
viewed using the Agilent MassHunter Qualitative Analysis B.05.00 software (Agilent 
Technologies, Santa Clara, USA). The total ion chromatogram (TICs) or extracted ion 
chromatograms (EICs) for a selected m/z at each CF were viewed in MassHunter Qualitative 
by extracting the data for the selected m/z range at a given ‘collision energy’ in the extract 
chromatograms window, as the CF values are automatically saved in the collision energy 
channel using the FAIMS Control acquisition software in combination with the MassHunter 
Acquisition software. However, due to all of the data being contained within one file, the 
individual scan points for each CF are not adjacent (10 other CF scan points and an interscan 
re-initialization step in-between) the MassHunter feature identification tools do not work. 
Therefore, each individual CF dataset was exported as a separate file for further processing, 
using a similar approach to Canterbury et al.23 CF deconvolution was achieved by extracting 
the mass spectra at the retention times associated with each CF (every 12th mass spectra, 
including the interscan re-initialization step) and exporting the extracted spectra from 
MassHunter in the mzData file format,36 resulting in 11 separate files containing all of the 
mass spectra acquired at each CF. 
The exported CF separated LC-FAIMS-MS mzData files were imported into MZmine 2.20,36 
an open-source software for mass spectrometry data processing and feature determination 
based on a signal-to-noise ratio (S:N) greater than three. Each identified feature is a 
combination of retention time and m/z, creating a feature list for each CF (at the selected DF) 
for the LC-FAIMS-MS files. Each generated feature list was filtered to remove isotopes and 
adducts. The feature lists for each CF were then aligned into one list based upon retention 
time and m/z, which was exported as a csv file and opened in Microsoft Excel 2010 
(Microsoft, Seattle, USA). A conditional format was applied to the aligned feature list in 
Excel to determine identified features in the FAIMS dimension, as features may be present in 
one CF or multiple CFs, which are either adjacent or separated into multiple features in the 
CF dimension (isobaric separation). The final feature list, with features identified by the 
combination of retention time, m/z and CF (at a selected DF), can then be searched against 
online databases, such as PubChem, the human metabolome database (HMDB), the METLIN 
database and the Kyoto Encyclopaedia of Genes and Genomics (KEGG) database.36  
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A similar approach was applied to the LC-MS data of urine and an ACN blank. The data 
were opened and exported from MassHunter as an mzData data file, opened in MZmine 2.20 
and a feature list generated based upon a S:N threshold greater than three, and filtered to 
remove isotopes and adducts. The feature lists were exported as CSV files for comparison 
with the LC-FAIMS-MS feature list in Excel.  
Features found from the blank ACN analysis were subtracted from the LC-MS and LC-
FAIMS-MS feature lists. The remaining features were manually searched in order to ensure 
no chemical noise was misinterpreted as a feature. Figures presented in this chapter were 
produced using OriginLab 2015 (Academic version, b9.2.272), MassHunter Qualitative 
Analysis, and Microsoft Excel and PowerPoint. 
5.4. Results and discussion 
5.4.1. FAIMS-MS profiling 
FAIMS-MS analysis was initially carried out on a urine extract prepared using solid phase 
extraction on an ODS column (Section 5.3.2). The extract was directly infused into the ESI-
FAIMS-MS and a two-dimensional FAIMS sweep performed in the range DF 180-280 Td 
(10 Td steps), CF -2-5 Td (0.05 Td steps). A plot of DF vs. CF for the total ion count (Figure 
5.2) shows that the majority of the ions are transmitted in the CF range -1 to 4 Td at DFs up 
to 250 Td.  
 
Figure 5.2 Heat plot of the ESI-FAIMS-MS analysis of a urine extract, via direct infusion, with 
DF vs CF with percentage intensity on the colour scale 
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The high level of orthogonality between FAIMS and MS can be observed in a plot of m/z vs 
CF (Figure 5.3 (a)) for the FAIMS-MS analysis of the directly infused urine extract. Ions are 
observed across the entire CF region (-1 to 4 Td) and mass range (m/z 80-1500) showing that 
FAIMS can significantly increase peak capacity for omics applications. Using drift tube 
travelling wave ion mobility spectrometry (TWIMS),37 the corresponding plot of m/z versus 
TWIMS drift time (bin number) shows that as the bin number increases the m/z also increases 
(Figure 5.3 (b)), because ion collision cross section (CCS) generally increases with mass.28 In 
comparison, FAIMS-MS shows a much weaker correlation between m/z and CF than m/z and 
bin number in TWIMS-MS. The difference between FAIMS-MS and TWIMS-MS is also 
apparent in Figure 5.4 (a) and (b). In the mass spectra extracted from the FAIMS-MS data at 
selected CF values (Figure 5.4 (a)), ions are observed across the entire m/z range (m/z 150-
500) in each of the mass spectra as the CF increases. Whereas, in the mass spectra extracted 
from TWIMS-MS data at selected bin numbers (Figure 5.4 (b)), the m/z values observed in 
the spectra increase as the bin number increases. The miniaturized FAIMS device used in this 
study can therefore be combined with mass spectrometry to profile urine with different 
selectivity to IM-MS yielding characteristic DF/CF conditions which can be matched against 
standards to provide a unique identifier in addition to m/z. The combination of other FAIMS 
and DMS devices with mass spectrometry has been previously shown to increase peak 
capacity and resolve isobars in metabolomics and proteomic applications.18,20 
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Figure 5.3 Heat plots for the direct infusion of urine (post SPE sample pre-treatment) using (a) 
ESI-FAIMS-MS (m/z vs CF) and (b) ESI-TWIMS-MS (m/z vs bin number)  
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Figure 5.4 Extracted mass spectra from (a) ESI-FAIMS-MS and (b) ESI-TWIMS-MS of urine 
at increasing CFs and bin numbers 
 
5.4.2. LC-FAIMS-MS profiling 
Hyphenation of liquid chromatography with mass spectrometry is widely used in omics 
applications, because of the orthogonal separation characteristics of the two techniques. It has 
also been shown that the fast scanning capability of the drift tube ion mobility spectrometry 
(MS timescale) allows the acquisition of nested LC-IM-MS data sets.8 In contrast, the 
relatively slow scan rates of most FAIMS and DMS devices means that similar datasets can 
only be acquired if compromises are made, such as scanning the CF over a partial range, 
stepping between selected CFs or using long LC run times. However, the fast scanning 
capability of miniaturized FAIMS (~1 s full scan), allows the acquisition of nested full scan 
FAIMS and MS spectra within the timescale of a UHPLC chromatographic peak width (~5-
10 s). For LC-FAIMS-MS analysis, a DF 240 Td was chosen as a compromise between 
sensitivity (at low CFs) and separation of ions (at high CFs) by the FAIMS device, based on 
the preliminary FAIMS-MS analysis of urine (Figure 5.2 (a)). The FAIMS was set to scan 
across the CF range -0.9 to 4.0 Td, in 0.49 Td steps, providing full coverage of the urine 
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profile, with a total scan time ~1 s. The total ion chromatogram for the acquired nested LC-
FAIMS-MS raw data set (DF 240 Td) for urine using a HILIC UHPLC column separation is 
presented in Figure 5.5 (a) and (b), with a single FAIMS CF scan acquired at a retention time 
of 7.4 min in Figure 5.5 (c). A total ion chromatogram at a selected CF (1.55 Td) extracted 
from the full scan FAIMS data is shown in Figure 5.5 (d). 
 
Figure 5.5 The LC-FAIMS-MS analysis of human urine (DF 240 Td), (a) whole TIC, (b) TIC 
zoomed in the region 6.6 – 8.4 min, (c) a single FAIMS scan acquired at a retention time of 7.4 
min, (d) FAIMS-selected extracted TIC at CF 1.55 Td 
 
The incorporation of a FAIMS separation into the LC-TOF-MS analysis adds an extra 
dimension of separation (Section 1.5) which is shown in Figure 5.6 (a) and (b). Figure 5.6 (a) 
is a plot of retention time vs. CF (at DF 240 Td) for all ions in the urine sample, where 
FAIMS separation of ions generated from molecules with the same retention time results in 
multiple peaks in the CF direction across the whole retention time range (0-10 min). Figure 
5.6 (b) shows examples of the mass spectra at different CFs using LC-FAIMS-MS (extracted 
from the apex of a peak in the total ion count). In this example (Figure 5.6 (b)), some ions can 
be seen in only one CF (e.g. m/z 400.3062, m/z 602.2941), different clusters of ions can be 
observed at different CFs (e.g. m/z 380.3317-452.3848, m/z 637.5551-719.6280), and there 
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are ions that can be observed at multiple CFs (e.g. m/z 166.0515, m/z 184.0608). It should be 
noted that ions are present across the entire mass spectral range with no apparent correlation 
between the increases in CF with an increase in the m/z values observed. 
 
 
Figure 5.6 (a) Three-dimensional plot, with two-dimensional projection, of retention time vs CF 
for LC-FAIMS-MS, with intensity on the colour scale; (b) mass spectra extracted from LC-
FAIMS-MS dataset at the same retention time and four different CF values 
 
The peak areas for chromatographic peaks observed at multiple CF values in the LC-FAIMS-
MS data can also be used to plot extracted FAIMS CF spectral scans of chromatographic 
peak area vs. CF (Figure 5.7 (a) and (b)). These extracted FAIMS CF scans can be extremely 
useful in determining whether there is more than one unique FAIMS feature at a selected m/z 
and retention time pair. For example, a peak assigned to urinary creatinine is observed in the 
LC-FAIMS-MS data set as the protonated and sodiated adducts at multiple CF values. The 
extracted FAIMS scans for these ions in urine (black) and for a creatinine standard (grey) are 
plotted in Figure 5.7 (a) and (b). From Figure 5.7 (a) we can observe that the protonated 
creatinine has one prominent feature at CF 0.08 Td, with a second weak feature present at CF 
2.04 Td in the urine, but not the standard, suggesting interference from the urine matrix. 
However, the sodiated creatinine has two main features, at CF 0.08 Td and 2.04 Td, in the 
extracted FAIMS scan (Figure 5.7 (b)) for both the urinary creatinine and the standard. The 
two features observed indicate that the creatinine ions may be present in the gas phase in 
more than one form, rather than isobaric interferences from the urine matrix, because the two 
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features are present in the standard creatinine FAIMS spectrum. Creatinine has previously 
been shown to coexist as two tautomers,38 and the LC-FAIMS-MS data suggest that the 
sodiated tautomers are separated by FAIMS. The separation of tautomers and isobars 
utilizing separation based on mobility is one example of the way that FAIMS can improve 
peak capacity in conjunction with LC-MS; two features are observed for [creatinine+Na]+ 
using LC-FAIMS-MS where only one feature is observed using LC-MS (Figure 5.7 (d)). 
 
 
Figure 5.7 FAIMS CF scans extracted from LC-FAIMS-MS (DF 240 Td) of creatinine in urine 
(black) and a creatinine standard (grey) for (a) [creatinine+H]+ (m/z 114.0662) and (b) 
[creatinine+Na]+ (m/z 136.0481); (c) and (d) EICs for creatinine in urine using LC-MS (grey) 
and at max CF for transmission of each FAIMS peak (black) for (c) [creatinine+H]+ (m/z 
114.0662) and (d) [creatinine+Na]+ (m/z 136.0481)  
 
The extent to which LC-FAIMS-MS can increase the peak capacity in comparison to LC-MS 
is shown in Figure 5.8 (a), for the analysis of a human urine extract. A molecular feature is a 
defined as a unique combination of m/z and retention time for LC-MS, and of m/z, retention 
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time and CF (at DF 240 Td) for LC-FAIMS-MS (Figure 5.8 (b)). The number of molecular 
features observed in LC-FAIMS-MS is represented in a three-dimensional plot of CF vs. 
retention time vs. m/z as shown in Figure 5.8 (b). The features uniquely observed in the LC-
MS are plotted in Figure 5.8 (b) as red triangles and the features unique to LC-FAIMS-MS as 
blue spheres. Features common to LC-FAIMS-MS and LC-MS are plotted as purple cubes. 
This three-dimensional representation shows how the separation of unique features in the CF 
dimension is across the entire analytical space with no observable correlation between CF 
and either m/z or retention time. 
The total number of features found in LC-MS was 681, of which 288 were detected only 
using LC-MS. The total number of features found in LC-FAIMS-MS was 1838, of which 
1445 were uniquely detected using LC-FAIMS-MS. Of the total features detected from both 
methods 68% were unique to LC-FAIMS-MS, 14% unique to LC-MS and 18% common to 
both methods. These results clearly demonstrate that the incorporation of a FAIMS separation 
into LC-MS analysis significantly enhances the number of features observed. The increase in 
peak capacity using LC-FAIMS-MS is due to a combination of the separation of isobaric 
species and the reduction of chemical noise and hence an increase the number of features 
with a S:N >3 (Figure 5.9). It should be noted that FAIMS separation does not result in a 
reduction in the linear dynamic range, as is usually the case for drift tube ion mobility-mass 
spectrometry systems. Improvements in signal to noise ratio near the detection limit can 
result in an extended dynamic range compared to MS alone.15 A total of 78 pairs of features 
(i.e. two features in the CF dimension at the same m/z and retention time) were detected from 
the separation of isobaric species, of which 34 pairs were uniquely detected using LC-
FAIMS-MS. 44 pairs were observed as one feature in the LC-MS and as two features in LC-
FAIMS-MS utilizing the FAIMS as an extra dimension of separation. The remaining 1333 
features were uniquely detected using LC-FAIMS-MS due to the reduction in chemical noise 
and increase in sensitivity. The peak capacity is therefore increased using the nested LC-
FAIMS-MS data set without a corresponding increase in the analysis time in comparison to 
LC-MS. 
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Figure 5.8 (a) The number of molecular features observed in LC-FAIMS-MS (blue) and LC-Ms 
(red), and the features common to both methods (purple) as a Venn diagram; (b) a three-
dimensional representation of the features observed in LC-FAIMS-MS with unique features 
observed in LC-FAIMS-MS (blue spheres) and LC-MS (red triangles), and the features 
common to both methods (purple cubes) 
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Figure 5.9 EICs for m/z 331.2100 showing the improvement in S:N for the chromatographic 
peak at 4.24 min using (a) LC-MS and (b) LC-FAIMS-MS (CF 0.08 Td, DF 240 Td)  
 
The LC-scanning FAIMS-MS non-targeted approach used a FAIMS scan rate of 1 s scan-1 to 
be compatible with UHPLC chromatographic peak widths. LC-FAIMS-MS peaks (in the 
deconvoluted CF chromatograms) were counted as features only if there were at least four or 
more data points (Figure 5.10) above the baseline amplitude of the noise (S:N >3), and all 
chromatographic peaks were visually inspected. In the data reported in this study, the FAIMS 
was scanned from -0.9 – 4 Td (11 steps) in 1 s. However, the FAIMS CF scan range and the 
number of data points acquired over the selected CF range, can both be changed to optimize 
the number of data points collected across a chromatographic peak, depending on the sample 
matrix and the chromatographic peak width. 
The identification of molecular features in LC-FAIMS-MS includes the additional unique 
identifier of the CF (at a selected DF) in addition to retention time and m/z. The features 
observed by LC-MS and LC-FAIMS-MS using this approach can be searched against online 
databases using the MZmine 2 software,36 by comparing m/z and retention time data against 
the databases. For the identification of features dependent upon CF, such as isobaric species 
(multiple features at the same m/z and retention time), standards would be required to confirm 
identities, as FAIMS parameters are very difficult to predict.39 The development of library 
data of the sort generated for LC-IM-MS would facilitate compound identification.40 
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Figure 5.10 EICs (at DF 240 Td) of (a) and (b) m/z 166.07 at CF 0.08 Td, and (c) and (d) m/z 
265.12 at CF 1.06 Td showing the number of data points across the deconvoluted 
chromatographic peaks, each extracted from a single CF acquired over the full CF range from 
the scanning LC-FAIMS-MS data acquisition 
 
An aid to the identification of molecular features is to generate fragment ions using collision 
induced dissociation (CID). This is possible if the FAIMS is interfaced to a tandem mass 
spectrometer, such as a Q-TOF or Q-Orbitrap. In this study, a single TOF mass analyser was 
used, allowing fragment ions to be generated by in-source CID without ion pre-selection on 
the basis of m/z and therefore the fragment ion mass spectrum at a particular retention time 
can be a complex array of overlapping fragmentation patterns. However, an approach 
previously described as FAIMS-in-source collision induced dissociation-MS (FISCID-MS),33 
can be used to simplify fragment ion spectra as a result of FAIMS pre-selection. Figure 5.11 
shows the fragmentation of an ion, with m/z 181.0727 and retention time 2.53 min, identified 
as protonated theophylline (a metabolite of caffeine) based on a comparison with a standard 
(data not shown). Using LC-MS, the identification of fragment ions in Figure 5.11 (black 
traces), at two different fragmentor voltages, is difficult as there is uncertainty as to which 
ions observed are derived from the pre-cursor ion rather than other higher m/z ions present at 
the same retention time. For example, the ion at m/z 105.0489 appears to be a fragment ion of 
protonated theophylline due to its increase in intensity at the higher fragmentor voltage (350 
V). However, utilizing FAIMS pre-selection at CF 1.06 Td (red traces), background ions in 
the mass spectra are significantly reduced allowing the identification of m/z 124.0481 as the 
fragment ion of the precursor at m/z 181.0727, which is a known fragment of theophylline.41 
The absolute fragment ion intensity using FISCID has decreased in comparison to LC-MS, 
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but so has the chemical noise, so that the S:N of the fragment m/z 124.0481 (fragmentor 
voltage 350 V) is increased by four times. 
 
Figure 5.11 Mass spectra at retention time 2.53 min (a) LC-MS (black) and (b) LC-FAIMS-MS 
(red, CF 1.06 Td, DF 240 Td) analysis of urine at fragmentor voltage 200 V, (c) LC-MS and (d) 
LC-FAIMS-MS at fragmentor voltage 350 V 
 
5.5. Conclusion 
Scanning FAIMS analysis has been combined with UHPLC and TOF-MS allowing the 
acquisition of nested LC-FAIMS-MS datasets for a non-targeted omics analysis. The scan 
rate of the FAIMS is compatible with the peak widths associated with UHPLC separations. 
The approach has been demonstrated for the molecular profiling of a complex biological 
matrix (urine), with the peak capacity increased by approximately 3-fold compared to LC-
MS. The increase in peak capacity observed was due to the reduction of chemical noise and 
the separation of isobaric ions. The absolute signal is reduced with the FAIMS, but the S:N is 
increases from the reduction in chemical noise, thereby enhancing the detection of low 
intensity ions. The FAIMS CF/DF dimension provides an additional unique molecular 
identifier in addition to m/z and retention time, which can be used alone or in conjunction 
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with fragment ion data generated by FISCID methodology to aid compound identification. 
The approach has been evaluated here for the molecular profiling of urine, but is applicable to 
other sample matrices as part of an omics workflow. This work should be of interest to those 
in the omics field who are looking for the opportunity to gain added information from their 
datasets, and could potentially be applied to omics analysis including metabolomics, 
lipidomics and proteomics.  
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 Chapter Six 
6. Thesis overview and further work 
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6.1. Thesis Overview 
The combination of a miniaturised field asymmetric waveform ion mobility spectrometry 
(FAIMS) device combined with mass spectrometry (FAIMS-MS) and liquid 
chromatography-mass spectrometry (LC-FAIMS-MS) has been employed to demonstrate 
how FAIMS can enhance MS and LC-MS analyses. Chapters 2 to 4 demonstrate the ability of 
FAIMS to improve the selectivity and sensitivity of the detection of analytes from complex 
samples, through the reduction of signal-to-noise ratios to improve limits of detection and 
quantification and removal of co-eluting background interferences, and to separate isobaric 
compounds that would otherwise not be separated by MS alone. Chapter 5 utilises all of these 
abilities of FAIMS to improve LC-MS analyses, by combining FAIMS with a fast scanning 
approach with LC-MS (on a UHPLC compatible timescale) to potentially revolutionise the 
‘omics field with an LC-FAIMS-MS methodology to determine more unique features from 
the analysis of complex biological samples in a high-throughput analysis timescale.  
In the following sections, individual chapters have been summarised and proposals to further 
the research discussed.  
6.2. Summary of chapter one 
Chapter one provides a theoretical background to the ion mobility, FAIMS, mass 
spectrometric and liquid chromatographic techniques used throughout the research presented 
in this thesis. The chapter also provides examples from literature of the application of 
FAIMS-MS and LC-FAIMS-MS in bioanalysis for both targeted and non-targeted 
applications.  
6.3. Summary of chapter two  
Chapter two describes an investigation into self-assembling, non-covalent supramolecular 
complexes of 3-methylxanthine (3-MX) in the gas phase. 3-MX was found to form a diverse 
range of supramolecular complexes, with single and multiple charge states, that were able to 
traverse both the FAIMS device and both drift tube and travelling wave ion mobility (DTIMS 
and TWIMS) devices. 3-MX was observed to form stable tetrameric complexes around an 
alkali metal (Na+, K+) or ammonium cation, where complexes of (3-MX)n observed include: 
singly charged complexes where n = 1-8 and 12 and doubly charged complexes where n = 
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12-24. The most intense ions are those associated with multiples of tetrameric units, where n 
= 4, 8, 12, 16, 20, 24. 
The main focus of the chapter is on the FAIMS-MS investigation of the non-covalent 
complexes of 3-MX. FAIMS selected transmission resulted in an improvement in signal-to-
noise (S:N) ratio for low intensity complexes and enabled the detection complexes that were 
previously concealed by more abundant overlapping isobaric species to be observed, 
demonstrating the potential of FAIMS to aid in the deconvolution of complicated mass 
spectra. Singly charged tetrameric complexes were found to be stable through the FAIMS 
device, even up to the highest DF values, over a wide dispersion field (DF) range of 194 to 
323 Td. Singly charged 3-MX complexes of a tetrameric based structure were shown to have 
different compensation field (CF) values for maximum transmission, with CF decreasing with 
increasing complex size. Doubly charged tetrameric species, showed increased CFs for 
transmission compared to singly charged species at high DFs, but declined in intensity as the 
DF increased. Indicating fragmentation of higher ordered complexes within the FAIMS 
electrodes (in-FAIMS dissociation), as well as in-source collision induced dissociation within 
the MS. FAIMS-MS, therefore, enabled the charge state separation of supramolecular 
complexes of 3-MX and was shown to be capable of separating species with overlapping 
mass-to-charge ratios. FAIMS-MS has also been applied to an array of supramolecular non-
covalent complexes of 3-MX with multiple cations present, and shown to aid in the 
identification of hetero-cation complexes.  
Hyphenation of FAIMS-MS and IM-MS has been used for a structural analysis of 3-MX 
complexes. Structural information can be inferred from the fragmentation of higher-order 3-
MX complexes via collisionally induced dissociation in the FAIMS device and within the 
source region of the MS. TWIMS and DTIMS combined with mass spectrometry and tandem 
mass spectrometry were used to obtain ion mobility spectra of 3-MX complex fragments and 
measure rotationally averaged collision cross section (CCS) values and compared with 
theoretically calculated values. 
Application of the FAIMS-MS approach to 3-MX from a biological matrix, such as urine 
(both spiked and endogenous), could to lead to insight as to the formation of these complexes 
from a biological origin, and evaluate the analysis and deconvolution of the complex mass 
spectra from a more challenging sample matrix. FAIMS-MS would most likely need to be 
combined with a rapid method of sample clean-up (such as off-line SPE) or a rapid 
chromatographic method, for the targeted analysis of non-covalent 3-MX complexes in a 
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biological matrix. Further investigations of supramolecular non-covalent complexes using 
FAIMS-MS could expand to include the analysis of similarly structured purine compounds 
such as guanine, which have also been previously reported to form similarly structured 
tetrameric based non-covalent complexes in vitro and in vivo and are referred to as G-
quadruplexes.1,2 Comparison of FAIMS-MS results of non-covalent structures of multiple 
compounds could lead to the inference of further structural information, such as relative bond 
strengths based upon fragmentation of higher ordered complexes at different DFs as one 
example.  
6.4. Summary of chapter three 
Chapter three describes the development of an LC-FAIMS-MS method for the analysis of 
salivary oxypurine compounds (hypoxanthine (HX) and xanthine (XA)), with a non-invasive 
passive drool saliva collection method. Separation of the oxypurines from interfering matrix 
components was investigated using FAIMS-MS, by the direct infusion of oxypurine 
standards and a pooled saliva extract. A short (7 min) liquid chromatographic method was 
combined with the selected FAIMS parameters (CF 0.9 Td at DF 230 Td) and MS, and 
applied to the analysis of salivary HX and XA. Using LC-FAIMS-MS, improved 
chromatographic peak integration was possible, in comparison to LC-MS, due to the 
reduction in the co-eluting chemical interferences from the saliva matrix. This also resulted in 
improved mass spectrometric observed mass error using HRMS, aiding in the qualitative 
identification and quantitation of the purine based derivatives, HX and XA. A quantitative 
evaluation (with internal standard) of the LC-FAIMS-MS method showed limits of detection 
of 2.0 ng mL-1 for HX and 1.8 ng mL-1 for XA, and limits of quantification of 6.6 ng mL-1 for 
HX and 6.0 ng mL-1 for XA. The developed LC-FAIMS-MS method was applied to the 
analysis of saliva collected from healthy male athletes both pre- and post- exercise designed 
to induce oxidative stress. Salivary concentrations of both HX and XA were lower 
immediately after physical exercise and one-hour post-exercise, compared to pre-exercise 
(rest) and twenty-four hours’ post-exercise, suggesting HX and XA could be used as 
biomarkers of oxidative stress.  
Further work would be to expand the analysis of oxypurine compounds to the end-product of 
the purine metabolism, uric acid (UA), to allow HX and XA ratios to UA to be determined. 
UA was detected in the analysis performed in chapter three, but was however found to be 
outside of the linear dynamic range of the instrumentation due to the high concentrations of 
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UA in saliva. Therefore, the analysis would need to be performed with further dilution of the 
saliva prior to analysis. Further work is required to understand the metabolic implications of 
the observed decrease in HX and XA after exercise, but the method developed and applied 
here, demonstrates the utility of the combination of LC-FAIMS-MS for the analysis of 
metabolic changes, and also the potential application as a rapid and high-throughput 
screening technique for oxidative stress.  
6.5. Summary of chapter four 
Chapter four describes the development of a rapid LC-FAIMS-MS analysis of glucuronide 
and sulfate metabolites of seven anabolic-androgenic steroids in urine. These seven steroid 
metabolites consisted of two pairs of isobaric glucuronide metabolites and a trio of isobaric 
sulfate metabolites. An investigation of the FAIMS-MS separation of the isobaric steroid 
metabolites was performed in positive ion mode for selected cationic adducts (H+, NH4
+, Na+, 
K+, Cs+), which resulted in the selection of the doubly sodiated adducts ([M+2Na-H]+) with 
the FAIMS settings of CF 1.35, 2.05 and 2.70 Td at DF 260 Td to be used for LC-FAIMS-
MS method development. Selection of these three FAIMS settings did not however result in 
the separation of two of the sulfate isobaric trio (dehydroepiandrosterone sulfate and 
testosterone sulfate), therefore development of the chromatographic method focused on the 
chromatographic separation of these two Hydrophilic interaction chromatography (HILIC) 
was selected for the chromatographic resolution of the sulfate metabolite isobars in a short 
chromatographic method (8 min), with post-column addition of sodium acetate for the 
formation of the doubly sodiated adducts of the steroid metabolites in the electrospray 
ionisation source. HILIC-FAIMS-MS was the only combination found to be capable of 
separating all seven of the targeted steroid metabolites in urine. The quantitative 
characteristics of the approach were evaluated giving limits of detection in the range 1-6 ng 
mL-1 and limits of quantification in the range 3-20 ng mL-1, with increases in S:N (>250%) of 
the steroid metabolites in unspiked urine, observed by the reduction of isobaric interferences 
from the matrix. An alternative or additional tool for identification of the steroid metabolites 
is presented, based on the observations of different patterns of sodium acetate clusters that are 
characteristic for each metabolite using FAIMS.  
The results reported here were validated for the use LC-FAIMS-MS using three FAIMS 
settings: CF 1.35 Td at DF 260 Td, CF 2.05 Td at DF 260 Td, and CF 2.70 Td at DF 260 Td, 
with the CF and DF kept static during the chromatographic analysis. This approach required 
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the injection and analysis to be performed in triplicate for each sample (at a different FAIMS 
setting each time). An alternative approach is demonstrated in the last section of this chapter 
which employs a targeted multi-CF scanning approach (static DF) by scanning through the 
three optimal CF conditions in a single chromatographic run. Application of this multi-CF 
scanning approach could be employed to allow for the discrimination of the steroid 
metabolites in a high-throughput analysis approach necessary to employ this method for the 
testing of drugs of abuse. However, further validation of the approach would be necessary to 
validate the qualitative and quantitative characteristics of the approach for the analysis of 
urine.  
6.6. Summary of chapter five 
Chapter five describes the proof-of-principle development of the acquisition of full scan 
FAIMS and MS nested data sets within the timescale of an ultra-high performance liquid 
chromatography (UHPLC) peak. The potential of the scanning LC-FAIMS-MS to enhance 
peak capacity in omics applications is demonstrated in the molecular profiling of a complex 
biological matrix (urine). The peak capacity for features detected using LC-FAIMS-MS was 
increased 3-fold compared to LC-MS alone, due to a combination of the reduction of 
chemical noise and separation of isobaric species across the whole analytical space. The 
absolute signal is reduced with the FAIMS, but the S:N is increases from the reduction in 
chemical noise, thereby enhancing the detection of low intensity ions. The methodology 
developed provides a high level of orthogonality between the three techniques of LC, FAIMS 
and MS, with features detected based on retention time, FAIMS DF and CF and m/z. FAIMS 
pre-selection with in source collision induced dissociation (FISCID) was also demonstrated 
to reduce sample complexity of overlapping fragmentation patterns, providing structural 
information on the selected precursor ions using a single mass analyser to aid in compound 
identification.  
The results reported here demonstrate that the miniaturised FAIMS device is suitable for a 
fast scanning of the full FAIMS CF range in 1 s making it compatible with UHPLC 
chromatographic peak widths, allowing for the acquisition of large LC-FAIMS-MS datasets 
while maintaining a high throughput for analyses. The scanning LC-FAIMS-MS approach 
was evaluated here for the molecular profiling of urine, but the methodology using the 
miniaturised FAIMS is applicable to other sample matrices as part of an omics workflow. 
The developed approach could be also applied to existing bioanalysis to explore whether the 
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increased peak capacity using the scanning LC-FAIMS-MS approach can improve existing 
datasets with meaningful feature extraction. However, further work is required to validate the 
use of LC-FAIMS-MS for the stratification of disease states and other metabolic changes and 
to extend the method to other sample matrices as part of an omics workflow.  
Further development of a data processing analysis workflow would also be required to 
process the nested LC-FAIMS-MS data sets for the discrimination of features. The approach 
used for the proof-of-principle analysis described in this chapter is unsustainable for an omics 
workflow especially for large datasets. Automation of a data pre-treatment process for the 
extraction of individual CFs from the acquired nested data files would facilitate analysis of 
the data as pseudo LC-MS data files (one extracted file per CF). The CF separated files in an 
open-source format, such as mzML, could then be used for feature extraction based upon 
existing omics LC-MS data processing workflows (such as MZmine 2 or XCMS).  
There is the potential for the acquisition of nested LC-FAIMS-MS data sets using two-
dimensional DF and CF scans. In the work presented in this chapter only the CF was scanned 
with the DF kept static throughout the analysis. A two-dimensional DF and CF scan could 
have the potential to further increase peak capacity, for the increased transmission of small 
molecules at low DFs, which could otherwise be lost due to field heating at high DFs, and 
could take advantage of increased FAIMS resolution and selectivity at higher DFs. An 
alternative to scanning both the DF and the CF within a single analysis, could be to perform 
multiple LC-FAIMS-MS analyses at a single DF each (same CF scan settings) to provide 
complementary data at different DFs.  
Further work could also include the development of a scanning LC-FAIMS-MS library using 
standards, of the sort being generated for IM-MS,3 which would further facilitate feature 
identification. This could further make the scanning LC-FAIMS-MS technique integrable and 
applicable to high throughput and robust analysis, and more widely available to a range of 
bioanalytical methodologies.  
6.7. Summary of thesis 
This thesis describes the development and application of methods utilising the combination of 
miniaturised FAIMS with mass spectrometry for the analysis a variety of compounds and 
biological matrices. Targeted analyses using LC-FAIMS-MS demonstrate the rapid, sensitive 
and selective analysis of challenging biological matrices, with the removal of co-eluting 
isobaric matrix interferences, and the separation of targeted isobars utilising FAIMS 
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separation for a rapid and high-throughput analysis. Miniaturised FAIMS has shown to be 
compatible with UHPLC peak timescales and utilised in a scanning LC-FAIMS-MS approach 
for the acquisition of full scan FAIMS and MS nested data sets, for the potential to enhance 
peak capacity in high-throughput omics applications, where the aim is to profile the whole of 
a complex matrix and detect small perturbations. Utilising the fast scanning capability of the 
miniaturised FAIMS, this complementary technology has the potential to enhance non-
targeted omics and bioanalytical applications.  
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British Mass Spectrometry Society 2015 36th annual meeting at the University of 
Birmingham, September 2015: ‘Field asymmetric waveform ion mobility spectrometry 
combined with mass spectrometry for the analysis of anabolic steroids’ 
RSC Separation Science Group conference entitled ‘What can ion mobility do for me?’, 
London, November 2015: ‘FAIMS studies of non-covalent complexes of 3-methylxanthine’  
British Mass Spectrometry Society 2016 37th annual meeting in Eastbourne, September 2016: 
‘Targeted and untargeted metabolic profiling by incorporating scanning FAIMS into LC-MS’ 
